faculty_name,faculty_email,publication_type,title,journal,year,doi,url,file_created
Gregory Pond,gpond@mcmaster.ca,journal_articles,Longitudinal changes in cognition in older individuals receiving lymphoma-directed therapy: A pilot feasibility study.,Journal of Geriatric Oncology,2025,10.1016/j.jgo.2025.102319,https://experts.mcmaster.ca/display/publication3612367,2025-07-27T15:12:23.218256
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?",Breast,2025,10.1016/j.breast.2025.104528,https://experts.mcmaster.ca/display/publication3610581,2025-07-27T15:12:23.218263
Gregory Pond,gpond@mcmaster.ca,journal_articles,Induction chemotherapy and immunotherapy followed by chemo-radiotherapy in incurable advanced head and neck squamous cell carcinoma: A case-series.,Oral Oncology,2025,10.1016/j.oraloncology.2025.107439,https://experts.mcmaster.ca/display/publication3600531,2025-07-27T15:12:23.218265
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Cost Disparities with Age in the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) in Ontario, Canada.",Current Oncology,2025,10.3390/curroncol32060346,https://experts.mcmaster.ca/display/publication3596582,2025-07-27T15:12:23.218266
Gregory Pond,gpond@mcmaster.ca,journal_articles,Does Facilitated Palliative Care Education Improve Patient Identification? A Cluster Randomized Controlled Trial of Primary Care Providers in the CAPACITI Training Program.,Journal of Palliative Medicine,2025,10.1089/jpm.2024.0453,https://experts.mcmaster.ca/display/publication3584108,2025-07-27T15:12:23.218267
Gregory Pond,gpond@mcmaster.ca,journal_articles,Partnering with patients to deliver window-of-opportunity clinical trials in immuno-oncology.,Journal of Clinical Oncology,2025,10.1200/jco.2025.43.16_suppl.e23023,https://experts.mcmaster.ca/display/publication3591174,2025-07-27T15:12:23.218268
Gregory Pond,gpond@mcmaster.ca,journal_articles,Time toxicity of nivolumab in metastatic head and neck squamous cell carcinoma patients: a single-institution experience.,Immunotherapy,2025,10.1080/1750743X.2025.2518913,https://experts.mcmaster.ca/display/publication3595978,2025-07-27T15:12:23.218269
Gregory Pond,gpond@mcmaster.ca,journal_articles,"A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study).",npj Breast Cancer,2025,10.1038/s41523-025-00762-7,https://experts.mcmaster.ca/display/publication3591175,2025-07-27T15:12:23.218270
Gregory Pond,gpond@mcmaster.ca,journal_articles,Metformin administration improves adverse outcomes in older adult burn patients: a single-centre cohort study.,npj Aging and Mechanisms of Disease,2025,10.1038/s41514-025-00224-1,https://experts.mcmaster.ca/display/publication3591176,2025-07-27T15:12:23.218271
Gregory Pond,gpond@mcmaster.ca,journal_articles,Guidance for discussants of randomized cancer trials at major meetings.,European Journal of Cancer,2025,10.1016/j.ejca.2025.115357,https://experts.mcmaster.ca/display/publication3554809,2025-07-27T15:12:23.218272
Gregory Pond,gpond@mcmaster.ca,journal_articles,Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis.,Leukemia,2025,10.1038/s41375-025-02552-3,https://experts.mcmaster.ca/display/publication3560310,2025-07-27T15:12:23.218273
Gregory Pond,gpond@mcmaster.ca,journal_articles,The Impact of Chronic Obstructive Pulmonary Disease on Immune Checkpoint Inhibitor Effectiveness in Non-small Cell Lung Cancer: A Population Health Study.,"Journal of immunotherapy (Hagerstown, Md. : 1997)",2025,10.1097/CJI.0000000000000551,https://experts.mcmaster.ca/display/publication3541081,2025-07-27T15:12:23.218274
Gregory Pond,gpond@mcmaster.ca,journal_articles,VISION: An Individual Patient Data Meta-analysis of Randomised Trials Comparing Magnetic Resonance Imaging Targeted Biopsy with Standard Transrectal Ultrasound Guided Biopsy in the Detection of Prostate Cancer.,European Urology,2025,10.1016/j.eururo.2024.08.022,https://experts.mcmaster.ca/display/publication3468684,2025-07-27T15:12:23.218275
Gregory Pond,gpond@mcmaster.ca,journal_articles,RADIANT: A window of opportunity trial exploring preoperative immunomodulatory radiotherapy and durvalumab prior to radical cystectomy in patients with cisplatin-ineligible muscle-invasive bladder carcinoma Free,Cancer Research,2025,10.1158/1538-7445.AM2025-CT128,https://experts.mcmaster.ca/display/publication3579733,2025-07-27T15:12:23.218276
Gregory Pond,gpond@mcmaster.ca,journal_articles,Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium.,The Lancet Oncology,2025,10.1016/S1470-2045(25)00034-8,https://experts.mcmaster.ca/display/publication3559740,2025-07-27T15:12:23.218277
Gregory Pond,gpond@mcmaster.ca,journal_articles,Radiation therapy and immigration status in women with breast cancer.,Radiotherapy and Oncology,2025,10.1016/j.radonc.2025.110774,https://experts.mcmaster.ca/display/publication3535712,2025-07-27T15:12:23.218278
Gregory Pond,gpond@mcmaster.ca,journal_articles,Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study.,Journal of Medical Internet Research,2025,10.2196/66821,https://experts.mcmaster.ca/display/publication3554810,2025-07-27T15:12:23.218279
Gregory Pond,gpond@mcmaster.ca,journal_articles,Evolving strategies for the routine follow-up of patients with early breast cancer and the impact of COVID-19: a survey of healthcare providers.,Supportive Care in Cancer,2025,10.1007/s00520-025-09205-2,https://experts.mcmaster.ca/display/publication3545232,2025-07-27T15:12:23.218280
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials.",The Lancet Oncology,2025,10.1016/S1470-2045(24)00451-0,https://experts.mcmaster.ca/display/publication3538940,2025-07-27T15:12:23.218281
Gregory Pond,gpond@mcmaster.ca,journal_articles,Early Mixed Donor Chimerism is a Strong Negative Prognostic Indicator in Allogeneic Stem Cell Transplant for AML and MDS.,Transplantation and Cellular Therapy,2025,10.1016/j.jtct.2024.11.006,https://experts.mcmaster.ca/display/publication3488179,2025-07-27T15:12:23.218282
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Patterns of Survivorship Follow-Up Care Among Patients With Breast Cancer: A Retrospective Population-Based Cohort Study in Ontario, Canada, Between 2006 and 2016",JCO Oncology Practice,2025,10.1200/op.23.00813,https://experts.mcmaster.ca/display/publication3454091,2025-07-27T15:12:23.218283
Gregory Pond,gpond@mcmaster.ca,journal_articles,Preoperative PET Scan Is Associated With Lower Rates Of Adjuvant Treatment In Surgically Treated Cervical Cancer Patients: A 4C Working Group Study,International Journal of Gynecological Cancer,2025,10.1016/j.ijgc.2024.100194,https://experts.mcmaster.ca/display/publication3545202,2025-07-27T15:12:23.218284
Gregory Pond,gpond@mcmaster.ca,journal_articles,Comparing the clinical trial efficacy versus real-world effectiveness of treatments for multiple myeloma: a population-based study.,Haematologica,2025,10.3324/haematol.2024.285768,https://experts.mcmaster.ca/display/publication3466243,2025-07-27T15:12:23.218285
Gregory Pond,gpond@mcmaster.ca,journal_articles,High- versus low-intensity knowledge translation interventions for surgeons and rates of local tumour recurrence after rectal cancer surgery: an Ontario study.,Canadian Journal of Surgery,2025,10.1503/cjs.012424,https://experts.mcmaster.ca/display/publication3596607,2025-07-27T15:12:23.218286
Gregory Pond,gpond@mcmaster.ca,journal_articles,A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer,Breast Cancer Research and Treatment,2024,10.1007/s10549-024-07443-2,https://experts.mcmaster.ca/display/publication3454321,2025-07-27T15:12:23.218287
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Reply to: Vaginal surgery for cervical cancer based on the recent results of LACC, SHAPE, SUCCOR and ConCerv trials.",European Journal of Surgical Oncology,2024,10.1016/j.ejso.2024.108656,https://experts.mcmaster.ca/display/publication3472587,2025-07-27T15:12:23.218288
Gregory Pond,gpond@mcmaster.ca,journal_articles,Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy.,Radiation Oncology,2024,10.1186/s13014-024-02546-y,https://experts.mcmaster.ca/display/publication3486370,2025-07-27T15:12:23.218289
Gregory Pond,gpond@mcmaster.ca,journal_articles,Longitudinal Changes in Cognition in Older Individuals Receiving Lymphoma-Directed Therapy: A Pilot Feasibility Study,Blood,2024,10.1182/blood-2024-200461,https://experts.mcmaster.ca/display/publication3502917,2025-07-27T15:12:23.218290
Gregory Pond,gpond@mcmaster.ca,journal_articles,Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis,Blood,2024,10.1182/blood-2024-200877,https://experts.mcmaster.ca/display/publication3504729,2025-07-27T15:12:23.218291
Gregory Pond,gpond@mcmaster.ca,journal_articles,Patient Characteristics and Outcomes of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in Allogeneic Stem Cell Transplant Patients- a Multicenter Canadian Study,Blood,2024,10.1182/blood-2024-200297,https://experts.mcmaster.ca/display/publication3504730,2025-07-27T15:12:23.218292
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Secondary Cancers Among Patients with Multiple Myeloma: A 15-Year Analysis of a Population-Based Cohort in Ontario, Canada",Blood,2024,10.1182/blood-2024-200956,https://experts.mcmaster.ca/display/publication3504728,2025-07-27T15:12:23.218293
Gregory Pond,gpond@mcmaster.ca,journal_articles,Subsequent Primary Malignancies in Patients with Indolent B Cell Non-Hodgkin Lymphoma Receiving Frontline Bendamustine Rituximab Therapy,Blood,2024,10.1182/blood-2024-211926,https://experts.mcmaster.ca/display/publication3504723,2025-07-27T15:12:23.218294
Gregory Pond,gpond@mcmaster.ca,journal_articles,Trajectories of Frailty Categorization over Time Among Real-World Patients with Multiple Myeloma: A Prospective Cohort Study (MFRAIL),Blood,2024,10.1182/blood-2024-205524,https://experts.mcmaster.ca/display/publication3494538,2025-07-27T15:12:23.218295
Gregory Pond,gpond@mcmaster.ca,journal_articles,Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study.,Blood Cancer Journal,2024,10.1038/s41408-024-01164-x,https://experts.mcmaster.ca/display/publication3480409,2025-07-27T15:12:23.218296
Gregory Pond,gpond@mcmaster.ca,journal_articles,EP.08B.03 Prognostic Value of Irradiated Cardiac and Metabolic Tumor Volume in Unresected LA-NSCLC Treated with Concurrent Chemo-Radiotherapy.,Journal of Thoracic Oncology,2024,10.1016/j.jtho.2024.09.1052,https://experts.mcmaster.ca/display/publication3482339,2025-07-27T15:12:23.218297
Gregory Pond,gpond@mcmaster.ca,journal_articles,Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer,Clinical Genitourinary Cancer,2024,10.1016/j.clgc.2024.102143,https://experts.mcmaster.ca/display/publication3446555,2025-07-27T15:12:23.218298
Gregory Pond,gpond@mcmaster.ca,journal_articles,Safety of vaginal surgery for early-stage cervical cancer: A retrospective multicenter cohort study,European Journal of Surgical Oncology,2024,10.1016/j.ejso.2024.108518,https://experts.mcmaster.ca/display/publication3446554,2025-07-27T15:12:23.218299
Gregory Pond,gpond@mcmaster.ca,journal_articles,Biopsychosocial Associates of Psychological Distress and Post-Traumatic Growth among Canadian Cancer Patients during the COVID-19 Pandemic.,Current Oncology,2024,10.3390/curroncol31090395,https://experts.mcmaster.ca/display/publication3471878,2025-07-27T15:12:23.218300
Gregory Pond,gpond@mcmaster.ca,journal_articles,124 Phase II Randomized Trial of Optimal Recurrence-Directed Therapy (RDT) Without or with Androgen-Deprivation Therapy (ADT) in Radio-Recurrent Oligo-Metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC): The OCOG-Rational-PCS Trial,Radiotherapy and Oncology,2024,10.1016/s0167-8140(24)03611-9,https://experts.mcmaster.ca/display/publication3484549,2025-07-27T15:12:23.218301
Gregory Pond,gpond@mcmaster.ca,journal_articles,Development and application of a weighted change score to evaluate interventions for vasomotor symptoms in patients with breast cancer using regression trees: a cohort study,Breast Cancer Research and Treatment,2024,10.1007/s10549-024-07360-4,https://experts.mcmaster.ca/display/publication3431619,2025-07-27T15:12:23.218302
Gregory Pond,gpond@mcmaster.ca,journal_articles,Error in Author Affiliations,JAMA Oncology,2024,10.1001/jamaoncol.2024.3507,https://experts.mcmaster.ca/display/publication3461000,2025-07-27T15:12:23.218302
Gregory Pond,gpond@mcmaster.ca,journal_articles,Final results: Randomized assessment of cisplatin dosing interval for ototoxicity (RADIO) trial comparing chemoradiation (CRT) with cisplatin q3weekly to weekly for locally advanced squamous cell carcinoma of the head and neck (LASCCHN),Annals of Oncology,2024,10.1016/j.annonc.2024.08.2276,https://experts.mcmaster.ca/display/publication3472586,2025-07-27T15:12:23.218303
Gregory Pond,gpond@mcmaster.ca,journal_articles,P-318 A Real-World Comparison of First-Line Regimens in Transplant Ineligible Patients with Multiple Myeloma,"Clinical Lymphoma, Myeloma and Leukemia",2024,10.1016/s2152-2650(24)02220-1,https://experts.mcmaster.ca/display/publication3480352,2025-07-27T15:12:23.218304
Gregory Pond,gpond@mcmaster.ca,journal_articles,Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy,BMC Cancer,2024,10.1186/s12885-024-12574-2,https://experts.mcmaster.ca/display/publication3458758,2025-07-27T15:12:23.218305
Gregory Pond,gpond@mcmaster.ca,journal_articles,"A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast Cancer",Current Oncology,2024,10.3390/curroncol31080338,https://experts.mcmaster.ca/display/publication3458985,2025-07-27T15:12:23.218306
Gregory Pond,gpond@mcmaster.ca,journal_articles,Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey,Breast Cancer Research and Treatment,2024,10.1007/s10549-024-07302-0,https://experts.mcmaster.ca/display/publication3416774,2025-07-27T15:12:23.218307
Gregory Pond,gpond@mcmaster.ca,journal_articles,HPV Self-Sampling for Cervical Cancer Screening in Under-Screened Saskatchewan Populations: A Pilot Study,Current Oncology,2024,10.3390/curroncol31080317,https://experts.mcmaster.ca/display/publication3454273,2025-07-27T15:12:23.218308
Gregory Pond,gpond@mcmaster.ca,journal_articles,Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL),Leukemia and Lymphoma,2024,10.1080/10428194.2024.2340052,https://experts.mcmaster.ca/display/publication3414617,2025-07-27T15:12:23.218309
Gregory Pond,gpond@mcmaster.ca,journal_articles,ASO Visual Abstract: Immigration Status and Breast Cancer Surgery Quality of Care Metrics: A Population-Level Analysis,Annals of Surgical Oncology,2024,10.1245/s10434-024-15376-9,https://experts.mcmaster.ca/display/publication3428504,2025-07-27T15:12:23.218310
Gregory Pond,gpond@mcmaster.ca,journal_articles,Comparison of Multiparametric MRI–targeted and Systematic                     Biopsies for Detection of Cribriform and Intraductal Carcinoma Prostate                     Cancer,Radiology,2024,10.1148/radiol.231948,https://experts.mcmaster.ca/display/publication3450412,2025-07-27T15:12:23.218311
Gregory Pond,gpond@mcmaster.ca,journal_articles,Immigration Status and Breast Cancer Surgery Quality of Care Metrics: A Population-Level Analysis,Annals of Surgical Oncology,2024,10.1245/s10434-024-15250-8,https://experts.mcmaster.ca/display/publication3416127,2025-07-27T15:12:23.218312
Gregory Pond,gpond@mcmaster.ca,journal_articles,Stereotactic Ablative Radiotherapy for Gynecological Oligometastatic and Oligoprogessive Tumors,JAMA Oncology,2024,10.1001/jamaoncol.2024.1796,https://experts.mcmaster.ca/display/publication3441712,2025-07-27T15:12:23.218313
Gregory Pond,gpond@mcmaster.ca,journal_articles,Patient and Provider Attitudes and Preferences Regarding Early Palliative Care Delivery for Patients with Advanced Gastrointestinal Cancers: A Prospective Survey,Current Oncology,2024,10.3390/curroncol31060253,https://experts.mcmaster.ca/display/publication3441618,2025-07-27T15:12:23.218314
Gregory Pond,gpond@mcmaster.ca,journal_articles,Oncologists’ Satisfaction with Virtual Care: A Questionnaire,Current Oncology,2024,10.3390/curroncol31060248,https://experts.mcmaster.ca/display/publication3437401,2025-07-27T15:12:23.218315
Gregory Pond,gpond@mcmaster.ca,journal_articles,Incidence of venous thromboembolism in newly diagnosed glioblastoma multiforme and associated risk factors: A retrospective chart review.,Journal of Clinical Oncology,2024,10.1200/jco.2024.42.16_suppl.e14040,https://experts.mcmaster.ca/display/publication3450358,2025-07-27T15:12:23.218316
Gregory Pond,gpond@mcmaster.ca,journal_articles,Magnetic Resonance Imaging–Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE),European urology oncology,2024,10.1016/j.euo.2023.09.013,https://experts.mcmaster.ca/display/publication3303010,2025-07-27T15:12:23.218317
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study","Clinical Lymphoma, Myeloma and Leukemia",2024,10.1016/j.clml.2024.02.006,https://experts.mcmaster.ca/display/publication3402560,2025-07-27T15:12:23.218318
Gregory Pond,gpond@mcmaster.ca,journal_articles,Abstract PO3-11-12: A Pragmatic Randomized Trial Comparing Morning versus Evening Dosing of Endocrine Therapy for Early Breast Cancer: Final Results (REaCT-CHRONO Study),Cancer Research,2024,10.1158/1538-7445.sabcs23-po3-11-12,https://experts.mcmaster.ca/display/publication3427020,2025-07-27T15:12:23.218319
Gregory Pond,gpond@mcmaster.ca,journal_articles,Abstract PO4-13-01: A randomised trial comparing 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early breast cancer (REaCT-ZOL): Quality of life and toxicity outcomes,Cancer Research,2024,10.1158/1538-7445.sabcs23-po4-13-01,https://experts.mcmaster.ca/display/publication3427019,2025-07-27T15:12:23.218320
Gregory Pond,gpond@mcmaster.ca,journal_articles,Abstract PO5-01-11: Breast Cancer Index and comparative analysis of late distant recurrence risk with results from the TEAM trial,Cancer Research,2024,10.1158/1538-7445.sabcs23-po5-01-11,https://experts.mcmaster.ca/display/publication3427018,2025-07-27T15:12:23.218321
Gregory Pond,gpond@mcmaster.ca,journal_articles,Abstract PS16-03: Intratumoral dosing of INT230-6 in Early-Stage Breast Cancer Patients Induces Tumor Cell Necrosis and Immunomodulatory Effects: A Phase II Randomized Window-Of-Opportunity Study – the INVINCIBLE Trial,Cancer Research,2024,10.1158/1538-7445.sabcs23-ps16-03,https://experts.mcmaster.ca/display/publication3427017,2025-07-27T15:12:23.218322
Gregory Pond,gpond@mcmaster.ca,journal_articles,126P A randomized controlled trial (RCT) comparing optimal local treatment with or without endocrine therapy (ET) in patients (pts) aged ≥70 with lower risk breast cancer (BC) [REaCT-70 Study],ESMO Open,2024,10.1016/j.esmoop.2024.103114,https://experts.mcmaster.ca/display/publication3431635,2025-07-27T15:12:23.218322
Gregory Pond,gpond@mcmaster.ca,journal_articles,Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial,Clinical Cancer Research,2024,10.1158/1078-0432.ccr-23-2436,https://experts.mcmaster.ca/display/publication3401088,2025-07-27T15:12:23.218323
Gregory Pond,gpond@mcmaster.ca,journal_articles,A structured oral chemotherapy teaching tool to improve adherence in adults with multiple myeloma: A pilot randomized controlled trial,Journal of Geriatric Oncology,2024,10.1016/j.jgo.2024.101735,https://experts.mcmaster.ca/display/publication3404967,2025-07-27T15:12:23.218324
Gregory Pond,gpond@mcmaster.ca,journal_articles,Acute Toxicity Results from the Randomized Assessment of Cisplatin Dosing Interval for Ototoxicity (RADIO) Trial Comparing Chemoradiation (CRT) with Cisplatin Q3weekly to Weekly for Locally Advanced Squamous Cell Carcinoma of the Head and neck (LASCCHN),International Journal of Radiation Oncology Biology Physics,2024,10.1016/j.ijrobp.2024.01.027,https://experts.mcmaster.ca/display/publication3407188,2025-07-27T15:12:23.218325
Gregory Pond,gpond@mcmaster.ca,journal_articles,Gender and Racial Diversity Among Obstetrics and Gynecology Departments and Gynecologic Oncology Divisions in Canada: Are We There Yet?,Journal of Obstetrics and Gynaecology Canada,2024,10.1016/j.jogc.2024.102350,https://experts.mcmaster.ca/display/publication3389597,2025-07-27T15:12:23.218326
Gregory Pond,gpond@mcmaster.ca,journal_articles,The COVID-19 pandemic and its effects on follow-up of patients with early breast cancer: A patient survey,Breast Cancer Research and Treatment,2024,10.1007/s10549-023-07232-3,https://experts.mcmaster.ca/display/publication3389596,2025-07-27T15:12:23.218327
Gregory Pond,gpond@mcmaster.ca,journal_articles,Abstract 4798: MRI screening for brain metastases (BrM) versus SYMptom-directed brain imaging for patients with triple negative (TN) or HER2+ metastatic breast cancer (MBC): An ad-hoc interim analysis of a randomized phase II pilot study,Cancer Research,2024,10.1158/1538-7445.am2024-4798,https://experts.mcmaster.ca/display/publication3409092,2025-07-27T15:12:23.218328
Gregory Pond,gpond@mcmaster.ca,journal_articles,Enhancing Nutrition Support for Esophageal Cancer Patients: Understanding Factors Influencing Feeding Tube Utilization,Nutrition and Cancer,2024,10.1080/01635581.2024.2301796,https://experts.mcmaster.ca/display/publication3389595,2025-07-27T15:12:23.218329
Gregory Pond,gpond@mcmaster.ca,journal_articles,The REthinking Clinical Trials Program Retreat 2023: Creating Partnerships to Optimize Quality Cancer Care,Current Oncology,2024,10.3390/curroncol31030104,https://experts.mcmaster.ca/display/publication3405219,2025-07-27T15:12:23.218330
Gregory Pond,gpond@mcmaster.ca,journal_articles,Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study,Current Oncology,2024,10.3390/curroncol31030096,https://experts.mcmaster.ca/display/publication3405220,2025-07-27T15:12:23.218331
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Evaluating equity of access and predictors of minimally invasive hysterectomy for endometrial and cervical cancer from 2000 to 2017 in Ontario, Canada: A population‐based cohort study",Journal of Surgical Oncology,2024,10.1002/jso.27461,https://experts.mcmaster.ca/display/publication3294057,2025-07-27T15:12:23.218332
Gregory Pond,gpond@mcmaster.ca,journal_articles,Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use,Current Oncology,2024,10.3390/curroncol31010028,https://experts.mcmaster.ca/display/publication3389730,2025-07-27T15:12:23.218333
Gregory Pond,gpond@mcmaster.ca,journal_articles,"2024 Canadian Surgery Forum: Sept. 25-28, 2024.",Canadian Journal of Surgery,2024,10.1503/cjs.012624,https://experts.mcmaster.ca/display/publication3490315,2025-07-27T15:12:23.218334
Gregory Pond,gpond@mcmaster.ca,journal_articles,Concurrent immunotherapy and radiation in cisplatin-ineligible patients with HNSCC: a systematic review & meta-analysis.,Immunotherapy,2024,10.1080/1750743X.2024.2436346,https://experts.mcmaster.ca/display/publication3492749,2025-07-27T15:12:23.218335
Gregory Pond,gpond@mcmaster.ca,journal_articles,Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending,BMJ Oncology,2024,10.1136/bmjonc-2023-000287,https://experts.mcmaster.ca/display/publication3401167,2025-07-27T15:12:23.218336
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective",Current Oncology,2023,10.3390/curroncol30120763,https://experts.mcmaster.ca/display/publication3385336,2025-07-27T15:12:23.218337
Gregory Pond,gpond@mcmaster.ca,journal_articles,Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors,Journal of the National Cancer Institute,2023,10.1093/jnci/djad155,https://experts.mcmaster.ca/display/publication3281903,2025-07-27T15:12:23.218338
Gregory Pond,gpond@mcmaster.ca,journal_articles,A randomised controlled trial evaluating two cognitive rehabilitation approaches for cancer survivors with perceived cognitive impairment,Journal of Cancer Survivorship,2023,10.1007/s11764-022-01261-5,https://experts.mcmaster.ca/display/publication2446658,2025-07-27T15:12:23.218339
Gregory Pond,gpond@mcmaster.ca,journal_articles,Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study,Haematologica,2023,10.3324/haematol.2023.282905,https://experts.mcmaster.ca/display/publication3269969,2025-07-27T15:12:23.218340
Gregory Pond,gpond@mcmaster.ca,journal_articles,Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Need for Early Treatment in Prostate Cancer Patients Managed with Active Surveillance,International Journal of Molecular Sciences,2023,10.3390/ijms242216022,https://experts.mcmaster.ca/display/publication3316475,2025-07-27T15:12:23.218341
Gregory Pond,gpond@mcmaster.ca,journal_articles,Analysis of the Impact of Whole Blood and T-Cell Donor Chimerism after Allogeneic Stem Cell Transplant,Blood,2023,10.1182/blood-2023-187458,https://experts.mcmaster.ca/display/publication3320331,2025-07-27T15:12:23.218342
Gregory Pond,gpond@mcmaster.ca,journal_articles,Comparison of the Efficacy in Clinical Trials Versus Effectiveness in the Real-World of Treatments for Multiple Myeloma: A Population-Based Cohort Study,Blood,2023,10.1182/blood-2023-189506,https://experts.mcmaster.ca/display/publication3320298,2025-07-27T15:12:23.218342
Gregory Pond,gpond@mcmaster.ca,journal_articles,Treatment Patterns and Healthcare Resource Utilization Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study,Blood,2023,10.1182/blood-2023-190426,https://experts.mcmaster.ca/display/publication3320332,2025-07-27T15:12:23.218343
Gregory Pond,gpond@mcmaster.ca,journal_articles,Rates of surgery and adjuvant chemotherapy use in patients with stage IB to IIIA non-small cell lung cancer: A provincial population-based study.,JCO Oncology Practice,2023,10.1200/op.2023.19.11_suppl.134,https://experts.mcmaster.ca/display/publication3307280,2025-07-27T15:12:23.218344
Gregory Pond,gpond@mcmaster.ca,journal_articles,Risk of cancer-specific death among octogenarians with multiple myeloma: A population-based analysis,Journal of Geriatric Oncology,2023,10.1016/j.jgo.2023.101592,https://experts.mcmaster.ca/display/publication3272933,2025-07-27T15:12:23.218345
Gregory Pond,gpond@mcmaster.ca,journal_articles,2361MO Impact of positron emission tomography (PET) imaging on staging of muscle-invasive bladder cancer (MIBC) [PET-MUSE],Annals of Oncology,2023,10.1016/j.annonc.2023.09.1010,https://experts.mcmaster.ca/display/publication3303065,2025-07-27T15:12:23.218346
Gregory Pond,gpond@mcmaster.ca,journal_articles,Circulating Growth Differentiation Factor 15 as a Biomarker in Patients with Unresected Locally Advanced Non-Small Cell Lung Cancer Treated with Chemo-Radiotherapy with or without Metformin,International Journal of Radiation Oncology Biology Physics,2023,10.1016/j.ijrobp.2023.06.678,https://experts.mcmaster.ca/display/publication3299067,2025-07-27T15:12:23.218347
Gregory Pond,gpond@mcmaster.ca,journal_articles,Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data Sets,JCO clinical cancer informatics,2023,10.1200/cci.23.00116,https://experts.mcmaster.ca/display/publication3320266,2025-07-27T15:12:23.218348
Gregory Pond,gpond@mcmaster.ca,journal_articles,Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer,New England Journal of Medicine,2023,10.1056/nejmoa2302344,https://experts.mcmaster.ca/display/publication3281881,2025-07-27T15:12:23.218349
Gregory Pond,gpond@mcmaster.ca,journal_articles,Trainee Evaluations of Preparedness for Clinical Trials in Medical Oncology—A National Questionnaire,Current Oncology,2023,10.3390/curroncol30080553,https://experts.mcmaster.ca/display/publication3283585,2025-07-27T15:12:23.218350
Gregory Pond,gpond@mcmaster.ca,journal_articles,A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer,Current Oncology,2023,10.3390/curroncol30080535,https://experts.mcmaster.ca/display/publication3281958,2025-07-27T15:12:23.218351
Gregory Pond,gpond@mcmaster.ca,journal_articles,Socioeconomic marginalization and health outcomes in newly diagnosed multiple myeloma: A population‐based cohort study,American Journal of Hematology,2023,10.1002/ajh.26957,https://experts.mcmaster.ca/display/publication3229386,2025-07-27T15:12:23.218352
Gregory Pond,gpond@mcmaster.ca,journal_articles,Can routinely collected administrative data effectively be used to evaluate and validate endpoints used in breast cancer clinical trials? Protocol for a scoping review of the literature,Systematic Reviews,2023,10.1186/s13643-023-02283-5,https://experts.mcmaster.ca/display/publication3269965,2025-07-27T15:12:23.218353
Gregory Pond,gpond@mcmaster.ca,journal_articles,BRACHY: A Randomized Trial to Evaluate Symptom Improvement in Advanced Non-Small Cell Lung Cancer Treated With External Beam Radiation With or Without High-Dose-Rate Intraluminal Brachytherapy,International Journal of Radiation Oncology Biology Physics,2023,10.1016/j.ijrobp.2022.12.049,https://experts.mcmaster.ca/display/publication2745705,2025-07-27T15:12:23.218354
Gregory Pond,gpond@mcmaster.ca,journal_articles,Surgical margin status in relation to surgical approach in the management of early-stage cervical Cancer: A Canadian cervical Cancer collaborative (4C) study,Gynecologic Oncology,2023,10.1016/j.ygyno.2023.03.005,https://experts.mcmaster.ca/display/publication3191048,2025-07-27T15:12:23.218355
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Assessment of risk of overall and late distant recurrence by Breast Cancer Index in postmenopausal women with early-stage, HR+ breast cancer in the TEAM trial.",Journal of Clinical Oncology,2023,10.1200/jco.2023.41.16_suppl.509,https://experts.mcmaster.ca/display/publication3247198,2025-07-27T15:12:23.218356
Gregory Pond,gpond@mcmaster.ca,journal_articles,Can synthetic data accurately mimic oncology clinical trials?,Journal of Clinical Oncology,2023,10.1200/jco.2023.41.16_suppl.1554,https://experts.mcmaster.ca/display/publication3247200,2025-07-27T15:12:23.218357
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, Influence, CTS-5)? A TEAM Pathology substudy.",Journal of Clinical Oncology,2023,10.1200/jco.2023.41.16_suppl.533,https://experts.mcmaster.ca/display/publication3247197,2025-07-27T15:12:23.218357
Gregory Pond,gpond@mcmaster.ca,journal_articles,Evaluating response to interventions for vasomotor symptoms in patients with breast cancer: A patient-centered approach.,Journal of Clinical Oncology,2023,10.1200/jco.2023.41.16_suppl.e24126,https://experts.mcmaster.ca/display/publication3247194,2025-07-27T15:12:23.218358
Gregory Pond,gpond@mcmaster.ca,journal_articles,Multisystem immune-related adverse events from dual agent immunotherapy use.,Journal of Clinical Oncology,2023,10.1200/jco.2023.41.16_suppl.2635,https://experts.mcmaster.ca/display/publication3247199,2025-07-27T15:12:23.218359
Gregory Pond,gpond@mcmaster.ca,journal_articles,P-418 Use of prophylactic and reactive feeding tubes in patients with esophageal cancer: A single-centre cohort study,Annals of Oncology,2023,10.1016/j.annonc.2023.04.507,https://experts.mcmaster.ca/display/publication3258401,2025-07-27T15:12:23.218360
Gregory Pond,gpond@mcmaster.ca,journal_articles,Phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE trial.,Journal of Clinical Oncology,2023,10.1200/jco.2023.41.16_suppl.573,https://experts.mcmaster.ca/display/publication3247196,2025-07-27T15:12:23.218361
Gregory Pond,gpond@mcmaster.ca,journal_articles,Regularly scheduled physical examinations and the detection of breast cancer recurrences,Breast,2023,10.1016/j.breast.2023.03.004,https://experts.mcmaster.ca/display/publication2980493,2025-07-27T15:12:23.218362
Gregory Pond,gpond@mcmaster.ca,journal_articles,Use of prophylactic and reactive feeding tubes in patients with esophageal cancer: A single-centre cohort study.,Journal of Clinical Oncology,2023,10.1200/jco.2023.41.16_suppl.e18694,https://experts.mcmaster.ca/display/publication3247195,2025-07-27T15:12:23.218363
Gregory Pond,gpond@mcmaster.ca,journal_articles,Differentiating Specialized and Advanced Nursing Roles: The Pathway to Role Optimization,Nursing Leadership,2023,10.12927/cjnl.2023.27123,https://experts.mcmaster.ca/display/publication3276982,2025-07-27T15:12:23.218364
Gregory Pond,gpond@mcmaster.ca,journal_articles,"P021 A pragmatic randomised, multicentre trial evaluating the dose timing (morning vs evening) of endocrine therapy for early breast cancer (REaCT-CHRONO Study)",Breast,2023,10.1016/s0960-9776(23)00140-6,https://experts.mcmaster.ca/display/publication2980492,2025-07-27T15:12:23.218365
Gregory Pond,gpond@mcmaster.ca,journal_articles,P279 A patient survey evaluating COVID-19-induced changes in follow-up of patients with EBC: opportunities for enhanced evidence-based practice?,Breast,2023,10.1016/s0960-9776(23)00397-1,https://experts.mcmaster.ca/display/publication2980491,2025-07-27T15:12:23.218366
Gregory Pond,gpond@mcmaster.ca,journal_articles,P291 Evolving strategies for the routine follow-up of patients with early breast cancer and the impact of COVID-19: a survey of healthcare providers,Breast,2023,10.1016/s0960-9776(23)00409-5,https://experts.mcmaster.ca/display/publication2980490,2025-07-27T15:12:23.218367
Gregory Pond,gpond@mcmaster.ca,journal_articles,Rurality index score and pediatric neuro-oncological outcome in Ontario,Journal of Neurosurgery: Pediatrics,2023,10.3171/2022.12.peds22446,https://experts.mcmaster.ca/display/publication2745704,2025-07-27T15:12:23.218368
Gregory Pond,gpond@mcmaster.ca,journal_articles,Abstract P2-02-04: De-escalation of bone-targeted treatment: Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12,Cancer Research,2023,10.1158/1538-7445.sabcs22-p2-02-04,https://experts.mcmaster.ca/display/publication2922495,2025-07-27T15:12:23.218369
Gregory Pond,gpond@mcmaster.ca,journal_articles,Abstract P2-11-10: Validation of the Breast Cancer Index (BCI) prognostic models optimized for late distant recurrence in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial,Cancer Research,2023,10.1158/1538-7445.sabcs22-p2-11-10,https://experts.mcmaster.ca/display/publication2922494,2025-07-27T15:12:23.218370
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Abstract P2-13-04: Inclusion of Patients with Leptomeningeal Disease in Phase III Randomized Clinical Trials of Patients with Advanced Breast Cancer, Lung Cancer, and Melanoma: A Systematic Review",Cancer Research,2023,10.1158/1538-7445.sabcs22-p2-13-04,https://experts.mcmaster.ca/display/publication2922493,2025-07-27T15:12:23.218371
Gregory Pond,gpond@mcmaster.ca,journal_articles,Abstract P5-04-04: Does reducing the frequency of regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer?,Cancer Research,2023,10.1158/1538-7445.sabcs22-p5-04-04,https://experts.mcmaster.ca/display/publication2922492,2025-07-27T15:12:23.218371
Gregory Pond,gpond@mcmaster.ca,journal_articles,Abstract P6-05-12: Understanding Patient Perspectives on Window of Opportunity Clinical Trial Participation in Breast Cancer,Cancer Research,2023,10.1158/1538-7445.sabcs22-p6-05-12,https://experts.mcmaster.ca/display/publication2922491,2025-07-27T15:12:23.218372
Gregory Pond,gpond@mcmaster.ca,journal_articles,Abstract PD11-02: PD11-02 A Phase II Randomized Window of Opportunity Trial Evaluating Cytotoxic and Immunomodulatory effects of Intratumoral INT230-6 in Early Stage Breast Cancer: the INVINCIBLE Trial,Cancer Research,2023,10.1158/1538-7445.sabcs22-pd11-02,https://experts.mcmaster.ca/display/publication2922490,2025-07-27T15:12:23.218373
Gregory Pond,gpond@mcmaster.ca,journal_articles,Developing a Data and Analytics Platform to Enable a Breast Cancer Learning Health System at a Regional Cancer Center,JCO clinical cancer informatics,2023,10.1200/cci.22.00182,https://experts.mcmaster.ca/display/publication3038606,2025-07-27T15:12:23.218374
Gregory Pond,gpond@mcmaster.ca,journal_articles,Feasibility and Effectiveness of Self-Management Education and Coaching on Patient Activation for Managing Cancer Treatment Toxicities,Journal of the National Comprehensive Cancer Network : JNCCN,2023,10.6004/jnccn.2022.7095,https://experts.mcmaster.ca/display/publication2922489,2025-07-27T15:12:23.218375
Gregory Pond,gpond@mcmaster.ca,journal_articles,FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study.,Journal of Clinical Oncology,2023,10.1200/jco.2023.41.6_suppl.460,https://experts.mcmaster.ca/display/publication2980489,2025-07-27T15:12:23.218376
Gregory Pond,gpond@mcmaster.ca,journal_articles,Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).,Journal of Clinical Oncology,2023,10.1200/jco.2023.41.6_suppl.tps750,https://experts.mcmaster.ca/display/publication2980309,2025-07-27T15:12:23.218377
Gregory Pond,gpond@mcmaster.ca,journal_articles,Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT).,Journal of Clinical Oncology,2023,10.1200/jco.2023.41.6_suppl.5,https://experts.mcmaster.ca/display/publication2980488,2025-07-27T15:12:23.218378
Gregory Pond,gpond@mcmaster.ca,journal_articles,Oncologic Outcomes of Surgically Treated Cervical Cancer with No Residual Disease on Hysterectomy Specimen: A 4C (Canadian Cervical Cancer Collaborative) Working Group Study,Current Oncology,2023,10.3390/curroncol30020153,https://experts.mcmaster.ca/display/publication2834926,2025-07-27T15:12:23.218379
Gregory Pond,gpond@mcmaster.ca,journal_articles,Cardiac Morbidity Following Chemoradiation in Stage III Non-small Cell Lung Cancer Patients: A Population-Based Cohort Study,Clinical Oncology,2023,10.1016/j.clon.2022.11.019,https://experts.mcmaster.ca/display/publication2632111,2025-07-27T15:12:23.218380
Gregory Pond,gpond@mcmaster.ca,journal_articles,Contemporary real-world radiotherapy outcomes of unresected locally advanced non-small cell lung cancer,Journal of Thoracic Disease,2023,10.21037/jtd-22-925,https://experts.mcmaster.ca/display/publication2835505,2025-07-27T15:12:23.218381
Gregory Pond,gpond@mcmaster.ca,journal_articles,Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12,European Journal of Cancer,2023,10.1016/j.ejca.2022.12.003,https://experts.mcmaster.ca/display/publication2632112,2025-07-27T15:12:23.218382
Gregory Pond,gpond@mcmaster.ca,journal_articles,Web-Based Asynchronous Tool to Facilitate Communication Between Primary Care Providers and Cancer Specialists: Pragmatic Randomized Controlled Trial,Journal of Medical Internet Research,2023,10.2196/40725,https://experts.mcmaster.ca/display/publication2745703,2025-07-27T15:12:23.218383
Gregory Pond,gpond@mcmaster.ca,journal_articles,Doxycycline-Induced Changes in Circulating MMP or TIMP2 Levels Are Not Associated with Skeletal-Related Event-Free or Overall Survival in Patients with Bone Metastases from Breast Cancer,Cancers,2023,10.3390/cancers15030571,https://experts.mcmaster.ca/display/publication2776363,2025-07-27T15:12:23.218384
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in patients with newly diagnosed glioblastoma",Neuro-Oncology Practice,2023,10.1093/nop/npac068,https://experts.mcmaster.ca/display/publication2552494,2025-07-27T15:12:23.218385
Gregory Pond,gpond@mcmaster.ca,journal_articles,Increasing palliative care capacity in primary care: study protocol of a cluster randomized controlled trial of the CAPACITI training program,BMC Palliative Care,2023,10.1186/s12904-022-01124-x,https://experts.mcmaster.ca/display/publication2687146,2025-07-27T15:12:23.218386
Gregory Pond,gpond@mcmaster.ca,journal_articles,Assessing Access to And Outcomes of Medical Oncology and Radiation Oncology Consultation in Non-Small Cell Lung Cancer Patients: A Population-Based Study Using Administrative Data,Medical Research Archives,2023,10.18103/mra.v11i7.2.4130,https://experts.mcmaster.ca/display/publication3281847,2025-07-27T15:12:23.218387
Gregory Pond,gpond@mcmaster.ca,journal_articles,"The impact of staging FDG-PET/CT on treatment for stage III NSCLC - an analysis of population-based data from Ontario, Canada",Frontiers in Oncology,2023,10.3389/fonc.2023.1210945,https://experts.mcmaster.ca/display/publication3286189,2025-07-27T15:12:23.218388
Gregory Pond,gpond@mcmaster.ca,journal_articles,Disparities in the survival of endometrial cancer patients in a public healthcare system: A population-based cohort study,Gynecologic Oncology,2022,10.1016/j.ygyno.2022.09.015,https://experts.mcmaster.ca/display/publication2441477,2025-07-27T15:12:23.218389
Gregory Pond,gpond@mcmaster.ca,journal_articles,Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis,Current Oncology,2022,10.3390/curroncol29120709,https://experts.mcmaster.ca/display/publication2632113,2025-07-27T15:12:23.218390
Gregory Pond,gpond@mcmaster.ca,journal_articles,Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphomas,Blood,2022,10.1182/blood-2022-165674,https://experts.mcmaster.ca/display/publication2579342,2025-07-27T15:12:23.218390
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Radiation Dose, Technique and Use of Brain Radiation on Overall Survival in Patients with Limited-Stage Small Cell Lung Cancer",International Journal of Radiation Oncology Biology Physics,2022,10.1016/j.ijrobp.2022.07.1593,https://experts.mcmaster.ca/display/publication2553048,2025-07-27T15:12:23.218391
Gregory Pond,gpond@mcmaster.ca,journal_articles,Exclusion of Patients With Brain Metastases in Published Phase III Clinical Trials for Advanced Breast Cancer,Clinical Breast Cancer,2022,10.1016/j.clbc.2022.07.004,https://experts.mcmaster.ca/display/publication2428002,2025-07-27T15:12:23.218392
Gregory Pond,gpond@mcmaster.ca,journal_articles,Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative.,Journal of Clinical Oncology,2022,10.1200/jco.2022.40.28_suppl.332,https://experts.mcmaster.ca/display/publication2552492,2025-07-27T15:12:23.218393
Gregory Pond,gpond@mcmaster.ca,journal_articles,116P Any regression of tumor (ART) as an intermediate endpoint in patients (pts) treated with immune checkpoint inhibitors (ICI): A pan-cancer analysis,Annals of Oncology,2022,10.1016/j.annonc.2022.07.148,https://experts.mcmaster.ca/display/publication2553050,2025-07-27T15:12:23.218394
Gregory Pond,gpond@mcmaster.ca,journal_articles,138MO Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial,Annals of Oncology,2022,10.1016/j.annonc.2022.07.173,https://experts.mcmaster.ca/display/publication2553049,2025-07-27T15:12:23.218395
Gregory Pond,gpond@mcmaster.ca,journal_articles,"139: Radiotherapy Dose, FDG-PET Utilization and Survival Outcomes of Unresected Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC). Ontario Population Outcomes of Contemporary Radiotherapy Alone and Standard of Care Chemo-Radiotherapy",Radiotherapy and Oncology,2022,10.1016/s0167-8140(22)04419-x,https://experts.mcmaster.ca/display/publication2552576,2025-07-27T15:12:23.218396
Gregory Pond,gpond@mcmaster.ca,journal_articles,"179: The Evolution of Technology in the Management of Early-Stage (T1) Cancer of the Larynx, an Institutional Review of Radiation Therapy Outcomes",Radiotherapy and Oncology,2022,10.1016/s0167-8140(22)04459-0,https://experts.mcmaster.ca/display/publication2552577,2025-07-27T15:12:23.218397
Gregory Pond,gpond@mcmaster.ca,journal_articles,"68: Radiation Dose, Technique, and Use of Brain Radiation on Overall Survival in Patients with Limited-Stage Small Cell Lung Cancer",Radiotherapy and Oncology,2022,10.1016/s0167-8140(22)04347-x,https://experts.mcmaster.ca/display/publication2552493,2025-07-27T15:12:23.218398
Gregory Pond,gpond@mcmaster.ca,journal_articles,88: Outcomes of Radiotherapy Alone for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) in Patients Unfit for Chemo-Radiotherapy,Radiotherapy and Oncology,2022,10.1016/s0167-8140(22)04367-5,https://experts.mcmaster.ca/display/publication2552578,2025-07-27T15:12:23.218399
Gregory Pond,gpond@mcmaster.ca,journal_articles,P1.15-10 Chronic Obstructive Pulmonary Disease Patients Receiving Immunotherapy for Lung Cancer: A Population-Based Study in Canada,Journal of Thoracic Oncology,2022,10.1016/j.jtho.2022.07.206,https://experts.mcmaster.ca/display/publication2553051,2025-07-27T15:12:23.218400
Gregory Pond,gpond@mcmaster.ca,journal_articles,Using machine learning to predict individual patient toxicities from cancer treatments,Supportive Care in Cancer,2022,10.1007/s00520-022-07156-6,https://experts.mcmaster.ca/display/publication2232358,2025-07-27T15:12:23.218401
Gregory Pond,gpond@mcmaster.ca,journal_articles,Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial,Journal of Experimental and Clinical Cancer Research,2022,10.1186/s13046-022-02455-6,https://experts.mcmaster.ca/display/publication2426293,2025-07-27T15:12:23.218402
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Comparison of outcomes between abdominal, minimally invasive and combined vaginal-laparoscopic hysterectomy in patients with stage IAI/IA2 cervical cancer: 4C (Canadian Cervical Cancer Collaborative) study",Gynecologic Oncology,2022,10.1016/j.ygyno.2022.05.011,https://experts.mcmaster.ca/display/publication2379214,2025-07-27T15:12:23.218403
Gregory Pond,gpond@mcmaster.ca,journal_articles,Germline BRCA mutations are associated with an increased likelihood of secondary cytoreductive surgery in ovarian cancer patients (116),Gynecologic Oncology,2022,10.1016/s0090-8258(22)01342-7,https://experts.mcmaster.ca/display/publication2552496,2025-07-27T15:12:23.218404
Gregory Pond,gpond@mcmaster.ca,journal_articles,The status of surgical margins in relation to the type of surgical approach in the management of early-stage cervical cancer: Canadian Cervical Cancer Collaborative (4C) study (533),Gynecologic Oncology,2022,10.1016/s0090-8258(22)01754-1,https://experts.mcmaster.ca/display/publication2552495,2025-07-27T15:12:23.218405
Gregory Pond,gpond@mcmaster.ca,journal_articles,Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast Cancer,Journal of Molecular Diagnostics,2022,10.1016/j.jmoldx.2022.04.002,https://experts.mcmaster.ca/display/publication2399905,2025-07-27T15:12:23.218406
Gregory Pond,gpond@mcmaster.ca,journal_articles,Lack of cognitive impairment in long-term survivors of colorectal cancer,Supportive Care in Cancer,2022,10.1007/s00520-022-07008-3,https://experts.mcmaster.ca/display/publication2184260,2025-07-27T15:12:23.218407
Gregory Pond,gpond@mcmaster.ca,journal_articles,LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0luminal A breast cancer (BC).,Journal of Clinical Oncology,2022,10.1200/jco.2022.40.17_suppl.lba501,https://experts.mcmaster.ca/display/publication2552499,2025-07-27T15:12:23.218407
Gregory Pond,gpond@mcmaster.ca,journal_articles,Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancer,"Cancer Epidemiology, Biomarkers and Prevention",2022,10.1007/s10552-022-01574-x,https://experts.mcmaster.ca/display/publication2184024,2025-07-27T15:12:23.218408
Gregory Pond,gpond@mcmaster.ca,journal_articles,Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative.,Journal of Clinical Oncology,2022,10.1200/jco.2022.40.16_suppl.e18628,https://experts.mcmaster.ca/display/publication2552503,2025-07-27T15:12:23.218409
Gregory Pond,gpond@mcmaster.ca,journal_articles,Intratumoral (IT) INT230-6 can cause tumor necrosis in vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study).,Journal of Clinical Oncology,2022,10.1200/jco.2022.40.16_suppl.605,https://experts.mcmaster.ca/display/publication2552506,2025-07-27T15:12:23.218410
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Overall survival of patients with chronic obstructive pulmonary disease receiving immunotherapy for non-small cell lung cancer: A population-based analysis in Ontario, Canada.",Journal of Clinical Oncology,2022,10.1200/jco.2022.40.16_suppl.e21172,https://experts.mcmaster.ca/display/publication2552501,2025-07-27T15:12:23.218411
Gregory Pond,gpond@mcmaster.ca,journal_articles,SALVO: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.,Journal of Clinical Oncology,2022,10.1200/jco.2022.40.16_suppl.9573,https://experts.mcmaster.ca/display/publication2552505,2025-07-27T15:12:23.218412
Gregory Pond,gpond@mcmaster.ca,journal_articles,Will COVID-19 directives to reduce regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer?,Journal of Clinical Oncology,2022,10.1200/jco.2022.40.16_suppl.1532,https://experts.mcmaster.ca/display/publication2552507,2025-07-27T15:12:23.218413
Gregory Pond,gpond@mcmaster.ca,journal_articles,Biased Evaluation in Cancer Drug Trials—How Use of Progression-Free Survival as the Primary End Point Can Mislead,JAMA Oncology,2022,10.1001/jamaoncol.2021.8206,https://experts.mcmaster.ca/display/publication2178257,2025-07-27T15:12:23.218414
Gregory Pond,gpond@mcmaster.ca,journal_articles,Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers,Supportive Care in Cancer,2022,10.1007/s00520-021-06714-8,https://experts.mcmaster.ca/display/publication2164523,2025-07-27T15:12:23.218415
Gregory Pond,gpond@mcmaster.ca,journal_articles,"The impact of preoperative imaging on wait times, surgical approach and overall survival in endometrioid endometrial cancers",Gynecologic Oncology,2022,10.1016/j.ygyno.2022.02.019,https://experts.mcmaster.ca/display/publication2172929,2025-07-27T15:12:23.218416
Gregory Pond,gpond@mcmaster.ca,journal_articles,Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis,BMJ Open,2022,10.1136/bmjopen-2021-055735,https://experts.mcmaster.ca/display/publication2232138,2025-07-27T15:12:23.218417
Gregory Pond,gpond@mcmaster.ca,journal_articles,Vasomotor symptoms in early breast cancer—a “real world” exploration of the patient experience,Supportive Care in Cancer,2022,10.1007/s00520-022-06848-3,https://experts.mcmaster.ca/display/publication2167703,2025-07-27T15:12:23.218418
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Abstract OT1-01-01: A randomized, pragmatic trial investigating the timing of radiotherapy and endocrine in patients with early stage breast cancer (REaCT-RETT trial)",Cancer Research,2022,10.1158/1538-7445.sabcs21-ot1-01-01,https://experts.mcmaster.ca/display/publication2552511,2025-07-27T15:12:23.218419
Gregory Pond,gpond@mcmaster.ca,journal_articles,Abstract OT1-06-01: A randomised trial comparing continuation or de-escalation of bone modifying agents (BMA) in patients treated for over 2 years for bone metastases from either breast or castration-resistant prostate cancer (REaCT-HOLD BMA),Cancer Research,2022,10.1158/1538-7445.sabcs21-ot1-06-01,https://experts.mcmaster.ca/display/publication2552510,2025-07-27T15:12:23.218420
Gregory Pond,gpond@mcmaster.ca,journal_articles,Abstract OT1-07-01: MRI screening versus symptom-directed surveillance for brain metastases among patients with triple negative or HER2+ metastatic breast cancer: A pilot study (nct03881605),Cancer Research,2022,10.1158/1538-7445.sabcs21-ot1-07-01,https://experts.mcmaster.ca/display/publication2552509,2025-07-27T15:12:23.218421
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Abstract OT1-11-02: A pragmatic, randomised, multicentre trial evaluating the dose timing (morning vs evening) of endocrine therapy and its effects on tolerability and compliance (REaCT-CHRONO Study)",Cancer Research,2022,10.1158/1538-7445.sabcs21-ot1-11-02,https://experts.mcmaster.ca/display/publication2552508,2025-07-27T15:12:23.218422
Gregory Pond,gpond@mcmaster.ca,journal_articles,Incidence and Predictors of Prosthetic Joint Infection Following Primary Total Knee Arthroplasty: A 15-Year Population-Based Cohort Study,Journal of Arthroplasty,2022,10.1016/j.arth.2021.10.006,https://experts.mcmaster.ca/display/publication2135419,2025-07-27T15:12:23.218422
Gregory Pond,gpond@mcmaster.ca,journal_articles,Metformin—A Thought-provoking Addition to Anticancer Therapies—Reply,JAMA Oncology,2022,10.1001/jamaoncol.2021.6729,https://experts.mcmaster.ca/display/publication2157294,2025-07-27T15:12:23.218423
Gregory Pond,gpond@mcmaster.ca,journal_articles,Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study,Blood Cancer Journal,2022,10.1038/s41408-021-00602-4,https://experts.mcmaster.ca/display/publication2165607,2025-07-27T15:12:23.218424
Gregory Pond,gpond@mcmaster.ca,journal_articles,A protocol for the VISION study: An indiVidual patient data meta-analysis of randomised trials comparing MRI-targeted biopsy to standard transrectal ultraSound guided bIopsy in the detection of prOstate cancer,PLoS ONE,2022,10.1371/journal.pone.0263345,https://experts.mcmaster.ca/display/publication2399906,2025-07-27T15:12:23.218425
Gregory Pond,gpond@mcmaster.ca,journal_articles,Abstract PO-142: Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancer,"Cancer Epidemiology, Biomarkers and Prevention",2022,10.1158/1538-7755.disp21-po-142,https://experts.mcmaster.ca/display/publication3446621,2025-07-27T15:12:23.218426
Gregory Pond,gpond@mcmaster.ca,journal_articles,A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer,Current Oncology,2021,10.3390/curroncol28060427,https://experts.mcmaster.ca/display/publication2161172,2025-07-27T15:12:23.218427
Gregory Pond,gpond@mcmaster.ca,journal_articles,A population-based analysis of spirometry use and the prevalence of chronic obstructive pulmonary disease in lung cancer,BMC Cancer,2021,10.1186/s12885-020-07719-y,https://experts.mcmaster.ca/display/publication1943953,2025-07-27T15:12:23.218428
Gregory Pond,gpond@mcmaster.ca,journal_articles,Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma,Clinical Genitourinary Cancer,2021,10.1016/j.clgc.2021.04.002,https://experts.mcmaster.ca/display/publication1969998,2025-07-27T15:12:23.218429
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration",BJU International,2021,10.1111/bju.15434,https://experts.mcmaster.ca/display/publication1967658,2025-07-27T15:12:23.218430
Gregory Pond,gpond@mcmaster.ca,journal_articles,Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey,Supportive Care in Cancer,2021,10.1007/s00520-021-06238-1,https://experts.mcmaster.ca/display/publication1969997,2025-07-27T15:12:23.218431
Gregory Pond,gpond@mcmaster.ca,journal_articles,100: The Role of FDG-PET in Staging and Treatment for Stage III NSCLC in Ontario between 2009-2017,Radiotherapy and Oncology,2021,10.1016/s0167-8140(21)08810-1,https://experts.mcmaster.ca/display/publication2552579,2025-07-27T15:12:23.218432
Gregory Pond,gpond@mcmaster.ca,journal_articles,Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors,Clinical Genitourinary Cancer,2021,10.1016/j.clgc.2021.04.008,https://experts.mcmaster.ca/display/publication1969240,2025-07-27T15:12:23.218433
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study",Breast Cancer Research and Treatment,2021,10.1007/s10549-021-06327-z,https://experts.mcmaster.ca/display/publication2048253,2025-07-27T15:12:23.218434
Gregory Pond,gpond@mcmaster.ca,journal_articles,Response to ‘Adverse cardiac outcomes in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors’,Heart,2021,10.1136/heartjnl-2021-319415,https://experts.mcmaster.ca/display/publication1985655,2025-07-27T15:12:23.218435
Gregory Pond,gpond@mcmaster.ca,journal_articles,Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer,Journal of Bone Oncology,2021,10.1016/j.jbo.2021.100388,https://experts.mcmaster.ca/display/publication2131450,2025-07-27T15:12:23.218436
Gregory Pond,gpond@mcmaster.ca,journal_articles,Hypofractionated Stereotactic Radiotherapy for the Treatment of Benign Intracranial Meningiomas: Long-Term Safety and Efficacy,Current Oncology,2021,10.3390/curroncol28050314,https://experts.mcmaster.ca/display/publication2133113,2025-07-27T15:12:23.218436
Gregory Pond,gpond@mcmaster.ca,journal_articles,Metformin in Combination With Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer,JAMA Oncology,2021,10.1001/jamaoncol.2021.2328,https://experts.mcmaster.ca/display/publication2048172,2025-07-27T15:12:23.218437
Gregory Pond,gpond@mcmaster.ca,journal_articles,Trajectory of Symptoms in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma: A Population-Based Cohort Study of Patient-Reported Outcomes,"Clinical Lymphoma, Myeloma and Leukemia",2021,10.1016/j.clml.2021.05.002,https://experts.mcmaster.ca/display/publication1977685,2025-07-27T15:12:23.218438
Gregory Pond,gpond@mcmaster.ca,journal_articles,A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia,Breast,2021,10.1016/j.breast.2021.03.012,https://experts.mcmaster.ca/display/publication1967433,2025-07-27T15:12:23.218439
Gregory Pond,gpond@mcmaster.ca,journal_articles,Risk Perception Among a Lung Cancer Screening Population,Chest,2021,10.1016/j.chest.2021.02.050,https://experts.mcmaster.ca/display/publication1960936,2025-07-27T15:12:23.218440
Gregory Pond,gpond@mcmaster.ca,journal_articles,Advancing Academic Cancer Clinical Trials Recruitment in Canada,Current Oncology,2021,10.3390/curroncol28040248,https://experts.mcmaster.ca/display/publication2122375,2025-07-27T15:12:23.218441
Gregory Pond,gpond@mcmaster.ca,journal_articles,Patterns of Relapse in Small Cell Lung Cancer: Competing Risks of Thoracic versus CNS Relapse,Current Oncology,2021,10.3390/curroncol28040243,https://experts.mcmaster.ca/display/publication2026282,2025-07-27T15:12:23.218442
Gregory Pond,gpond@mcmaster.ca,journal_articles,Comparative survival analysis of multiparametric tests—when molecular tests disagree—A TEAM Pathology study,npj Breast Cancer,2021,10.1038/s41523-021-00297-7,https://experts.mcmaster.ca/display/publication2010123,2025-07-27T15:12:23.218443
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Central Nervous System–Specific Outcomes of Phase 3 Randomized Clinical Trials in Patients With Advanced Breast Cancer, Lung Cancer, and Melanoma",JAMA Oncology,2021,10.1001/jamaoncol.2021.1359,https://experts.mcmaster.ca/display/publication1969996,2025-07-27T15:12:23.218444
Gregory Pond,gpond@mcmaster.ca,journal_articles,Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers,Breast Cancer Research and Treatment,2021,10.1007/s10549-021-06186-8,https://experts.mcmaster.ca/display/publication1986940,2025-07-27T15:12:23.218445
Gregory Pond,gpond@mcmaster.ca,journal_articles,Symptom burden in transplant-ineligible patients with newly diagnosed multiple myeloma: a population-based cohort study,Haematologica,2021,10.3324/haematol.2020.267757,https://experts.mcmaster.ca/display/publication1943448,2025-07-27T15:12:23.218446
Gregory Pond,gpond@mcmaster.ca,journal_articles,Outcomes in Elderly Patients with Glioblastoma Multiforme Treated with Short-Course Radiation Alone Compared to Short-Course Radiation and Concurrent and Adjuvant Temozolomide Based on Performance Status and Extent of Resection,Current Oncology,2021,10.3390/curroncol28040220,https://experts.mcmaster.ca/display/publication1986752,2025-07-27T15:12:23.218447
Gregory Pond,gpond@mcmaster.ca,journal_articles,A randomized clinical trial comparing physician-directed or fixed-dose steroid replacement strategies for incomplete dexamethasone dosing prior to docetaxel chemotherapy,Supportive Care in Cancer,2021,10.1007/s00520-020-05791-5,https://experts.mcmaster.ca/display/publication1935975,2025-07-27T15:12:23.218448
Gregory Pond,gpond@mcmaster.ca,journal_articles,Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey,Breast Cancer Research and Treatment,2021,10.1007/s10549-021-06147-1,https://experts.mcmaster.ca/display/publication1964800,2025-07-27T15:12:23.218449
Gregory Pond,gpond@mcmaster.ca,journal_articles,EPCT-11. RURALITY INDEX SCORE AND PEDIATRIC NEURO-ONCOLOGICAL OUTCOME IN ONTARIO,Neuro-Oncology,2021,10.1093/neuonc/noab090.197,https://experts.mcmaster.ca/display/publication1977683,2025-07-27T15:12:23.218450
Gregory Pond,gpond@mcmaster.ca,journal_articles,EPCT-11. RURALITY INDEX SCORE AND PEDIATRIC NEURO-ONCOLOGICAL OUTCOME IN ONTARIO,Neuro-Oncology,2021,,https://experts.mcmaster.ca/display/publication2182123,2025-07-27T15:12:23.218451
Gregory Pond,gpond@mcmaster.ca,journal_articles,External validation of the FIRST trial’s simplified frailty score in a population-based cohort,Leukemia,2021,10.1038/s41375-021-01247-9,https://experts.mcmaster.ca/display/publication1966165,2025-07-27T15:12:23.218452
Gregory Pond,gpond@mcmaster.ca,journal_articles,Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer,Current Oncology,2021,10.3390/curroncol28030171,https://experts.mcmaster.ca/display/publication1977684,2025-07-27T15:12:23.218453
Gregory Pond,gpond@mcmaster.ca,journal_articles,Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: A population-based study,Journal of Geriatric Oncology,2021,10.1016/j.jgo.2020.10.009,https://experts.mcmaster.ca/display/publication1936314,2025-07-27T15:12:23.218456
Gregory Pond,gpond@mcmaster.ca,journal_articles,The use of imaging in endometrial cancer prior to potential surgery: Are guidelines being followed?,Gynecologic Oncology,2021,10.1016/j.ygyno.2021.02.021,https://experts.mcmaster.ca/display/publication1963836,2025-07-27T15:12:23.218458
Gregory Pond,gpond@mcmaster.ca,journal_articles,Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation,Journal of Bone Oncology,2021,10.1016/j.jbo.2021.100351,https://experts.mcmaster.ca/display/publication1961793,2025-07-27T15:12:23.218459
Gregory Pond,gpond@mcmaster.ca,journal_articles,Comparison of Multiparametric Magnetic Resonance Imaging–Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer,JAMA Oncology,2021,10.1001/jamaoncol.2020.7589,https://experts.mcmaster.ca/display/publication1959552,2025-07-27T15:12:23.218460
Gregory Pond,gpond@mcmaster.ca,journal_articles,Errors in Author Names and Affiliations.,JAMA Oncology,2021,10.1001/jamaoncol.2021.0685,https://experts.mcmaster.ca/display/publication3512508,2025-07-27T15:12:23.218461
Gregory Pond,gpond@mcmaster.ca,journal_articles,Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease,Heart,2021,10.1136/heartjnl-2020-318251,https://experts.mcmaster.ca/display/publication1944366,2025-07-27T15:12:23.218461
Gregory Pond,gpond@mcmaster.ca,journal_articles,Abstract PS14-18: A physician survey evaluating real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast cancer,Cancer Research,2021,10.1158/1538-7445.sabcs20-ps14-18,https://experts.mcmaster.ca/display/publication2552513,2025-07-27T15:12:23.218463
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer",Journal of Bone Oncology,2021,10.1016/j.jbo.2020.100343,https://experts.mcmaster.ca/display/publication1944125,2025-07-27T15:12:23.218464
Gregory Pond,gpond@mcmaster.ca,journal_articles,Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey,Journal of Bone Oncology,2021,10.1016/j.jbo.2020.100339,https://experts.mcmaster.ca/display/publication1941192,2025-07-27T15:12:23.218465
Gregory Pond,gpond@mcmaster.ca,journal_articles,A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer,European Journal of Cancer,2021,10.1016/j.ejca.2020.08.019,https://experts.mcmaster.ca/display/publication1934325,2025-07-27T15:12:23.218466
Gregory Pond,gpond@mcmaster.ca,journal_articles,Management and outcomes of patients with chronic obstructive lung disease and lung cancer in a public healthcare system,PLoS ONE,2021,10.1371/journal.pone.0251886,https://experts.mcmaster.ca/display/publication1969149,2025-07-27T15:12:23.218466
Gregory Pond,gpond@mcmaster.ca,journal_articles,Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging,Advances in Radiation Oncology,2021,10.1016/j.adro.2020.08.010,https://experts.mcmaster.ca/display/publication1936582,2025-07-27T15:12:23.218467
Gregory Pond,gpond@mcmaster.ca,journal_articles,A Randomized Controlled Trial Comparing Alloderm-RTU with DermACELL in Immediate Subpectoral Implant-Based Breast Reconstruction,Current Oncology,2020,10.3390/curroncol28010020,https://experts.mcmaster.ca/display/publication1961792,2025-07-27T15:12:23.218468
Gregory Pond,gpond@mcmaster.ca,journal_articles,Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population,BMC Pulmonary Medicine,2020,10.1186/s12890-020-01344-y,https://experts.mcmaster.ca/display/publication1937780,2025-07-27T15:12:23.218469
Gregory Pond,gpond@mcmaster.ca,journal_articles,Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors,Investigative Urology,2020,10.1097/ju.0000000000001199,https://experts.mcmaster.ca/display/publication1915666,2025-07-27T15:12:23.218470
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Assessment of spring water quality in Jhimruk River Watershed, Lesser Himalaya, Nepal",Environmental Earth Sciences,2020,10.1007/s12665-020-09252-4,https://experts.mcmaster.ca/display/publication3274101,2025-07-27T15:12:23.218471
Gregory Pond,gpond@mcmaster.ca,journal_articles,Disparities in surgical management of endometrial cancers in a public healthcare system: A question of equity,Gynecologic Oncology,2020,10.1016/j.ygyno.2020.08.029,https://experts.mcmaster.ca/display/publication1925967,2025-07-27T15:12:23.218472
Gregory Pond,gpond@mcmaster.ca,journal_articles,Geriatric assessment and quality of life changes in older adults with newly diagnosed multiple myeloma undergoing treatment,Journal of Geriatric Oncology,2020,10.1016/j.jgo.2020.05.004,https://experts.mcmaster.ca/display/publication1913221,2025-07-27T15:12:23.218473
Gregory Pond,gpond@mcmaster.ca,journal_articles,Investigating the appropriateness of different concordance measures in a time‐to‐event setting,Pharmaceutical Statistics,2020,10.1002/pst.2029,https://experts.mcmaster.ca/display/publication1906774,2025-07-27T15:12:23.218474
Gregory Pond,gpond@mcmaster.ca,journal_articles,Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study,European urology oncology,2020,10.1016/j.euo.2019.02.004,https://experts.mcmaster.ca/display/publication1660050,2025-07-27T15:12:23.218475
Gregory Pond,gpond@mcmaster.ca,journal_articles,Oncologists and Medical Assistance in Dying: Where Do We Stand? Results of a National Survey of Canadian Oncologists,Current Oncology,2020,10.3747/co.27.6295,https://experts.mcmaster.ca/display/publication1936651,2025-07-27T15:12:23.218476
Gregory Pond,gpond@mcmaster.ca,journal_articles,Oncologists and Medical Assistance in Dying: Where Do We Stand? Results of a National Survey of Canadian Oncologists.,Current Oncology,2020,10.3747/co.27.6295,https://experts.mcmaster.ca/display/publication1961663,2025-07-27T15:12:23.218477
Gregory Pond,gpond@mcmaster.ca,journal_articles,212: Cardiac Morbidity Following Radical Thoracic Chemoradiotherapy for Locally Advanced Lung Cancer: A Population-Based Cohort Study,Radiotherapy and Oncology,2020,10.1016/s0167-8140(20)31104-x,https://experts.mcmaster.ca/display/publication2552515,2025-07-27T15:12:23.218478
Gregory Pond,gpond@mcmaster.ca,journal_articles,"77: Dosimetric Comparison of Conformal Radiation Therapy (Crt), Imrt and Vmat for Esophageal Cancer Treated with External Radiation",Radiotherapy and Oncology,2020,10.1016/s0167-8140(20)30969-5,https://experts.mcmaster.ca/display/publication2552514,2025-07-27T15:12:23.218479
Gregory Pond,gpond@mcmaster.ca,journal_articles,Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials,European urology oncology,2020,10.1016/j.euo.2018.11.006,https://experts.mcmaster.ca/display/publication1660236,2025-07-27T15:12:23.218480
Gregory Pond,gpond@mcmaster.ca,journal_articles,"A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer",Annals of Oncology,2020,10.1016/j.annonc.2020.04.005,https://experts.mcmaster.ca/display/publication1746660,2025-07-27T15:12:23.218481
Gregory Pond,gpond@mcmaster.ca,journal_articles,Endometrial cancer presentation is associated with social determinants of health in a public healthcare system: A population-based cohort study,Gynecologic Oncology,2020,10.1016/j.ygyno.2020.04.693,https://experts.mcmaster.ca/display/publication1840302,2025-07-27T15:12:23.218482
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Erratum to: Liu W, Zukotynski K, Emmett L, Chung HT, Chung P, Wolfson R, Rachinsky I, Kapoor A, Metser U, Loblaw A, Morton G, Sexton T, Lock M, Helou J, Berlin A, Boylan C, Archer S, Pond GR, Bauman G. A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. Int J Radiat Oncol Biol Phys 2020;106:546-555.",International Journal of Radiation Oncology Biology Physics,2020,10.1016/j.ijrobp.2020.02.632,https://experts.mcmaster.ca/display/publication1910928,2025-07-27T15:12:23.218482
Gregory Pond,gpond@mcmaster.ca,journal_articles,A multicenter study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of taxotere/cyclophosphamide-induced febrile neutropenia in patients with early-stage breast cancer.,Journal of Clinical Oncology,2020,10.1200/jco.2020.38.15_suppl.7001,https://experts.mcmaster.ca/display/publication1977690,2025-07-27T15:12:23.218484
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Dissecting outcomes of patients (pts) with <ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration.",Journal of Clinical Oncology,2020,10.1200/jco.2020.38.15_suppl.5043,https://experts.mcmaster.ca/display/publication1977692,2025-07-27T15:12:23.218484
Gregory Pond,gpond@mcmaster.ca,journal_articles,Impact of concurrent angiotensin inhibitors on outcomes with PD1/L1 inhibitors for patients (pts) with metastatic urothelial carcinoma (mUC).,Journal of Clinical Oncology,2020,10.1200/jco.2020.38.15_suppl.e17044,https://experts.mcmaster.ca/display/publication1977689,2025-07-27T15:12:23.218485
Gregory Pond,gpond@mcmaster.ca,journal_articles,Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV): Emergence of a new unmet need.,Journal of Clinical Oncology,2020,10.1200/jco.2020.38.15_suppl.5048,https://experts.mcmaster.ca/display/publication1977691,2025-07-27T15:12:23.218486
Gregory Pond,gpond@mcmaster.ca,journal_articles,High triple‐negative breast cancer prevalence and aggressive prognostic factors in Barbadian women with breast cancer,Cancer,2020,10.1002/cncr.32771,https://experts.mcmaster.ca/display/publication1698156,2025-07-27T15:12:23.218487
Gregory Pond,gpond@mcmaster.ca,journal_articles,Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer,Journal of the Canadian Urological Association,2020,10.5489/cuaj.5945,https://experts.mcmaster.ca/display/publication1676788,2025-07-27T15:12:23.218488
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Routine Imaging or No Routine Imaging, Is That the Question?",Journal of the National Comprehensive Cancer Network : JNCCN,2020,10.6004/jnccn.2020.7556,https://experts.mcmaster.ca/display/publication1813255,2025-07-27T15:12:23.218489
Gregory Pond,gpond@mcmaster.ca,journal_articles,Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study,Clinical Trials,2020,10.1177/1740774519895966,https://experts.mcmaster.ca/display/publication1686904,2025-07-27T15:12:23.218490
Gregory Pond,gpond@mcmaster.ca,journal_articles,Risk Factors for Periprosthetic Joint Infection Following Primary Total Hip Arthroplasty,Journal of Bone and Joint Surgery. American volume,2020,10.2106/jbjs.19.00537,https://experts.mcmaster.ca/display/publication1910812,2025-07-27T15:12:23.218491
Gregory Pond,gpond@mcmaster.ca,journal_articles,A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy,International Journal of Radiation Oncology Biology Physics,2020,10.1016/j.ijrobp.2019.11.001,https://experts.mcmaster.ca/display/publication1680484,2025-07-27T15:12:23.218492
Gregory Pond,gpond@mcmaster.ca,journal_articles,Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors,Journal for ImmunoTherapy of Cancer,2020,10.1136/jitc-2019-000371,https://experts.mcmaster.ca/display/publication1701891,2025-07-27T15:12:23.218493
Gregory Pond,gpond@mcmaster.ca,journal_articles,Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up,European Urology,2020,10.1016/j.eururo.2019.10.007,https://experts.mcmaster.ca/display/publication1676961,2025-07-27T15:12:23.218494
Gregory Pond,gpond@mcmaster.ca,journal_articles,The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer.,npj Breast Cancer,2020,10.1038/s41523-020-0149-z,https://experts.mcmaster.ca/display/publication1959551,2025-07-27T15:12:23.218495
Gregory Pond,gpond@mcmaster.ca,journal_articles,A comparison of combined immune checkpoint inhibitors (IO) versus vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in the treatment of advanced clear cell renal cell carcinoma.,Journal of Clinical Oncology,2020,10.1200/jco.2020.38.6_suppl.692,https://experts.mcmaster.ca/display/publication1973954,2025-07-27T15:12:23.218496
Gregory Pond,gpond@mcmaster.ca,journal_articles,Any regression of tumor (ART) within 12 weeks versus RECIST 1.1 response category as an intermediate endpoint to assess the activity of immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC).,Journal of Clinical Oncology,2020,10.1200/jco.2020.38.6_suppl.473,https://experts.mcmaster.ca/display/publication1977694,2025-07-27T15:12:23.218497
Gregory Pond,gpond@mcmaster.ca,journal_articles,Conditional immune adverse event rate in urothelial and renal cell carcinoma patients treated with immune checkpoint inhibitors.,Journal of Clinical Oncology,2020,10.1200/jco.2020.38.6_suppl.481,https://experts.mcmaster.ca/display/publication1977695,2025-07-27T15:12:23.218497
Gregory Pond,gpond@mcmaster.ca,journal_articles,Impact of histology and toxicities on outcomes of patients with muscle invasive bladder cancer receiving neoadjuvant chemotherapy.,Journal of Clinical Oncology,2020,10.1200/jco.2020.38.6_suppl.540,https://experts.mcmaster.ca/display/publication1977497,2025-07-27T15:12:23.218498
Gregory Pond,gpond@mcmaster.ca,journal_articles,SALVO: Single-arm phase II study of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.,Journal of Clinical Oncology,2020,10.1200/jco.2020.38.5_suppl.tps65,https://experts.mcmaster.ca/display/publication1977706,2025-07-27T15:12:23.218499
Gregory Pond,gpond@mcmaster.ca,journal_articles,Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic Information,Clinical Breast Cancer,2020,10.1016/j.clbc.2019.07.006,https://experts.mcmaster.ca/display/publication1669545,2025-07-27T15:12:23.218500
Gregory Pond,gpond@mcmaster.ca,journal_articles,The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer,npj Breast Cancer,2020,10.1038/s41523-020-0149-z,https://experts.mcmaster.ca/display/publication1697201,2025-07-27T15:12:23.218501
Gregory Pond,gpond@mcmaster.ca,journal_articles,The impact of synchronous malignancies on survival in patients with early stage curable non-small-cell lung cancer,Cancer Treatment and Research Communications,2020,10.1016/j.ctarc.2020.100246,https://experts.mcmaster.ca/display/publication1940154,2025-07-27T15:12:23.218502
Gregory Pond,gpond@mcmaster.ca,journal_articles,A Phase II Multi-institutional Clinical Trial Assessing Fractionated Simultaneous In-Field Boost Radiotherapy for Brain Oligometastases,Cureus,2019,10.7759/cureus.6394,https://experts.mcmaster.ca/display/publication1688116,2025-07-27T15:12:23.218503
Gregory Pond,gpond@mcmaster.ca,journal_articles,Learning Health System for Breast Cancer: Pilot Project Experience,JCO clinical cancer informatics,2019,10.1200/cci.19.00032,https://experts.mcmaster.ca/display/publication1656916,2025-07-27T15:12:23.218504
Gregory Pond,gpond@mcmaster.ca,journal_articles,Age-Related Survival Differences in Patients With Inflammatory Bowel Disease–Associated Colorectal Cancer: A Population-Based Cohort Study,Inflammatory Bowel Diseases,2019,10.1093/ibd/izz088,https://experts.mcmaster.ca/display/publication1640997,2025-07-27T15:12:23.218505
Gregory Pond,gpond@mcmaster.ca,journal_articles,"A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients",Breast Cancer Research and Treatment,2019,10.1007/s10549-019-05381-y,https://experts.mcmaster.ca/display/publication1658924,2025-07-27T15:12:23.218506
Gregory Pond,gpond@mcmaster.ca,journal_articles,Is Access to Care Associated With Stage at Presentation and Survival for Melanoma Patients?,Journal of Cutaneous Medicine and Surgery,2019,10.1177/1203475419870177,https://experts.mcmaster.ca/display/publication1663318,2025-07-27T15:12:23.218507
Gregory Pond,gpond@mcmaster.ca,journal_articles,Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients,Breast Cancer Research and Treatment,2019,10.1007/s10549-019-05392-9,https://experts.mcmaster.ca/display/publication1660237,2025-07-27T15:12:23.218508
Gregory Pond,gpond@mcmaster.ca,journal_articles,105 Cyberknife Stereotactic Radiosurgery for Treatment of Benign Intracranial Meningioma: Long-Term Safety and Efficacy,Radiotherapy and Oncology,2019,10.1016/s0167-8140(19)33155-x,https://experts.mcmaster.ca/display/publication2552531,2025-07-27T15:12:23.218509
Gregory Pond,gpond@mcmaster.ca,journal_articles,122 A Comparison of Radiation Techniques in Patients Treated with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer,Radiotherapy and Oncology,2019,10.1016/s0167-8140(19)33174-3,https://experts.mcmaster.ca/display/publication2552580,2025-07-27T15:12:23.218510
Gregory Pond,gpond@mcmaster.ca,journal_articles,Changes in Soft-Tissue Sarcoma Treatment Patterns over Time: A Population-Based Study in a Country with Universal and Centralized Healthcare,Sarcoma,2019,10.1155/2019/8409406,https://experts.mcmaster.ca/display/publication1672911,2025-07-27T15:12:23.218510
Gregory Pond,gpond@mcmaster.ca,journal_articles,The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of18F-Fluoromethylcholine or68Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy,Journal of Nuclear Medicine,2019,10.2967/jnumed.118.225185,https://experts.mcmaster.ca/display/publication1635956,2025-07-27T15:12:23.218511
Gregory Pond,gpond@mcmaster.ca,journal_articles,MEDiastinal Irradiation and CArdio-Toxic Effects (MEDICATE): Exploring the Relationship between Cardiac Irradiation and High Sensitivity Troponins,Clinical Oncology,2019,10.1016/j.clon.2019.04.003,https://experts.mcmaster.ca/display/publication1639721,2025-07-27T15:12:23.218512
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Prospective, Multisite, International Comparison of18F-Fluoromethylcholine PET/CT, Multiparametric MRI, and68Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes",Journal of Nuclear Medicine,2019,10.2967/jnumed.118.220103,https://experts.mcmaster.ca/display/publication1609666,2025-07-27T15:12:23.218513
Gregory Pond,gpond@mcmaster.ca,journal_articles,"A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration-resistant prostate cancer.",Journal of Clinical Oncology,2019,10.1200/jco.2019.37.15_suppl.11501,https://experts.mcmaster.ca/display/publication1973493,2025-07-27T15:12:23.218514
Gregory Pond,gpond@mcmaster.ca,journal_articles,Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).,Journal of Clinical Oncology,2019,10.1200/jco.2019.37.15_suppl.e16038,https://experts.mcmaster.ca/display/publication1977709,2025-07-27T15:12:23.218515
Gregory Pond,gpond@mcmaster.ca,journal_articles,"A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases",Annals of Oncology,2019,10.1093/annonc/mdz118.002,https://experts.mcmaster.ca/display/publication2552532,2025-07-27T15:12:23.218516
Gregory Pond,gpond@mcmaster.ca,journal_articles,Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer,Cancer,2019,10.1002/cncr.31959,https://experts.mcmaster.ca/display/publication1618990,2025-07-27T15:12:23.218517
Gregory Pond,gpond@mcmaster.ca,journal_articles,A prospective intervention to improve happiness and reduce burnout in oncologists,Supportive Care in Cancer,2019,10.1007/s00520-018-4567-5,https://experts.mcmaster.ca/display/publication1612273,2025-07-27T15:12:23.218518
Gregory Pond,gpond@mcmaster.ca,journal_articles,Methods to improve the estimation of time‐to‐event outcomes when data is de‐identified,Statistics in Medicine,2019,10.1002/sim.7990,https://experts.mcmaster.ca/display/publication1600009,2025-07-27T15:12:23.218519
Gregory Pond,gpond@mcmaster.ca,journal_articles,Abstract PD6-04: Lifestyle intervention study (LISA) in early breast cancer (BC): An RCT of the effects of a telephone-based weight loss intervention (with educational materials) vs educational materials alone on disease-free survival (DFS),Cancer Research,2019,10.1158/1538-7445.sabcs18-pd6-04,https://experts.mcmaster.ca/display/publication2552533,2025-07-27T15:12:23.218520
Gregory Pond,gpond@mcmaster.ca,journal_articles,A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer,Brain Imaging and Behavior,2019,10.1007/s11682-017-9728-5,https://experts.mcmaster.ca/display/publication276870,2025-07-27T15:12:23.218521
Gregory Pond,gpond@mcmaster.ca,journal_articles,Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial,European Urology,2019,10.1016/j.eururo.2018.06.025,https://experts.mcmaster.ca/display/publication1570370,2025-07-27T15:12:23.218522
Gregory Pond,gpond@mcmaster.ca,journal_articles,Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer,Clinical Genitourinary Cancer,2019,10.1016/j.clgc.2018.09.008,https://experts.mcmaster.ca/display/publication1600089,2025-07-27T15:12:23.218523
Gregory Pond,gpond@mcmaster.ca,journal_articles,Early initiation of palliative care is associated with reduced late-life acute-hospital use: A population-based retrospective cohort study,Palliative Medicine,2019,10.1177/0269216318815794,https://experts.mcmaster.ca/display/publication1612272,2025-07-27T15:12:23.218524
Gregory Pond,gpond@mcmaster.ca,journal_articles,Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology,Journal of the National Cancer Institute,2019,10.1093/jnci/djy196,https://experts.mcmaster.ca/display/publication1615461,2025-07-27T15:12:23.218525
Gregory Pond,gpond@mcmaster.ca,journal_articles,Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer,American Journal of Clinical Oncology,2019,10.1097/coc.0000000000000474,https://experts.mcmaster.ca/display/publication1561494,2025-07-27T15:12:23.218526
Gregory Pond,gpond@mcmaster.ca,journal_articles,Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist’s Perspective from a Multicentre Study,European Urology Focus,2018,10.1016/j.euf.2017.03.011,https://experts.mcmaster.ca/display/publication1324576,2025-07-27T15:12:23.218527
Gregory Pond,gpond@mcmaster.ca,journal_articles,Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate,European Urology Focus,2018,10.1016/j.euf.2017.03.015,https://experts.mcmaster.ca/display/publication1322122,2025-07-27T15:12:23.218528
Gregory Pond,gpond@mcmaster.ca,journal_articles,Teaching Residents how to Effectively Prescribe Nicotine Replacement Therapy on the Clinical Teaching Unit,Canadian Journal of General Internal Medicine,2018,10.22374/cjgim.v13i4.271,https://experts.mcmaster.ca/display/publication1977719,2025-07-27T15:12:23.218529
Gregory Pond,gpond@mcmaster.ca,journal_articles,RBTT-04. DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS,Neuro-Oncology,2018,10.1093/neuonc/noy148.974,https://experts.mcmaster.ca/display/publication1977720,2025-07-27T15:12:23.218530
Gregory Pond,gpond@mcmaster.ca,journal_articles,RBTT-04. DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS,Neuro-Oncology,2018,,https://experts.mcmaster.ca/display/publication3224552,2025-07-27T15:12:23.218531
Gregory Pond,gpond@mcmaster.ca,journal_articles,Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study,Breast Cancer Research and Treatment,2018,10.1007/s10549-018-4844-5,https://experts.mcmaster.ca/display/publication1556003,2025-07-27T15:12:23.218532
Gregory Pond,gpond@mcmaster.ca,journal_articles,Outcomes of Adjuvant Therapy for Stage IA Serous Endometrial Cancer,Cureus,2018,10.7759/cureus.3387,https://experts.mcmaster.ca/display/publication1613991,2025-07-27T15:12:23.218533
Gregory Pond,gpond@mcmaster.ca,journal_articles,Effect of Positron Emission Tomography Imaging in Women With Locally Advanced Cervical Cancer,JAMA network open,2018,10.1001/jamanetworkopen.2018.2081,https://experts.mcmaster.ca/display/publication1620829,2025-07-27T15:12:23.218533
Gregory Pond,gpond@mcmaster.ca,journal_articles,Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma: a validation study using the COMPARZ cohort,World Journal of Urology,2018,10.1007/s00345-018-2297-4,https://experts.mcmaster.ca/display/publication1521843,2025-07-27T15:12:23.218534
Gregory Pond,gpond@mcmaster.ca,journal_articles,Pretreatment neurocognitive function and self‐reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort,Head and Neck,2018,10.1002/hed.25198,https://experts.mcmaster.ca/display/publication1521842,2025-07-27T15:12:23.218535
Gregory Pond,gpond@mcmaster.ca,journal_articles,Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study,Supportive Care in Cancer,2018,10.1007/s00520-018-4161-x,https://experts.mcmaster.ca/display/publication1521845,2025-07-27T15:12:23.218536
Gregory Pond,gpond@mcmaster.ca,journal_articles,Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy,Clinical Genitourinary Cancer,2018,10.1016/j.clgc.2018.03.016,https://experts.mcmaster.ca/display/publication1518753,2025-07-27T15:12:23.218537
Gregory Pond,gpond@mcmaster.ca,journal_articles,Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab,Breast Cancer Research and Treatment,2018,10.1007/s10549-018-4734-x,https://experts.mcmaster.ca/display/publication1521846,2025-07-27T15:12:23.218538
Gregory Pond,gpond@mcmaster.ca,journal_articles,Uncertain times: A survey of Canadian women's perspectives toward mammography screening,Preventive Medicine,2018,10.1016/j.ypmed.2018.04.021,https://experts.mcmaster.ca/display/publication1512354,2025-07-27T15:12:23.218539
Gregory Pond,gpond@mcmaster.ca,journal_articles,41 Does exercise improve progression free survival (PFS) and quality of life (QOL) in patients with glioblastoma? A trial in progress,Canadian Journal of Neurological Sciences,2018,10.1017/cjn.2018.282,https://experts.mcmaster.ca/display/publication2552534,2025-07-27T15:12:23.218540
Gregory Pond,gpond@mcmaster.ca,journal_articles,Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis,"Cancer Epidemiology, Biomarkers and Prevention",2018,10.1158/1055-9965.epi-17-0936,https://experts.mcmaster.ca/display/publication1513416,2025-07-27T15:12:23.218541
Gregory Pond,gpond@mcmaster.ca,journal_articles,Association of circulating tumor (ct)-DNA genomic alterations (GA) with outcomes in metastatic urothelial carcinoma (mUC).,Journal of Clinical Oncology,2018,10.1200/jco.2018.36.15_suppl.4540,https://experts.mcmaster.ca/display/publication1977713,2025-07-27T15:12:23.218542
Gregory Pond,gpond@mcmaster.ca,journal_articles,Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA,Cancer,2018,10.1002/cncr.31314,https://experts.mcmaster.ca/display/publication1521847,2025-07-27T15:12:23.218543
Gregory Pond,gpond@mcmaster.ca,journal_articles,Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study,Oncotarget,2018,10.18632/oncotarget.24888,https://experts.mcmaster.ca/display/publication1521744,2025-07-27T15:12:23.218544
Gregory Pond,gpond@mcmaster.ca,journal_articles,Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population,Clinical Genitourinary Cancer,2018,10.1016/j.clgc.2017.10.012,https://experts.mcmaster.ca/display/publication1521824,2025-07-27T15:12:23.218545
Gregory Pond,gpond@mcmaster.ca,journal_articles,Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies,Clinical Genitourinary Cancer,2018,10.1016/j.clgc.2017.12.006,https://experts.mcmaster.ca/display/publication1521807,2025-07-27T15:12:23.218546
Gregory Pond,gpond@mcmaster.ca,journal_articles,Perceived cognitive impairment in people with colorectal cancer who do and do not receive chemotherapy,Journal of Cancer Survivorship,2018,10.1007/s11764-017-0656-6,https://experts.mcmaster.ca/display/publication1521767,2025-07-27T15:12:23.218546
Gregory Pond,gpond@mcmaster.ca,journal_articles,Quality of preoperative pelvic computed tomography (CT) and magnetic resonance imaging (MRI) for rectal cancer in a region in Ontario: A retrospective population‐based study,Journal of Surgical Oncology,2018,10.1002/jso.25000,https://experts.mcmaster.ca/display/publication1500852,2025-07-27T15:12:23.218547
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Active surveillance magnetic resonance imaging study (ASIST): Results of a prospective, multicentre, randomized trial",European Urology Open Science,2018,10.1016/s1569-9056(18)32038-4,https://experts.mcmaster.ca/display/publication2552536,2025-07-27T15:12:23.218548
Gregory Pond,gpond@mcmaster.ca,journal_articles,Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer,Journal of Bone Oncology,2018,10.1016/j.jbo.2017.11.001,https://experts.mcmaster.ca/display/publication1482941,2025-07-27T15:12:23.218549
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study",European Urology Open Science,2018,10.1016/s1569-9056(18)31209-0,https://experts.mcmaster.ca/display/publication2552535,2025-07-27T15:12:23.218550
Gregory Pond,gpond@mcmaster.ca,journal_articles,Abstract P3-08-12: Prognostic relevance of neutrophil-to-lymphocyte ratio (NLR) in young women with breast cancer (BC),Cancer Research,2018,10.1158/1538-7445.sabcs17-p3-08-12,https://experts.mcmaster.ca/display/publication2552537,2025-07-27T15:12:23.218551
Gregory Pond,gpond@mcmaster.ca,journal_articles,"C-statistic: A brief explanation of its construction, interpretation and limitations",European Journal of Cancer,2018,10.1016/j.ejca.2017.10.027,https://experts.mcmaster.ca/display/publication1498520,2025-07-27T15:12:23.218552
Gregory Pond,gpond@mcmaster.ca,journal_articles,Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer,JAMA Otolaryngology - Head and Neck Surgery,2018,10.1001/jamaoto.2017.2235,https://experts.mcmaster.ca/display/publication1495645,2025-07-27T15:12:23.218553
Gregory Pond,gpond@mcmaster.ca,journal_articles,Outcome analysis of visual acuity and side effect after ruthenium-106 plaque brachytherapy for medium-sized choroidal melanoma,Middle East African Journal of Ophthalmology,2018,10.4103/meajo.meajo_198_16,https://experts.mcmaster.ca/display/publication1586591,2025-07-27T15:12:23.218554
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer",ESMO Open,2018,10.1136/esmoopen-2017-000302,https://experts.mcmaster.ca/display/publication1521844,2025-07-27T15:12:23.218555
Gregory Pond,gpond@mcmaster.ca,journal_articles,Validation of a modified VOICES survey to measure end-of-life care quality: the CaregiverVoice survey,BMC Palliative Care,2017,10.1186/s12904-017-0227-7,https://experts.mcmaster.ca/display/publication1449814,2025-07-27T15:12:23.218556
Gregory Pond,gpond@mcmaster.ca,journal_articles,Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421,Clinical Genitourinary Cancer,2017,10.1016/j.clgc.2017.05.014,https://experts.mcmaster.ca/display/publication335908,2025-07-27T15:12:23.218557
Gregory Pond,gpond@mcmaster.ca,journal_articles,Association between the Lynch syndrome gene MSH2 and breast cancer susceptibility in a Canadian familial cancer registry,Journal of Medical Genetics,2017,10.1136/jmedgenet-2017-104542,https://experts.mcmaster.ca/display/publication1431023,2025-07-27T15:12:23.218558
Gregory Pond,gpond@mcmaster.ca,journal_articles,Pattern of relapse after perioperative chemotherapy and radical cystectomy versus radical cystectomy alone in patients with muscle-invasive bladder cancer (MIBC): A multicenter study,European Urology Open Science,2017,10.1016/s1569-9056(17)31923-1,https://experts.mcmaster.ca/display/publication2552538,2025-07-27T15:12:23.218559
Gregory Pond,gpond@mcmaster.ca,journal_articles,Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis,Clinical Genitourinary Cancer,2017,10.1016/j.clgc.2017.02.002,https://experts.mcmaster.ca/display/publication1521825,2025-07-27T15:12:23.218560
Gregory Pond,gpond@mcmaster.ca,journal_articles,Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population,Annals of Oncology,2017,10.1093/annonc/mdx371.029,https://experts.mcmaster.ca/display/publication1977714,2025-07-27T15:12:23.218560
Gregory Pond,gpond@mcmaster.ca,journal_articles,Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials,Oncotarget,2017,10.18632/oncotarget.17496,https://experts.mcmaster.ca/display/publication276868,2025-07-27T15:12:23.218561
Gregory Pond,gpond@mcmaster.ca,journal_articles,Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials.,Oncotarget,2017,10.18632/oncotarget.17496,https://experts.mcmaster.ca/display/publication1458392,2025-07-27T15:12:23.218562
Gregory Pond,gpond@mcmaster.ca,journal_articles,A Novel Neoadjuvant Therapy for Operable Locally Invasive Non–Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574),Clinical Lung Cancer,2017,10.1016/j.cllc.2017.01.007,https://experts.mcmaster.ca/display/publication177512,2025-07-27T15:12:23.218563
Gregory Pond,gpond@mcmaster.ca,journal_articles,PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide,Medicine (United States),2017,10.1097/md.0000000000006817,https://experts.mcmaster.ca/display/publication276867,2025-07-27T15:12:23.218564
Gregory Pond,gpond@mcmaster.ca,journal_articles,"A randomized, double-blind, placebo-controlled window of opportunity trial evaluating clinical effects of high dose vitamin D in patients with breast cancer",Annals of Oncology,2017,10.1093/annonc/mdx142.004,https://experts.mcmaster.ca/display/publication2552539,2025-07-27T15:12:23.218565
Gregory Pond,gpond@mcmaster.ca,journal_articles,A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors,Clinical Genitourinary Cancer,2017,10.1016/j.clgc.2016.07.022,https://experts.mcmaster.ca/display/publication1521799,2025-07-27T15:12:23.218566
Gregory Pond,gpond@mcmaster.ca,journal_articles,A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors,Clinical Genitourinary Cancer,2017,10.1016/j.clgc.2016.07.022,https://experts.mcmaster.ca/display/publication1521848,2025-07-27T15:12:23.218567
Gregory Pond,gpond@mcmaster.ca,journal_articles,Comparative Survival in Patients with Brain Metastases from Non-small-Cell Lung Cancer Treated before and after Implementation of Radiosurgery,Current Oncology,2017,10.3747/co.24.3420,https://experts.mcmaster.ca/display/publication276869,2025-07-27T15:12:23.218568
Gregory Pond,gpond@mcmaster.ca,journal_articles,Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)‐1 orPDligand 1 inhibitor therapy,BJU International,2017,10.1111/bju.13674,https://experts.mcmaster.ca/display/publication1521826,2025-07-27T15:12:23.218569
Gregory Pond,gpond@mcmaster.ca,journal_articles,Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer,Prostate Cancer and Prostatic Diseases,2017,10.1038/pcan.2016.44,https://experts.mcmaster.ca/display/publication310535,2025-07-27T15:12:23.218570
Gregory Pond,gpond@mcmaster.ca,journal_articles,Circulating tumor (ct)-DNA alterations in advanced urothelial carcinoma: Association with outcomes and evolution with therapy.,Journal of Clinical Oncology,2017,10.1200/jco.2017.35.6_suppl.334,https://experts.mcmaster.ca/display/publication1977716,2025-07-27T15:12:23.218571
Gregory Pond,gpond@mcmaster.ca,journal_articles,Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy.,Journal of Clinical Oncology,2017,10.1200/jco.2017.35.6_suppl.149,https://experts.mcmaster.ca/display/publication1977717,2025-07-27T15:12:23.218572
Gregory Pond,gpond@mcmaster.ca,journal_articles,Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival.,Journal of Clinical Oncology,2017,10.1200/jco.2017.35.6_suppl.346,https://experts.mcmaster.ca/display/publication1977715,2025-07-27T15:12:23.218573
Gregory Pond,gpond@mcmaster.ca,journal_articles,Abstract P4-12-09: The immune response in triple negative breast cancer,Cancer Research,2017,10.1158/1538-7445.sabcs16-p4-12-09,https://experts.mcmaster.ca/display/publication2552546,2025-07-27T15:12:23.218573
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Abstract P6-12-11: A randomized, double-blind, placebo-controlled window of opportunity trial evaluating clinical effects of high dose vitamin D in patients with breast cancer",Cancer Research,2017,10.1158/1538-7445.sabcs16-p6-12-11,https://experts.mcmaster.ca/display/publication3488350,2025-07-27T15:12:23.218574
Gregory Pond,gpond@mcmaster.ca,journal_articles,A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group,Lung Cancer,2017,10.1016/j.lungcan.2016.12.004,https://experts.mcmaster.ca/display/publication525142,2025-07-27T15:12:23.218575
Gregory Pond,gpond@mcmaster.ca,journal_articles,Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis,Clinical Genitourinary Cancer,2017,10.1016/j.clgc.2016.05.003,https://experts.mcmaster.ca/display/publication1521838,2025-07-27T15:12:23.218576
Gregory Pond,gpond@mcmaster.ca,journal_articles,Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer,Clinical Genitourinary Cancer,2017,10.1016/j.clgc.2016.05.009,https://experts.mcmaster.ca/display/publication336065,2025-07-27T15:12:23.218577
Gregory Pond,gpond@mcmaster.ca,journal_articles,Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer,Clinical Genitourinary Cancer,2017,10.1016/j.clgc.2016.05.009,https://experts.mcmaster.ca/display/publication336965,2025-07-27T15:12:23.218578
Gregory Pond,gpond@mcmaster.ca,journal_articles,Utility of the Edmonton Frail Scale in identifying frail elderly patients during treatment of colorectal cancer,Journal of Gastrointestinal Oncology,2017,10.21037/jgo.2016.11.12,https://experts.mcmaster.ca/display/publication694917,2025-07-27T15:12:23.218579
Gregory Pond,gpond@mcmaster.ca,journal_articles,Claudin-Low Breast Cancer; Clinical & Pathological Characteristics,PLoS ONE,2017,10.1371/journal.pone.0168669,https://experts.mcmaster.ca/display/publication190742,2025-07-27T15:12:23.218580
Gregory Pond,gpond@mcmaster.ca,journal_articles,Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma,Clinical Genitourinary Cancer,2016,10.1016/j.clgc.2016.05.001,https://experts.mcmaster.ca/display/publication310534,2025-07-27T15:12:23.218581
Gregory Pond,gpond@mcmaster.ca,journal_articles,A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer,Journal of Bone Oncology,2016,10.1016/j.jbo.2016.06.003,https://experts.mcmaster.ca/display/publication276872,2025-07-27T15:12:23.218582
Gregory Pond,gpond@mcmaster.ca,journal_articles,Assessment of Referral and Chemotherapy Treatment Patterns for Elderly Patients With Non–small-Cell Lung Cancer,Clinical Lung Cancer,2016,10.1016/j.cllc.2016.05.012,https://experts.mcmaster.ca/display/publication1521794,2025-07-27T15:12:23.218583
Gregory Pond,gpond@mcmaster.ca,journal_articles,Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study,Journal of Clinical Oncology,2016,10.1200/jco.2016.68.1585,https://experts.mcmaster.ca/display/publication936452,2025-07-27T15:12:23.218584
Gregory Pond,gpond@mcmaster.ca,journal_articles,PS1 -125 Assessment of Function and Quality of Life in a Phase II Multi-Institutional Clinical Trial of Fractionated Simultaneous In-Field Boost Radiotherapy for Patients with 1-2 Brain Metastases,Canadian Journal of Neurological Sciences,2016,10.1017/cjn.2016.351,https://experts.mcmaster.ca/display/publication1977721,2025-07-27T15:12:23.218585
Gregory Pond,gpond@mcmaster.ca,journal_articles,140: Indentification of Curculating MIRNA Associated with Development of Castrate Resistance in High-Risk and Biochemically Recurrent Prostate Cancer Patients,Radiotherapy and Oncology,2016,10.1016/s0167-8140(16)33539-3,https://experts.mcmaster.ca/display/publication2552568,2025-07-27T15:12:23.218586
Gregory Pond,gpond@mcmaster.ca,journal_articles,228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus,Radiotherapy and Oncology,2016,10.1016/s0167-8140(16)33627-1,https://experts.mcmaster.ca/display/publication2552562,2025-07-27T15:12:23.218587
Gregory Pond,gpond@mcmaster.ca,journal_articles,Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study,Annals of Oncology,2016,10.1093/annonc/mdw252,https://experts.mcmaster.ca/display/publication310538,2025-07-27T15:12:23.218588
Gregory Pond,gpond@mcmaster.ca,journal_articles,Cisplatin- Versus Non–Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin,Clinical Genitourinary Cancer,2016,10.1016/j.clgc.2015.10.005,https://experts.mcmaster.ca/display/publication336181,2025-07-27T15:12:23.218588
Gregory Pond,gpond@mcmaster.ca,journal_articles,Metformin for chemo-radio-sensitization of NSCLC,Radiotherapy and Oncology,2016,10.1016/j.radonc.2016.06.018,https://experts.mcmaster.ca/display/publication276873,2025-07-27T15:12:23.218589
Gregory Pond,gpond@mcmaster.ca,journal_articles,Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with 1–3 metastases,Journal of Neuro-Oncology,2016,10.1007/s11060-016-2128-7,https://experts.mcmaster.ca/display/publication276875,2025-07-27T15:12:23.218590
Gregory Pond,gpond@mcmaster.ca,journal_articles,Prospective comparison of rectal dose reduction during intracavitary brachytherapy for cervical cancer using three rectal retraction techniques,Brachytherapy,2016,10.1016/j.brachy.2016.03.005,https://experts.mcmaster.ca/display/publication276484,2025-07-27T15:12:23.218591
Gregory Pond,gpond@mcmaster.ca,journal_articles,Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration,Investigative Urology,2016,10.1016/j.juro.2015.12.082,https://experts.mcmaster.ca/display/publication1521828,2025-07-27T15:12:23.218592
Gregory Pond,gpond@mcmaster.ca,journal_articles,Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel,European Urology,2016,10.1016/j.eururo.2015.10.008,https://experts.mcmaster.ca/display/publication1521821,2025-07-27T15:12:23.218593
Gregory Pond,gpond@mcmaster.ca,journal_articles,Can the Referring Surgeon Enhance Accrual of Breast Cancer Patients to Medical and Radiation Oncology Trials? The Enhance Study,Current Oncology,2016,10.3747/co.23.2394,https://experts.mcmaster.ca/display/publication276874,2025-07-27T15:12:23.218594
Gregory Pond,gpond@mcmaster.ca,journal_articles,84P Metabolic stress to sensitize non-small cell lung cancer (NSCLC) to radiotherapy: Studies from bench to bedside,Journal of Thoracic Oncology,2016,10.1016/s1556-0864(16)30197-6,https://experts.mcmaster.ca/display/publication200467,2025-07-27T15:12:23.218595
Gregory Pond,gpond@mcmaster.ca,journal_articles,"A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma",Investigational New Drugs,2016,10.1007/s10637-016-0324-0,https://experts.mcmaster.ca/display/publication276876,2025-07-27T15:12:23.218596
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer — At What Cost? Eur Urol 2016;69:642–44",European Urology,2016,10.1016/j.eururo.2015.09.015,https://experts.mcmaster.ca/display/publication1521801,2025-07-27T15:12:23.218597
Gregory Pond,gpond@mcmaster.ca,journal_articles,Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma,European Urology,2016,10.1016/j.eururo.2015.07.042,https://experts.mcmaster.ca/display/publication1521827,2025-07-27T15:12:23.218598
Gregory Pond,gpond@mcmaster.ca,journal_articles,Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.,European Urology,2016,10.1016/j.eururo.2015.07.042,https://experts.mcmaster.ca/display/publication1521849,2025-07-27T15:12:23.218599
Gregory Pond,gpond@mcmaster.ca,journal_articles,The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis,European Urology,2016,10.1016/j.eururo.2015.09.051,https://experts.mcmaster.ca/display/publication1521813,2025-07-27T15:12:23.218600
Gregory Pond,gpond@mcmaster.ca,journal_articles,A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non–Small-Cell Lung Cancer,Clinical Lung Cancer,2016,10.1016/j.cllc.2015.09.008,https://experts.mcmaster.ca/display/publication465848,2025-07-27T15:12:23.218601
Gregory Pond,gpond@mcmaster.ca,journal_articles,Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma,Investigative Urology,2016,10.1016/j.juro.2015.07.111,https://experts.mcmaster.ca/display/publication1521829,2025-07-27T15:12:23.218602
Gregory Pond,gpond@mcmaster.ca,journal_articles,Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study,"Clinical Lymphoma, Myeloma and Leukemia",2016,10.1016/j.clml.2015.11.008,https://experts.mcmaster.ca/display/publication276877,2025-07-27T15:12:23.218603
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study",Frontiers in Pharmacology,2016,10.3389/fphar.2016.00487,https://experts.mcmaster.ca/display/publication276871,2025-07-27T15:12:23.218604
Gregory Pond,gpond@mcmaster.ca,journal_articles,A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial,Journal of Cancer Survivorship,2015,10.1007/s11764-015-0443-1,https://experts.mcmaster.ca/display/publication863665,2025-07-27T15:12:23.218605
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study",Journal of Clinical Oncology,2015,10.1200/jco.2015.63.0905,https://experts.mcmaster.ca/display/publication575330,2025-07-27T15:12:23.218606
Gregory Pond,gpond@mcmaster.ca,journal_articles,Epigenetic silencing of miR-145-5p contributes to brain metastasis,Oncotarget,2015,10.18632/oncotarget.5930,https://experts.mcmaster.ca/display/publication276879,2025-07-27T15:12:23.218606
Gregory Pond,gpond@mcmaster.ca,journal_articles,Gemcitabine and Platinum (GC) chemotherapy alone or with a Taxane (GC-T) as first-line therapy for urothelial cancer (UC): a meta-analysis,Annals of Oncology,2015,10.1093/annonc/mdv341.09,https://experts.mcmaster.ca/display/publication1977718,2025-07-27T15:12:23.218607
Gregory Pond,gpond@mcmaster.ca,journal_articles,Factors associated with acute care use among nursing home residents dying of cancer: a population-based study,International Journal of Palliative Nursing,2015,10.12968/ijpn.2015.21.7.349,https://experts.mcmaster.ca/display/publication276880,2025-07-27T15:12:23.218608
Gregory Pond,gpond@mcmaster.ca,journal_articles,Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study,Journal of Bone Oncology,2015,10.1016/j.jbo.2015.04.001,https://experts.mcmaster.ca/display/publication863661,2025-07-27T15:12:23.218609
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Factors associated with not receiving homecare, end-of-life homecare, or early homecare referral among cancer decedents: A population-based cohort study",Health Policy,2015,10.1016/j.healthpol.2014.11.019,https://experts.mcmaster.ca/display/publication276884,2025-07-27T15:12:23.218610
Gregory Pond,gpond@mcmaster.ca,journal_articles,Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design,Clinical Genitourinary Cancer,2015,10.1016/j.clgc.2014.10.005,https://experts.mcmaster.ca/display/publication1521837,2025-07-27T15:12:23.218611
Gregory Pond,gpond@mcmaster.ca,journal_articles,Independent predictors of prolonged operative time during robotic-assisted radical prostatectomy,Journal of Robotic Surgery,2015,10.1007/s11701-015-0497-0,https://experts.mcmaster.ca/display/publication1082169,2025-07-27T15:12:23.218612
Gregory Pond,gpond@mcmaster.ca,journal_articles,Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma,BJU International,2015,10.1111/bju.12922,https://experts.mcmaster.ca/display/publication1521817,2025-07-27T15:12:23.218613
Gregory Pond,gpond@mcmaster.ca,journal_articles,Time Interval Between Endometrial Biopsy and Surgical Staging for Type I Endometrial Cancer,Obstetrics and Gynecology,2015,10.1097/aog.0000000000000889,https://experts.mcmaster.ca/display/publication276882,2025-07-27T15:12:23.218614
Gregory Pond,gpond@mcmaster.ca,journal_articles,Cancer-related cognitive dysfunction (CRCD) and psychosocial development in young adult cancer survivors.,Journal of Clinical Oncology,2015,10.1200/jco.2015.33.15_suppl.tps9636,https://experts.mcmaster.ca/display/publication1977710,2025-07-27T15:12:23.218615
Gregory Pond,gpond@mcmaster.ca,journal_articles,Expression of thyroid hormone receptor alpha (THRα) isoforms in triple negative breast cancer (TNBC).,Journal of Clinical Oncology,2015,10.1200/jco.2015.33.15_suppl.e12082,https://experts.mcmaster.ca/display/publication1977711,2025-07-27T15:12:23.218616
Gregory Pond,gpond@mcmaster.ca,journal_articles,596 Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation (TMT): An international collaboration,European Urology Open Science,2015,10.1016/s1569-9056(15)60589-9,https://experts.mcmaster.ca/display/publication2552564,2025-07-27T15:12:23.218617
Gregory Pond,gpond@mcmaster.ca,journal_articles,Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy,Clinical Genitourinary Cancer,2015,10.1016/j.clgc.2014.08.010,https://experts.mcmaster.ca/display/publication336289,2025-07-27T15:12:23.218618
Gregory Pond,gpond@mcmaster.ca,journal_articles,Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma,Clinical Genitourinary Cancer,2015,10.1016/j.clgc.2014.09.004,https://experts.mcmaster.ca/display/publication1521782,2025-07-27T15:12:23.218619
Gregory Pond,gpond@mcmaster.ca,journal_articles,Influence of censoring on conclusions of trials for women with metastatic breast cancer,European Journal of Cancer,2015,10.1016/j.ejca.2014.12.016,https://experts.mcmaster.ca/display/publication1521761,2025-07-27T15:12:23.218620
Gregory Pond,gpond@mcmaster.ca,journal_articles,Treatment-induced cell cycle kinetics dictate tumor response to chemotherapy,Oncotarget,2015,10.18632/oncotarget.3140,https://experts.mcmaster.ca/display/publication212294,2025-07-27T15:12:23.218621
Gregory Pond,gpond@mcmaster.ca,journal_articles,Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implications for Trial Design,Clinical Genitourinary Cancer,2015,10.1016/j.clgc.2014.06.004,https://experts.mcmaster.ca/display/publication310544,2025-07-27T15:12:23.218622
Gregory Pond,gpond@mcmaster.ca,journal_articles,A prospective comparison of MRI‐US fused targeted biopsy versus systematic ultrasound‐guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance,Journal of Magnetic Resonance Imaging,2015,10.1002/jmri.24710,https://experts.mcmaster.ca/display/publication1521790,2025-07-27T15:12:23.218622
Gregory Pond,gpond@mcmaster.ca,journal_articles,Evaluating the Feasibility of Performing Window of Opportunity Trials in Breast Cancer,International Journal of Surgical Oncology,2015,10.1155/2015/785793,https://experts.mcmaster.ca/display/publication1521850,2025-07-27T15:12:23.218623
Gregory Pond,gpond@mcmaster.ca,journal_articles,Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications,Breast Cancer Research and Treatment,2015,10.1007/s10549-014-3235-9,https://experts.mcmaster.ca/display/publication584699,2025-07-27T15:12:23.218624
Gregory Pond,gpond@mcmaster.ca,journal_articles,Cognitive function and fatigue after diagnosis of colorectal cancer,Annals of Oncology,2014,10.1093/annonc/mdu448,https://experts.mcmaster.ca/display/publication310548,2025-07-27T15:12:23.218625
Gregory Pond,gpond@mcmaster.ca,journal_articles,Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma,Clinical Genitourinary Cancer,2014,10.1016/j.clgc.2014.03.009,https://experts.mcmaster.ca/display/publication1521831,2025-07-27T15:12:23.218626
Gregory Pond,gpond@mcmaster.ca,journal_articles,Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases,SpringerPlus,2014,10.1186/2193-1801-3-577,https://experts.mcmaster.ca/display/publication1521762,2025-07-27T15:12:23.218627
Gregory Pond,gpond@mcmaster.ca,journal_articles,Patient Eligibility and Trial Design for the Salvage Therapy of Advanced Urothelial Carcinoma,Clinical Genitourinary Cancer,2014,10.1016/j.clgc.2014.03.016,https://experts.mcmaster.ca/display/publication1521787,2025-07-27T15:12:23.218628
Gregory Pond,gpond@mcmaster.ca,journal_articles,Radiographic progression by Prostate Cancer Working Group (PCWG)‐2 criteria as an intermediate endpoint for drug development in metastatic castration‐resistant prostate cancer,BJU International,2014,10.1111/bju.12589,https://experts.mcmaster.ca/display/publication1521835,2025-07-27T15:12:23.218629
Gregory Pond,gpond@mcmaster.ca,journal_articles,Evaluation of second line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first line cediranib,Journal of the Canadian Urological Association,2014,10.5489/cuaj.2426,https://experts.mcmaster.ca/display/publication740972,2025-07-27T15:12:23.218630
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer",Annals of Oncology,2014,10.1093/annonc/mdu371,https://experts.mcmaster.ca/display/publication310565,2025-07-27T15:12:23.218631
Gregory Pond,gpond@mcmaster.ca,journal_articles,Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer,Clinical Genitourinary Cancer,2014,10.1016/j.clgc.2014.03.005,https://experts.mcmaster.ca/display/publication1521764,2025-07-27T15:12:23.218632
Gregory Pond,gpond@mcmaster.ca,journal_articles,Angiogenic Switch As Predictor of Response to Chemotherapy+ Bevacizumab in Patients with Metastatic Colorectal Cancer,Annals of Oncology,2014,10.1093/annonc/mdu333.33,https://experts.mcmaster.ca/display/publication2552551,2025-07-27T15:12:23.218633
Gregory Pond,gpond@mcmaster.ca,journal_articles,Outcomes with Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma (Uc) Following Previous Perioperative Cisplatin-Based Therapy,Annals of Oncology,2014,10.1093/annonc/mdu337.60,https://experts.mcmaster.ca/display/publication2552549,2025-07-27T15:12:23.218637
Gregory Pond,gpond@mcmaster.ca,journal_articles,The Significance of Complete Response (Cr) in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma (Uc),Annals of Oncology,2014,10.1093/annonc/mdu337.58,https://experts.mcmaster.ca/display/publication2552550,2025-07-27T15:12:23.218638
Gregory Pond,gpond@mcmaster.ca,journal_articles,Factors Associated with Publication of Randomized Phase iii Cancer Trials in Journals with a High Impact Factor,Current Oncology,2014,10.3747/co.21.1937,https://experts.mcmaster.ca/display/publication310575,2025-07-27T15:12:23.218639
Gregory Pond,gpond@mcmaster.ca,journal_articles,Randomized Trial of a Telephone-Based Weight Loss Intervention in Postmenopausal Women With Breast Cancer Receiving Letrozole: The LISA Trial,Journal of Clinical Oncology,2014,10.1200/jco.2013.53.1517,https://experts.mcmaster.ca/display/publication882290,2025-07-27T15:12:23.218640
Gregory Pond,gpond@mcmaster.ca,journal_articles,Assessing the necessity of including a crossover period with dual reporting when changing total prostate-specific antigen methods,Clinical Biochemistry,2014,10.1016/j.clinbiochem.2014.03.027,https://experts.mcmaster.ca/display/publication1521797,2025-07-27T15:12:23.218641
Gregory Pond,gpond@mcmaster.ca,journal_articles,Phase 1 Trial Design: Is 3 + 3 the Best?,Cancer Control,2014,10.1177/107327481402100304,https://experts.mcmaster.ca/display/publication1521759,2025-07-27T15:12:23.218641
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study",Breast Cancer Research and Treatment,2014,10.1007/s10549-014-3015-6,https://experts.mcmaster.ca/display/publication599198,2025-07-27T15:12:23.218642
Gregory Pond,gpond@mcmaster.ca,journal_articles,Reply to J. Menczer,Journal of Clinical Oncology,2014,10.1200/jco.2014.55.7215,https://experts.mcmaster.ca/display/publication276885,2025-07-27T15:12:23.218643
Gregory Pond,gpond@mcmaster.ca,journal_articles,Treatment Delay in Endometrial Cancer,Journal of Clinical Oncology,2014,10.1200/jco.2014.55.6746,https://experts.mcmaster.ca/display/publication1979310,2025-07-27T15:12:23.218644
Gregory Pond,gpond@mcmaster.ca,journal_articles,A nomogram including baseline prognostic factors to estimate the activity of second‐line therapy for advanced urothelial carcinoma,BJU International,2014,10.1111/bju.12564,https://experts.mcmaster.ca/display/publication336498,2025-07-27T15:12:23.218645
Gregory Pond,gpond@mcmaster.ca,journal_articles,Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy,Urologic Oncology: Seminars and Original Investigations,2014,10.1016/j.urolonc.2013.10.007,https://experts.mcmaster.ca/display/publication610069,2025-07-27T15:12:23.218646
Gregory Pond,gpond@mcmaster.ca,journal_articles,Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy,Annals of Oncology,2014,10.1093/annonc/mdu090,https://experts.mcmaster.ca/display/publication195144,2025-07-27T15:12:23.218647
Gregory Pond,gpond@mcmaster.ca,journal_articles,"A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events",Breast Cancer Research and Treatment,2014,10.1007/s10549-014-2906-x,https://experts.mcmaster.ca/display/publication276886,2025-07-27T15:12:23.218648
Gregory Pond,gpond@mcmaster.ca,journal_articles,Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial,Journal of Geriatric Oncology,2014,10.1016/j.jgo.2013.12.001,https://experts.mcmaster.ca/display/publication1521851,2025-07-27T15:12:23.218653
Gregory Pond,gpond@mcmaster.ca,journal_articles,Cost Effectiveness of a Survivorship Care Plan for Breast Cancer Survivors,JCO Oncology Practice,2014,10.1200/jop.2013.001142,https://experts.mcmaster.ca/display/publication276888,2025-07-27T15:12:23.218654
Gregory Pond,gpond@mcmaster.ca,journal_articles,Are family physician visits and continuity of care associated with acute care use at end-of-life? A population-based cohort study of homecare cancer patients,Palliative Medicine,2014,10.1177/0269216313493125,https://experts.mcmaster.ca/display/publication469123,2025-07-27T15:12:23.218655
Gregory Pond,gpond@mcmaster.ca,journal_articles,Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer,Urologic Oncology: Seminars and Original Investigations,2014,10.1016/j.urolonc.2013.02.015,https://experts.mcmaster.ca/display/publication1521811,2025-07-27T15:12:23.218656
Gregory Pond,gpond@mcmaster.ca,journal_articles,High-Sensitivity Cardiac Troponin I for Predicting Death in a Female Emergency Department Population,Clinical Chemistry,2014,10.1373/clinchem.2013.211557,https://experts.mcmaster.ca/display/publication276890,2025-07-27T15:12:23.218657
Gregory Pond,gpond@mcmaster.ca,journal_articles,Impact of Wait Times on Survival for Women With Uterine Cancer,Journal of Clinical Oncology,2014,10.1200/jco.2013.51.3671,https://experts.mcmaster.ca/display/publication1122002,2025-07-27T15:12:23.218658
Gregory Pond,gpond@mcmaster.ca,journal_articles,Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy,Urologic Oncology: Seminars and Original Investigations,2014,10.1016/j.urolonc.2013.07.001,https://experts.mcmaster.ca/display/publication276892,2025-07-27T15:12:23.218659
Gregory Pond,gpond@mcmaster.ca,journal_articles,Prognostic Impact of C-Reactive Protein in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis,Onkologie (Czech Republic),2014,10.1159/000369545,https://experts.mcmaster.ca/display/publication1521800,2025-07-27T15:12:23.218660
Gregory Pond,gpond@mcmaster.ca,journal_articles,The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer,European Urology,2014,10.1016/j.eururo.2013.09.024,https://experts.mcmaster.ca/display/publication1521746,2025-07-27T15:12:23.218661
Gregory Pond,gpond@mcmaster.ca,journal_articles,Glasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel-Based Chemotherapy,Clinical Genitourinary Cancer,2013,10.1016/j.clgc.2013.04.020,https://experts.mcmaster.ca/display/publication276896,2025-07-27T15:12:23.218661
Gregory Pond,gpond@mcmaster.ca,journal_articles,Impact of Response to Prior Chemotherapy in Patients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications for Trial Design,Clinical Genitourinary Cancer,2013,10.1016/j.clgc.2013.04.025,https://experts.mcmaster.ca/display/publication336584,2025-07-27T15:12:23.218662
Gregory Pond,gpond@mcmaster.ca,journal_articles,Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials,Annals of Oncology,2013,10.1093/annonc/mdt397,https://experts.mcmaster.ca/display/publication117185,2025-07-27T15:12:23.218663
Gregory Pond,gpond@mcmaster.ca,journal_articles,Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials,Urologic Oncology: Seminars and Original Investigations,2013,10.1016/j.urolonc.2012.02.008,https://experts.mcmaster.ca/display/publication1521798,2025-07-27T15:12:23.218664
Gregory Pond,gpond@mcmaster.ca,journal_articles,"The wait time creep: Changes in the surgical wait time for women with uterine cancer in Ontario, Canada, during 2000–2009",Gynecologic Oncology,2013,10.1016/j.ygyno.2013.06.036,https://experts.mcmaster.ca/display/publication276894,2025-07-27T15:12:23.218665
Gregory Pond,gpond@mcmaster.ca,journal_articles,Data collection in cancer clinical trials: Too much of a good thing?,Clinical Trials,2013,10.1177/1740774513491337,https://experts.mcmaster.ca/display/publication854516,2025-07-27T15:12:23.218666
Gregory Pond,gpond@mcmaster.ca,journal_articles,"The wait time creep: Changes in the surgical wait time for women with uterine cancer in Ontario, Canada during 2000-2009",Gynecologic Oncology,2013,10.1016/j.ygyno.2013.04.155,https://experts.mcmaster.ca/display/publication1977722,2025-07-27T15:12:23.218667
Gregory Pond,gpond@mcmaster.ca,journal_articles,Potential Value of Gleason Score in Predicting the Benefit of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer,Future Oncology,2013,10.2217/fon.13.39,https://experts.mcmaster.ca/display/publication1004964,2025-07-27T15:12:23.218668
Gregory Pond,gpond@mcmaster.ca,journal_articles,A Comparison of Patient Knowledge of Clinical Trials and Trialist Priorities,Current Oncology,2013,10.3747/co.20.1323,https://experts.mcmaster.ca/display/publication310588,2025-07-27T15:12:23.218669
Gregory Pond,gpond@mcmaster.ca,journal_articles,Intraoperative Sonographically Assisted Radioactive Iodine 125 Plaque Brachytherapy for Choroidal Melanoma,Journal of Ultrasound in Medicine,2013,10.7863/ultra.32.6.995,https://experts.mcmaster.ca/display/publication276898,2025-07-27T15:12:23.218670
Gregory Pond,gpond@mcmaster.ca,journal_articles,"First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.",Journal of Clinical Oncology,2013,10.1200/jco.2013.31.15_suppl.2505,https://experts.mcmaster.ca/display/publication2552517,2025-07-27T15:12:23.218671
Gregory Pond,gpond@mcmaster.ca,journal_articles,Impact of response to prior chemotherapy (RTPC) on outcomes in second-line therapy for advanced urothelial carcinoma (UC): Implications for trial design.,Journal of Clinical Oncology,2013,10.1200/jco.2013.31.15_suppl.4539,https://experts.mcmaster.ca/display/publication1977698,2025-07-27T15:12:23.218672
Gregory Pond,gpond@mcmaster.ca,journal_articles,Impact of wait times on survival of women with uterine cancer.,Journal of Clinical Oncology,2013,10.1200/jco.2013.31.15_suppl.5586,https://experts.mcmaster.ca/display/publication1977697,2025-07-27T15:12:23.218673
Gregory Pond,gpond@mcmaster.ca,journal_articles,Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC).,Journal of Clinical Oncology,2013,10.1200/jco.2013.31.15_suppl.4524,https://experts.mcmaster.ca/display/publication1977700,2025-07-27T15:12:23.218674
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study—NCT00811369.",Journal of Clinical Oncology,2013,10.1200/jco.2013.31.15_suppl.574,https://experts.mcmaster.ca/display/publication1977696,2025-07-27T15:12:23.218675
Gregory Pond,gpond@mcmaster.ca,journal_articles,Weekly vinblastine in chemotherapy-naive children with unresectable or progressive low grade glioma: A Canadian cooperative study.,Journal of Clinical Oncology,2013,10.1200/jco.2013.31.15_suppl.10029,https://experts.mcmaster.ca/display/publication1977701,2025-07-27T15:12:23.218676
Gregory Pond,gpond@mcmaster.ca,journal_articles,Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK,British Journal of Cancer,2013,10.1038/bjc.2013.187,https://experts.mcmaster.ca/display/publication276902,2025-07-27T15:12:23.218677
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials",European Urology,2013,10.1016/j.eururo.2012.11.042,https://experts.mcmaster.ca/display/publication1521775,2025-07-27T15:12:23.218678
Gregory Pond,gpond@mcmaster.ca,journal_articles,Influence of statistician involvement on reporting of randomized clinical trials in medical oncology,Anti-Cancer Drugs,2013,10.1097/cad.0b013e32835c3561,https://experts.mcmaster.ca/display/publication1521758,2025-07-27T15:12:23.218679
Gregory Pond,gpond@mcmaster.ca,journal_articles,Cardiac and Inflammation Biomarker Profile after Initiation of Adjuvant Trastuzumab Therapy,Clinical Chemistry,2013,10.1373/clinchem.2012.192419,https://experts.mcmaster.ca/display/publication584748,2025-07-27T15:12:23.218680
Gregory Pond,gpond@mcmaster.ca,journal_articles,Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study,Journal of the Canadian Urological Association,2013,10.5489/cuaj.267,https://experts.mcmaster.ca/display/publication276900,2025-07-27T15:12:23.218680
Gregory Pond,gpond@mcmaster.ca,journal_articles,A phase II multi-institutional study assessing simultaneous in-field boost helical tomotherapy for 1-3 brain metastases,Radiation Oncology,2012,10.1186/1748-717x-7-42,https://experts.mcmaster.ca/display/publication1521804,2025-07-27T15:12:23.218681
Gregory Pond,gpond@mcmaster.ca,journal_articles,A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy,BMC Medical Genetics,2012,10.1186/1755-8794-5-16,https://experts.mcmaster.ca/display/publication276909,2025-07-27T15:12:23.218682
Gregory Pond,gpond@mcmaster.ca,journal_articles,Ability of C‐reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel‐based chemotherapy,BJU International,2012,10.1111/j.1464-410x.2012.11148.x,https://experts.mcmaster.ca/display/publication1521814,2025-07-27T15:12:23.218683
Gregory Pond,gpond@mcmaster.ca,journal_articles,Neutropenia as a Potential Pharmacodynamic Marker for Docetaxel-Based Chemotherapy in Men With Metastatic Castration-Resistant Prostate Cancer,Clinical Genitourinary Cancer,2012,10.1016/j.clgc.2012.06.004,https://experts.mcmaster.ca/display/publication1521802,2025-07-27T15:12:23.218684
Gregory Pond,gpond@mcmaster.ca,journal_articles,A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer,Breast Cancer Research and Treatment,2012,10.1007/s10549-012-2205-3,https://experts.mcmaster.ca/display/publication276908,2025-07-27T15:12:23.218685
Gregory Pond,gpond@mcmaster.ca,journal_articles,Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods,Annals of Oncology,2012,10.1093/annonc/mds174,https://experts.mcmaster.ca/display/publication310580,2025-07-27T15:12:23.218686
Gregory Pond,gpond@mcmaster.ca,journal_articles,Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods.,Annals of Oncology,2012,10.1093/annonc/mds174,https://experts.mcmaster.ca/display/publication1689206,2025-07-27T15:12:23.218687
Gregory Pond,gpond@mcmaster.ca,journal_articles,Do High Symptom Scores Trigger Clinical Actions? An Audit After Implementing Electronic Symptom Screening,JCO Oncology Practice,2012,10.1200/jop.2011.000525,https://experts.mcmaster.ca/display/publication276904,2025-07-27T15:12:23.218688
Gregory Pond,gpond@mcmaster.ca,journal_articles,Enregistrement et publication du critère d’évaluation principal dans les essais contrôlés randomisés en oncologie,Bulletin du Cancer,2012,10.1684/bdc.2012.1651,https://experts.mcmaster.ca/display/publication276906,2025-07-27T15:12:23.218689
Gregory Pond,gpond@mcmaster.ca,journal_articles,Association of Progression by Prostate Cancer Working Group (PCWG)-2 Criteria and Survival in Metastatic Castration Resistant Prostate Cancer,Annals of Oncology,2012,10.1016/s0923-7534(20)33529-8,https://experts.mcmaster.ca/display/publication1977463,2025-07-27T15:12:23.218690
Gregory Pond,gpond@mcmaster.ca,journal_articles,Do beta-blockers alter dyspnea and fatigue in advanced lung cancer? A retrospective analysis,Palliative Medicine,2012,10.1177/0269216311415454,https://experts.mcmaster.ca/display/publication1521815,2025-07-27T15:12:23.218691
Gregory Pond,gpond@mcmaster.ca,journal_articles,Prognostic Stratification of Advanced Urothelial Carcinoma (UC) Receiving Second-Line Systemic Therapy Including Time from Prior Chemotherapy (TFPC) as a Prognostic Factor,Annals of Oncology,2012,10.1016/s0923-7534(20)33372-x,https://experts.mcmaster.ca/display/publication1977707,2025-07-27T15:12:23.218692
Gregory Pond,gpond@mcmaster.ca,journal_articles,Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy,Urologic Oncology: Seminars and Original Investigations,2012,10.1016/j.urolonc.2010.07.002,https://experts.mcmaster.ca/display/publication1521748,2025-07-27T15:12:23.218693
Gregory Pond,gpond@mcmaster.ca,journal_articles,Quality of Reporting of Modern Randomized Controlled Trials in Medical Oncology: A Systematic Review,Journal of the National Cancer Institute,2012,10.1093/jnci/djs259,https://experts.mcmaster.ca/display/publication1521769,2025-07-27T15:12:23.218694
Gregory Pond,gpond@mcmaster.ca,journal_articles,Fertility Risk Discussions in Young Patients Diagnosed with Colorectal Cancer,Current Oncology,2012,10.3747/co.19.942,https://experts.mcmaster.ca/display/publication310600,2025-07-27T15:12:23.218694
Gregory Pond,gpond@mcmaster.ca,journal_articles,Heterogeneity among lists of cautioned or prohibited drugs in protocols of early-phase oncology trials,Annals of Oncology,2012,10.1093/annonc/mdr476,https://experts.mcmaster.ca/display/publication276913,2025-07-27T15:12:23.218695
Gregory Pond,gpond@mcmaster.ca,journal_articles,P-0215 Patient Factors Involved in Referral for Lynch Syndrome,Annals of Oncology,2012,10.1016/s0923-7534(20)30140-x,https://experts.mcmaster.ca/display/publication1977708,2025-07-27T15:12:23.218696
Gregory Pond,gpond@mcmaster.ca,journal_articles,Cognitive function and fatigue in colorectal cancer (CRC) patients: A prospective longitudinal controlled study.,Journal of Clinical Oncology,2012,10.1200/jco.2012.30.15_suppl.9021,https://experts.mcmaster.ca/display/publication1977703,2025-07-27T15:12:23.218697
Gregory Pond,gpond@mcmaster.ca,journal_articles,Pretreatment neurocognitive function (NCF) status in head and neck cancer (HNC) patients (pts) with comparison to control cohort.,Journal of Clinical Oncology,2012,10.1200/jco.2012.30.15_suppl.5587,https://experts.mcmaster.ca/display/publication1977704,2025-07-27T15:12:23.218698
Gregory Pond,gpond@mcmaster.ca,journal_articles,Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial.,Journal of Clinical Oncology,2012,10.1200/jco.2012.30.15_suppl.4644,https://experts.mcmaster.ca/display/publication1977481,2025-07-27T15:12:23.218699
Gregory Pond,gpond@mcmaster.ca,journal_articles,Quantitative immunohistochemical (IHC) assessment of ataxia-telangiectasia mutated (ATM) in estrogen receptor (ER) negative early breast cancer (BC).,Journal of Clinical Oncology,2012,10.1200/jco.2012.30.15_suppl.e21083,https://experts.mcmaster.ca/display/publication1977702,2025-07-27T15:12:23.218700
Gregory Pond,gpond@mcmaster.ca,journal_articles,Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy.,Journal of Clinical Oncology,2012,10.1200/jco.2012.30.15_suppl.4522,https://experts.mcmaster.ca/display/publication1977705,2025-07-27T15:12:23.218701
Gregory Pond,gpond@mcmaster.ca,journal_articles,Reply to M. Jefford et al and C.T. Stricker et al,Journal of Clinical Oncology,2012,10.1200/jco.2011.40.6892,https://experts.mcmaster.ca/display/publication310610,2025-07-27T15:12:23.218702
Gregory Pond,gpond@mcmaster.ca,journal_articles,Assumptions of Expected Benefits in Randomized Phase III Trials Evaluating Systemic Treatments for Cancer,Journal of the National Cancer Institute,2012,10.1093/jnci/djs141,https://experts.mcmaster.ca/display/publication1521753,2025-07-27T15:12:23.218703
Gregory Pond,gpond@mcmaster.ca,journal_articles,The Impact of Chemotherapy-Induced Cognitive Impairment on the Psychosocial Adjustment of Patients With Nonmetastatic Colorectal Cancer,Clinical Journal of Oncology Nursing,2012,10.1188/12.cjon.163-169,https://experts.mcmaster.ca/display/publication1521816,2025-07-27T15:12:23.218704
Gregory Pond,gpond@mcmaster.ca,journal_articles,"357 Impact of Survivorship Care Plans (SCP) On Adherence to Guidelines, Health Service Measures, and Patient-reported Outcomes (PRO): Extended Results of a Multicenter Randomized Clinical Trial (RCT) with Breast Cancer Survivors",European Journal of Cancer,2012,10.1016/s0959-8049(12)70423-9,https://experts.mcmaster.ca/display/publication2552560,2025-07-27T15:12:23.218705
Gregory Pond,gpond@mcmaster.ca,journal_articles,Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer,European Urology,2012,10.1016/j.eururo.2011.06.034,https://experts.mcmaster.ca/display/publication1521760,2025-07-27T15:12:23.218706
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Reply to YiJun Shen and DingWei Ye's Letter to the Editor re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer. Eur Urol 2012;61:363–9",European Urology,2012,10.1016/j.eururo.2011.07.055,https://experts.mcmaster.ca/display/publication1521796,2025-07-27T15:12:23.218707
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Statistical and analytical approaches for assessing biomarkers: New approaches, new technologies, with the same-old rigor for evaluation",Clinical Biochemistry,2012,10.1016/j.clinbiochem.2012.01.003,https://experts.mcmaster.ca/display/publication1521806,2025-07-27T15:12:23.218708
Gregory Pond,gpond@mcmaster.ca,journal_articles,Consistency in the Analysis and Reporting of Primary End Points in Oncology Randomized Controlled Trials From Registration to Publication: A Systematic Review,Journal of Clinical Oncology,2012,10.1200/jco.2011.37.0890,https://experts.mcmaster.ca/display/publication276911,2025-07-27T15:12:23.218709
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Evaluating Survivorship Care Plans: Results of a Randomized, Clinical Trial of Patients With Breast Cancer",Journal of Clinical Oncology,2011,10.1200/jco.2011.36.8373,https://experts.mcmaster.ca/display/publication276914,2025-07-27T15:12:23.218710
Gregory Pond,gpond@mcmaster.ca,journal_articles,A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials,BMC Medical Research Methodology,2011,10.1186/1471-2288-11-95,https://experts.mcmaster.ca/display/publication1521852,2025-07-27T15:12:23.218711
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials",BMC Medical Research Methodology,2011,10.1186/1471-2288-11-164,https://experts.mcmaster.ca/display/publication1521853,2025-07-27T15:12:23.218711
Gregory Pond,gpond@mcmaster.ca,journal_articles,Early stopping rules in oncology: Considerations for clinicians,European Journal of Cancer,2011,10.1016/j.ejca.2011.05.019,https://experts.mcmaster.ca/display/publication741087,2025-07-27T15:12:23.218712
Gregory Pond,gpond@mcmaster.ca,journal_articles,A Prospective Quality Assurance Study of Proper Utilization of Metered-Dose Inhalers in the Medical Inpatient Population,Chest,2011,10.1378/chest.1117095,https://experts.mcmaster.ca/display/publication3492725,2025-07-27T15:12:23.218713
Gregory Pond,gpond@mcmaster.ca,journal_articles,The association between radiographic response and overall survival in men with metastatic castration‐resistant prostate cancer receiving chemotherapy,Cancer,2011,10.1002/cncr.25982,https://experts.mcmaster.ca/display/publication1521756,2025-07-27T15:12:23.218714
Gregory Pond,gpond@mcmaster.ca,journal_articles,Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials,Clinical Trials,2011,10.1177/1740774511401764,https://experts.mcmaster.ca/display/publication1521809,2025-07-27T15:12:23.218715
Gregory Pond,gpond@mcmaster.ca,journal_articles,Frequency of fertility discussions among young patients diagnosed with colorectal cancer.,Journal of Clinical Oncology,2011,10.1200/jco.2011.29.15_suppl.e19735,https://experts.mcmaster.ca/display/publication2552582,2025-07-27T15:12:23.218716
Gregory Pond,gpond@mcmaster.ca,journal_articles,Neurocognitive function (NCF) in patients (pts) treated with chemo/bio-radiotherapy (C/B-RT) for head and neck cancers (HNC).,Journal of Clinical Oncology,2011,10.1200/jco.2011.29.15_suppl.5522,https://experts.mcmaster.ca/display/publication2552548,2025-07-27T15:12:23.218717
Gregory Pond,gpond@mcmaster.ca,journal_articles,Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors.,Journal of Clinical Oncology,2011,10.1200/jco.2011.29.15_suppl.9005,https://experts.mcmaster.ca/display/publication2552547,2025-07-27T15:12:23.218718
Gregory Pond,gpond@mcmaster.ca,journal_articles,Statistical issues in the use of dynamic allocation methods for balancing baseline covariates,British Journal of Cancer,2011,10.1038/bjc.2011.157,https://experts.mcmaster.ca/display/publication310608,2025-07-27T15:12:23.218719
Gregory Pond,gpond@mcmaster.ca,journal_articles,Non–Risk-Adapted Surveillance in Clinical Stage I Nonseminomatous Germ Cell Tumors: The Princess Margaret Hospital’s Experience,European Urology,2011,10.1016/j.eururo.2010.12.010,https://experts.mcmaster.ca/display/publication1521854,2025-07-27T15:12:23.218720
Gregory Pond,gpond@mcmaster.ca,journal_articles,Multidisciplinary Health Care Professionals' Perceptions of the Use and Utility of a Symptom Assessment System for Oncology Patients,JCO Oncology Practice,2011,10.1200/jop.2010.000015,https://experts.mcmaster.ca/display/publication276916,2025-07-27T15:12:23.218721
Gregory Pond,gpond@mcmaster.ca,journal_articles,Reply to D.J. Stewart,Journal of Clinical Oncology,2010,10.1200/jco.2010.31.5028,https://experts.mcmaster.ca/display/publication1521765,2025-07-27T15:12:23.218722
Gregory Pond,gpond@mcmaster.ca,journal_articles,The unclear zone in phase II clinical trials,European Journal of Cancer,2010,10.1016/j.ejca.2010.05.027,https://experts.mcmaster.ca/display/publication1521786,2025-07-27T15:12:23.218723
Gregory Pond,gpond@mcmaster.ca,journal_articles,The Contents and Readability of Informed Consent Forms for Oncology Clinical Trials,American Journal of Clinical Oncology,2010,10.1097/coc.0b013e3181b20641,https://experts.mcmaster.ca/display/publication1521788,2025-07-27T15:12:23.218723
Gregory Pond,gpond@mcmaster.ca,journal_articles,A Phase III Randomized Trial of the Timing of Meloxicam With Iodine-125 Prostate Brachytherapy,International Journal of Radiation Oncology Biology Physics,2010,10.1016/j.ijrobp.2009.04.078,https://experts.mcmaster.ca/display/publication276919,2025-07-27T15:12:23.218724
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Expression of EGFR, HER-2/neu and KIT in germ cell tumours",Clinical and Translational Oncology,2010,10.1007/s12094-010-0532-6,https://experts.mcmaster.ca/display/publication1521785,2025-07-27T15:12:23.218725
Gregory Pond,gpond@mcmaster.ca,journal_articles,Trends in the application of dynamic allocation methods in multi-arm cancer clinical trials,Clinical Trials,2010,10.1177/1740774510368301,https://experts.mcmaster.ca/display/publication1521754,2025-07-27T15:12:23.218726
Gregory Pond,gpond@mcmaster.ca,journal_articles,Randomized Phase II Trials: Inevitable or Inadvisable?,Journal of Clinical Oncology,2010,10.1200/jco.2009.26.3343,https://experts.mcmaster.ca/display/publication1521763,2025-07-27T15:12:23.218727
Gregory Pond,gpond@mcmaster.ca,journal_articles,Impact of Chemotherapy on Thrombin Generation and on the Protein C Pathway in Breast Cancer Patients,Pathophysiology of Haemostasis and Thrombosis: international journal on haemostasis and thrombosis research,2010,10.1159/000324166,https://experts.mcmaster.ca/display/publication276918,2025-07-27T15:12:23.218728
Gregory Pond,gpond@mcmaster.ca,journal_articles,Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials,Annals of Oncology,2010,10.1093/annonc/mdp478,https://experts.mcmaster.ca/display/publication310616,2025-07-27T15:12:23.218729
Gregory Pond,gpond@mcmaster.ca,journal_articles,Examining the safety and efficacy of a chemotherapy dosing method in Allogeneic Stem Cell Transplant patients of extreme body size,Journal of Oncology Pharmacy Practice,2009,10.1177/1078155208101960,https://experts.mcmaster.ca/display/publication276921,2025-07-27T15:12:23.218730
Gregory Pond,gpond@mcmaster.ca,journal_articles,A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium,Journal of Thoracic Oncology,2009,10.1097/jto.0b013e3181a949b2,https://experts.mcmaster.ca/display/publication585076,2025-07-27T15:12:23.218731
Gregory Pond,gpond@mcmaster.ca,journal_articles,Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib,Head and Neck,2009,10.1002/hed.21052,https://experts.mcmaster.ca/display/publication757598,2025-07-27T15:12:23.218732
Gregory Pond,gpond@mcmaster.ca,journal_articles,Comparison of randomized phase II studies (RP2s) and subsequent randomized controlled studies (RCTs) using identical systemic therapies,Journal of Clinical Oncology,2009,10.1200/jco.2009.27.15_suppl.e17515,https://experts.mcmaster.ca/display/publication1977687,2025-07-27T15:12:23.218733
Gregory Pond,gpond@mcmaster.ca,journal_articles,Trends in the application of dynamic allocation methods in multiarm cancer clinical trials,Journal of Clinical Oncology,2009,10.1200/jco.2009.27.15_suppl.6550,https://experts.mcmaster.ca/display/publication1977688,2025-07-27T15:12:23.218734
Gregory Pond,gpond@mcmaster.ca,journal_articles,The effect of obesity on rectal dosimetry after permanent prostate brachytherapy,Brachytherapy,2009,10.1016/j.brachy.2008.12.001,https://experts.mcmaster.ca/display/publication276922,2025-07-27T15:12:23.218735
Gregory Pond,gpond@mcmaster.ca,journal_articles,Esthesioneuroblastoma: The Princess Margaret Hospital experience,Head and Neck,2008,10.1002/hed.20920,https://experts.mcmaster.ca/display/publication276923,2025-07-27T15:12:23.218736
Gregory Pond,gpond@mcmaster.ca,journal_articles,Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis,BMC Cancer,2008,10.1186/1471-2407-8-43,https://experts.mcmaster.ca/display/publication276927,2025-07-27T15:12:23.218736
Gregory Pond,gpond@mcmaster.ca,journal_articles,Improving Observer Variability in Target Delineation for Gastro-oesophageal Cancer—the Role of 18Ffluoro-2-deoxy-d-glucose Positron Emission Tomography/Computed Tomography,Clinical Oncology,2008,10.1016/j.clon.2008.06.004,https://experts.mcmaster.ca/display/publication276924,2025-07-27T15:12:23.218737
Gregory Pond,gpond@mcmaster.ca,journal_articles,Medication Reconciliation at Hospital Discharge: Evaluating Discrepancies,Annals of Pharmacotherapy,2008,10.1345/aph.1l190,https://experts.mcmaster.ca/display/publication1521774,2025-07-27T15:12:23.218738
Gregory Pond,gpond@mcmaster.ca,journal_articles,Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa,Annals of Oncology,2008,10.1093/annonc/mdn288,https://experts.mcmaster.ca/display/publication310472,2025-07-27T15:12:23.218739
Gregory Pond,gpond@mcmaster.ca,journal_articles,The use and toxicity of steroids in the management of patients with brain metastases,Supportive Care in Cancer,2008,10.1007/s00520-007-0395-8,https://experts.mcmaster.ca/display/publication276926,2025-07-27T15:12:23.218740
Gregory Pond,gpond@mcmaster.ca,journal_articles,Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma,Transplantation and Cellular Therapy,2008,10.1016/j.bbmt.2008.04.007,https://experts.mcmaster.ca/display/publication276925,2025-07-27T15:12:23.218741
Gregory Pond,gpond@mcmaster.ca,journal_articles,Adherence to Surveillance Guidelines After Curative Resection for Stage II/III Colorectal Cancer,Clinical Colorectal Cancer,2008,10.3816/ccc.2008.n.025,https://experts.mcmaster.ca/display/publication1521789,2025-07-27T15:12:23.218742
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study",Clinical Cancer Research,2008,10.1158/1078-0432.ccr-07-0944,https://experts.mcmaster.ca/display/publication1521791,2025-07-27T15:12:23.218743
Gregory Pond,gpond@mcmaster.ca,journal_articles,"A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798)",Investigational New Drugs,2008,10.1007/s10637-007-9104-1,https://experts.mcmaster.ca/display/publication276928,2025-07-27T15:12:23.218744
Gregory Pond,gpond@mcmaster.ca,journal_articles,Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation,Cancer,2008,10.1002/cncr.23325,https://experts.mcmaster.ca/display/publication1521793,2025-07-27T15:12:23.218745
Gregory Pond,gpond@mcmaster.ca,journal_articles,Improving the Quality of Abstract Reporting for Phase I Cancer Trials,Clinical Cancer Research,2008,10.1158/1078-0432.ccr-07-4886,https://experts.mcmaster.ca/display/publication1521778,2025-07-27T15:12:23.218746
Gregory Pond,gpond@mcmaster.ca,journal_articles,Nomograms to Predict Serious Adverse Events in Phase II Clinical Trials of Molecularly Targeted Agents,Journal of Clinical Oncology,2008,10.1200/jco.2007.14.0673,https://experts.mcmaster.ca/display/publication886155,2025-07-27T15:12:23.218747
Gregory Pond,gpond@mcmaster.ca,journal_articles,A Phase 2 study of perifosine in advanced or metastatic breast cancer,Breast Cancer Research and Treatment,2008,10.1007/s10549-007-9584-x,https://experts.mcmaster.ca/display/publication517956,2025-07-27T15:12:23.218748
Gregory Pond,gpond@mcmaster.ca,journal_articles,Neuroendocrine Tumors of the Gastrointestinal Tract,American Journal of Clinical Oncology,2008,10.1097/coc.0b013e31807a2f49,https://experts.mcmaster.ca/display/publication682704,2025-07-27T15:12:23.218749
Gregory Pond,gpond@mcmaster.ca,journal_articles,Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study,Journal of Clinical Oncology,2008,10.1200/jco.2007.12.4008,https://experts.mcmaster.ca/display/publication1521784,2025-07-27T15:12:23.218750
Gregory Pond,gpond@mcmaster.ca,journal_articles,Long-Term Urinary Sequelae Following125Iodine Prostate Brachytherapy,Investigative Urology,2008,10.1016/j.juro.2007.08.136,https://experts.mcmaster.ca/display/publication276929,2025-07-27T15:12:23.218751
Gregory Pond,gpond@mcmaster.ca,journal_articles,A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium,Investigational New Drugs,2007,10.1007/s10637-007-9066-3,https://experts.mcmaster.ca/display/publication276932,2025-07-27T15:12:23.218752
Gregory Pond,gpond@mcmaster.ca,journal_articles,Role of Fractionated External Beam Radiotherapy in Hemangioblastoma of the Central Nervous System,International Journal of Radiation Oncology Biology Physics,2007,10.1016/j.ijrobp.2007.05.025,https://experts.mcmaster.ca/display/publication276930,2025-07-27T15:12:23.218753
Gregory Pond,gpond@mcmaster.ca,journal_articles,The Influence of Mentorship on Research Productivity in Oncology,American Journal of Clinical Oncology,2007,10.1097/coc.0b013e31805c13f0,https://experts.mcmaster.ca/display/publication1521755,2025-07-27T15:12:23.218753
Gregory Pond,gpond@mcmaster.ca,journal_articles,Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer,Cancer,2007,10.1002/cncr.22902,https://experts.mcmaster.ca/display/publication1521776,2025-07-27T15:12:23.218754
Gregory Pond,gpond@mcmaster.ca,journal_articles,MP-21.03: Penile brachytherapy: results for 60 patients,Urology,2007,10.1016/j.urology.2007.06.121,https://experts.mcmaster.ca/display/publication2552565,2025-07-27T15:12:23.218755
Gregory Pond,gpond@mcmaster.ca,journal_articles,POS-03.95: Long-term urinary sequellae following iodine 125 prostate brachytherapy,Urology,2007,10.1016/j.urology.2007.06.986,https://experts.mcmaster.ca/display/publication2552571,2025-07-27T15:12:23.218756
Gregory Pond,gpond@mcmaster.ca,journal_articles,POS-03.96: The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry,Urology,2007,10.1016/j.urology.2007.06.642,https://experts.mcmaster.ca/display/publication2552559,2025-07-27T15:12:23.218757
Gregory Pond,gpond@mcmaster.ca,journal_articles,Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands,Journal of Clinical Oncology,2007,10.1200/jco.2007.11.8612,https://experts.mcmaster.ca/display/publication757683,2025-07-27T15:12:23.218758
Gregory Pond,gpond@mcmaster.ca,journal_articles,Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors,Clinical Cancer Research,2007,10.1158/1078-0432.ccr-07-0382,https://experts.mcmaster.ca/display/publication618905,2025-07-27T15:12:23.218759
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Abstracts of presentations to the Annual Meetings of the Canadian Society of Colon and Rectal Surgeons Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons: Canadian Surgery Forum, Toronto, Ont., September 6-9, 2007.",Canadian Journal of Surgery,2007,,https://experts.mcmaster.ca/display/publication3254972,2025-07-27T15:12:23.218760
Gregory Pond,gpond@mcmaster.ca,journal_articles,P2-165: A phase I/II study of concurrent pemetrexed/cisplatin/radiation in stage IIIa/b non-small cell lung cancer,Journal of Thoracic Oncology,2007,10.1097/01.jto.0000283823.54863.21,https://experts.mcmaster.ca/display/publication1977743,2025-07-27T15:12:23.218761
Gregory Pond,gpond@mcmaster.ca,journal_articles,UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium,Gynecologic Oncology,2007,10.1016/j.ygyno.2007.02.018,https://experts.mcmaster.ca/display/publication886161,2025-07-27T15:12:23.218762
Gregory Pond,gpond@mcmaster.ca,journal_articles,A comparison of patient adherence and preference of packaging method for oral anticancer agents using conventional pill bottles versus daily pill boxes,European Journal of Cancer Care,2007,10.1111/j.1365-2354.2006.00758.x,https://experts.mcmaster.ca/display/publication310478,2025-07-27T15:12:23.218763
Gregory Pond,gpond@mcmaster.ca,journal_articles,Intraobserver and Interobserver Variability in GTV Delineation on FDG-PET-CT Images of Head and Neck Cancers,International Journal of Radiation Oncology Biology Physics,2007,10.1016/j.ijrobp.2006.12.039,https://experts.mcmaster.ca/display/publication276933,2025-07-27T15:12:23.218764
Gregory Pond,gpond@mcmaster.ca,journal_articles,The impact of an educational DVD on cancer patients considering participation in a phase I clinical trial,Supportive Care in Cancer,2007,10.1007/s00520-006-0199-2,https://experts.mcmaster.ca/display/publication1521768,2025-07-27T15:12:23.218765
Gregory Pond,gpond@mcmaster.ca,journal_articles,The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry,Brachytherapy,2007,10.1016/j.brachy.2007.03.003,https://experts.mcmaster.ca/display/publication276931,2025-07-27T15:12:23.218766
Gregory Pond,gpond@mcmaster.ca,journal_articles,A phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors,Journal of Clinical Oncology,2007,10.1200/jco.2007.25.18_suppl.3576,https://experts.mcmaster.ca/display/publication2552527,2025-07-27T15:12:23.218767
Gregory Pond,gpond@mcmaster.ca,journal_articles,A review of 565 phase II trial abstracts from ASCO 2005: Design characteristics of contemporary trials evaluating cytotoxic versus non-cytotoxic regimens,Journal of Clinical Oncology,2007,10.1200/jco.2007.25.18_suppl.6569,https://experts.mcmaster.ca/display/publication2552523,2025-07-27T15:12:23.218768
Gregory Pond,gpond@mcmaster.ca,journal_articles,"A single agent, phase I pharmacodynamic study of nimotuzumab (TheraCIM-h-R3) in patients with advanced refractory solid tumors",Journal of Clinical Oncology,2007,10.1200/jco.2007.25.18_suppl.14030,https://experts.mcmaster.ca/display/publication2552528,2025-07-27T15:12:23.218768
Gregory Pond,gpond@mcmaster.ca,journal_articles,Adherence to surveillance guidelines following curative resection for stage II and III colorectal cancer,Journal of Clinical Oncology,2007,10.1200/jco.2007.25.18_suppl.4051,https://experts.mcmaster.ca/display/publication1977742,2025-07-27T15:12:23.218769
Gregory Pond,gpond@mcmaster.ca,journal_articles,CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib—A trial of the PMH Phase II Consortium,Journal of Clinical Oncology,2007,10.1200/jco.2007.25.18_suppl.5519,https://experts.mcmaster.ca/display/publication2552525,2025-07-27T15:12:23.218770
Gregory Pond,gpond@mcmaster.ca,journal_articles,Cognitive function and fatigue in cancer patients after chemotherapy: A longitudinal cohort study in patients with colorectal cancer (CRC),Journal of Clinical Oncology,2007,10.1200/jco.2007.25.18_suppl.9099,https://experts.mcmaster.ca/display/publication1977736,2025-07-27T15:12:23.218771
Gregory Pond,gpond@mcmaster.ca,journal_articles,Correlation between changes in 2- or 3-year disease-free survival (DFS) and 5-year overall survival (OS) in adjuvant breast cancer trials from 1966–2006,Journal of Clinical Oncology,2007,10.1200/jco.2007.25.18_suppl.581,https://experts.mcmaster.ca/display/publication1977739,2025-07-27T15:12:23.218772
Gregory Pond,gpond@mcmaster.ca,journal_articles,Cytokine levels in patients (pts) with colorectal cancer and breast cancer and their relationship to fatigue and cognitive function,Journal of Clinical Oncology,2007,10.1200/jco.2007.25.18_suppl.9070,https://experts.mcmaster.ca/display/publication1977737,2025-07-27T15:12:23.218773
Gregory Pond,gpond@mcmaster.ca,journal_articles,Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival of the TAX 327 study,Journal of Clinical Oncology,2007,10.1200/jco.2007.25.18_suppl.5005,https://experts.mcmaster.ca/display/publication2552526,2025-07-27T15:12:23.218774
Gregory Pond,gpond@mcmaster.ca,journal_articles,Initial versus recent outcomes with a non–risk adapted surveillance policy in stage I non-seminomatous germ cell tumors (NSGCT),Journal of Clinical Oncology,2007,10.1200/jco.2007.25.18_suppl.5021,https://experts.mcmaster.ca/display/publication1977741,2025-07-27T15:12:23.218775
Gregory Pond,gpond@mcmaster.ca,journal_articles,Nomograms to predict serious adverse events (SAEs) in patients (pts) enrolled in phase II clinical trials of molecularly targeted agents (MTAs),Journal of Clinical Oncology,2007,10.1200/jco.2007.25.18_suppl.6601,https://experts.mcmaster.ca/display/publication1977738,2025-07-27T15:12:23.218776
Gregory Pond,gpond@mcmaster.ca,journal_articles,The quality of phase I trial (P1T) abstracts submitted to ASCO meetings,Journal of Clinical Oncology,2007,10.1200/jco.2007.25.18_suppl.6532,https://experts.mcmaster.ca/display/publication2552524,2025-07-27T15:12:23.218777
Gregory Pond,gpond@mcmaster.ca,journal_articles,Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib,Journal of Clinical Oncology,2007,10.1200/jco.2006.07.6554,https://experts.mcmaster.ca/display/publication757687,2025-07-27T15:12:23.218778
Gregory Pond,gpond@mcmaster.ca,journal_articles,A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia,Investigational New Drugs,2007,10.1007/s10637-006-9009-4,https://experts.mcmaster.ca/display/publication276934,2025-07-27T15:12:23.218779
Gregory Pond,gpond@mcmaster.ca,journal_articles,Penile brachytherapy: Results for 60 patients,Brachytherapy,2007,10.1016/j.brachy.2007.02.018,https://experts.mcmaster.ca/display/publication2552566,2025-07-27T15:12:23.218780
Gregory Pond,gpond@mcmaster.ca,journal_articles,The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry,Brachytherapy,2007,10.1016/j.brachy.2007.02.091,https://experts.mcmaster.ca/display/publication1977726,2025-07-27T15:12:23.218781
Gregory Pond,gpond@mcmaster.ca,journal_articles,Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: A phase I-II study,International Journal of Radiation Oncology Biology Physics,2007,10.1016/j.ijrobp.2006.10.015,https://experts.mcmaster.ca/display/publication682754,2025-07-27T15:12:23.218781
Gregory Pond,gpond@mcmaster.ca,journal_articles,A feasibility study of an internal control methodology using hydrocortisone cream for the management of skin reactions in patients receiving radical radiation therapy for cancers of the head and neck,Journal of Radiotherapy in Practice,2006,10.1017/s1460396906000306,https://experts.mcmaster.ca/display/publication1730546,2025-07-27T15:12:23.218782
Gregory Pond,gpond@mcmaster.ca,journal_articles,Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital,BMC Cancer,2006,10.1186/1471-2407-6-263,https://experts.mcmaster.ca/display/publication757722,2025-07-27T15:12:23.218783
Gregory Pond,gpond@mcmaster.ca,journal_articles,Understanding the attitudes of the elderly towards enrolment into cancer clinical trials,BMC Cancer,2006,10.1186/1471-2407-6-34,https://experts.mcmaster.ca/display/publication1521858,2025-07-27T15:12:23.218784
Gregory Pond,gpond@mcmaster.ca,journal_articles,Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus,European Journal of Cancer,2006,10.1016/j.ejca.2006.03.015,https://experts.mcmaster.ca/display/publication310502,2025-07-27T15:12:23.218785
Gregory Pond,gpond@mcmaster.ca,journal_articles,Computerized tomographic simulation compared with clinical mark-up in palliative radiotherapy: A prospective study,International Journal of Radiation Oncology Biology Physics,2006,10.1016/j.ijrobp.2006.01.034,https://experts.mcmaster.ca/display/publication276935,2025-07-27T15:12:23.218786
Gregory Pond,gpond@mcmaster.ca,journal_articles,Radiation dose to the internal pudendal arteries from permanent-seed prostate brachytherapy as determined by time-of-flight MR angiography,International Journal of Radiation Oncology Biology Physics,2006,10.1016/j.ijrobp.2006.01.037,https://experts.mcmaster.ca/display/publication276936,2025-07-27T15:12:23.218787
Gregory Pond,gpond@mcmaster.ca,journal_articles,A phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) TheraCIM-h-R3 (nimotuzumab) in patients with advanced solid tumors,Journal of Clinical Oncology,2006,10.1200/jco.2006.24.18_suppl.13054,https://experts.mcmaster.ca/display/publication1977734,2025-07-27T15:12:23.218788
Gregory Pond,gpond@mcmaster.ca,journal_articles,A phase II trial of oblimersen sodium (G3139) in combination with doxorubicin (DOX) in advanced hepatocellular carcinoma (HCC). NCI protocol # 5798,Journal of Clinical Oncology,2006,10.1200/jco.2006.24.18_suppl.14072,https://experts.mcmaster.ca/display/publication1977733,2025-07-27T15:12:23.218789
Gregory Pond,gpond@mcmaster.ca,journal_articles,A randomized controlled trial to evaluate the impact of an educational DVD on cancer patients considering participation in a phase I clinical trial,Journal of Clinical Oncology,2006,10.1200/jco.2006.24.18_suppl.6011,https://experts.mcmaster.ca/display/publication2552520,2025-07-27T15:12:23.218790
Gregory Pond,gpond@mcmaster.ca,journal_articles,Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study,Journal of Clinical Oncology,2006,10.1200/jco.2006.24.18_suppl.4516,https://experts.mcmaster.ca/display/publication2552522,2025-07-27T15:12:23.218791
Gregory Pond,gpond@mcmaster.ca,journal_articles,Cognitive impairment associated with chemotherapy for breast cancer: An exploratory case-control study,Journal of Clinical Oncology,2006,10.1200/jco.2006.24.18_suppl.8501,https://experts.mcmaster.ca/display/publication2552516,2025-07-27T15:12:23.218792
Gregory Pond,gpond@mcmaster.ca,journal_articles,Cytokine levels in patients (pts) with localized colorectal cancer (CRC) after surgery and their relationship to fatigue and cognitive function,Journal of Clinical Oncology,2006,10.1200/jco.2006.24.18_suppl.3623,https://experts.mcmaster.ca/display/publication1977732,2025-07-27T15:12:23.218793
Gregory Pond,gpond@mcmaster.ca,journal_articles,Long-term results of concurrent gemcitabine (G) and radiotherapy (GRT) for locally advanced (LA) or high-risk resected (R) pancreatic cancer,Journal of Clinical Oncology,2006,10.1200/jco.2006.24.18_suppl.4101,https://experts.mcmaster.ca/display/publication1977730,2025-07-27T15:12:23.218794
Gregory Pond,gpond@mcmaster.ca,journal_articles,Neuroendocrine tumors (NET) of the gastrointestinal tract: A decade of experience at the Princess Margaret Hospital,Journal of Clinical Oncology,2006,10.1200/jco.2006.24.18_suppl.4093,https://experts.mcmaster.ca/display/publication1977731,2025-07-27T15:12:23.218795
Gregory Pond,gpond@mcmaster.ca,journal_articles,Phase II study of sorafenib (BAY 43–9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial,Journal of Clinical Oncology,2006,10.1200/jco.2006.24.18_suppl.5084,https://experts.mcmaster.ca/display/publication2552521,2025-07-27T15:12:23.218795
Gregory Pond,gpond@mcmaster.ca,journal_articles,Quality of life (QOL) of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) following treatment with docetaxel or mitoxantrone in the TAX-327 study,Journal of Clinical Oncology,2006,10.1200/jco.2006.24.18_suppl.4557,https://experts.mcmaster.ca/display/publication1977729,2025-07-27T15:12:23.218796
Gregory Pond,gpond@mcmaster.ca,journal_articles,Natural History and Chemotherapy Effectiveness for Advanced Adenocarcinoma of the Small Bowel: A Retrospective Review of 113 Cases,American Journal of Clinical Oncology,2006,10.1097/01.coc.0000214931.01062.01,https://experts.mcmaster.ca/display/publication2552512,2025-07-27T15:12:23.218797
Gregory Pond,gpond@mcmaster.ca,journal_articles,Natural History and Chemotherapy Effectiveness for Advanced Adenocarcinoma of the Small Bowel: A Retrospective Review of 113 Cases,American Journal of Clinical Oncology,2006,10.1097/01.coc.0000214931.01062.01,https://experts.mcmaster.ca/display/publication682774,2025-07-27T15:12:23.218798
Gregory Pond,gpond@mcmaster.ca,journal_articles,Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer,Lung Cancer,2006,10.1016/j.lungcan.2006.02.006,https://experts.mcmaster.ca/display/publication1521864,2025-07-27T15:12:23.218799
Gregory Pond,gpond@mcmaster.ca,journal_articles,Rectal-wall dose dependence on postplan timing after permanent-seed prostate brachytherapy,International Journal of Radiation Oncology Biology Physics,2006,10.1016/j.ijrobp.2005.12.024,https://experts.mcmaster.ca/display/publication276938,2025-07-27T15:12:23.218800
Gregory Pond,gpond@mcmaster.ca,journal_articles,Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination,Clinical Cancer Research,2006,10.1158/1078-0432.ccr-05-1798,https://experts.mcmaster.ca/display/publication886168,2025-07-27T15:12:23.218801
Gregory Pond,gpond@mcmaster.ca,journal_articles,Long-Term Survival after Blood and Marrow Transplantation: Comparison with an Age- and Gender-Matched Normative Population,Transplantation and Cellular Therapy,2006,10.1016/j.bbmt.2005.11.518,https://experts.mcmaster.ca/display/publication1521871,2025-07-27T15:12:23.218802
Gregory Pond,gpond@mcmaster.ca,journal_articles,Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer.,Canadian Journal of Urology,2006,,https://experts.mcmaster.ca/display/publication1521866,2025-07-27T15:12:23.218803
Gregory Pond,gpond@mcmaster.ca,journal_articles,Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer,British Journal of Cancer,2006,10.1038/sj.bjc.6603055,https://experts.mcmaster.ca/display/publication471265,2025-07-27T15:12:23.218804
Gregory Pond,gpond@mcmaster.ca,journal_articles,Radiation dose to the internal pudendal arteries from permanent seed prostate brachytherapy as determined by time-of-flight angiography,Brachytherapy,2006,10.1016/j.brachy.2006.03.009,https://experts.mcmaster.ca/display/publication1977727,2025-07-27T15:12:23.218805
Gregory Pond,gpond@mcmaster.ca,journal_articles,Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy,British Journal of Cancer,2006,10.1038/sj.bjc.6603048,https://experts.mcmaster.ca/display/publication1521862,2025-07-27T15:12:23.218806
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: Effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival",International Journal of Radiation Oncology Biology Physics,2006,10.1016/j.ijrobp.2005.08.012,https://experts.mcmaster.ca/display/publication947822,2025-07-27T15:12:23.218807
Gregory Pond,gpond@mcmaster.ca,journal_articles,Identification of Small Molecules that Sensitize Resistant Tumor Cells to Tumor Necrosis Factor-Family Death Receptors,Cancer Research,2006,10.1158/0008-5472.can-05-1061,https://experts.mcmaster.ca/display/publication194182,2025-07-27T15:12:23.218808
Gregory Pond,gpond@mcmaster.ca,journal_articles,Making Sense of Prostate Specific Antigen: Improving its Predictive Value in Patients Undergoing Prostate Biopsy,Investigative Urology,2006,10.1016/s0022-5347(05)00159-x,https://experts.mcmaster.ca/display/publication1521868,2025-07-27T15:12:23.218809
Gregory Pond,gpond@mcmaster.ca,journal_articles,Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study,Annals of Oncology,2006,10.1093/annonc/mdj076,https://experts.mcmaster.ca/display/publication886169,2025-07-27T15:12:23.218809
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors",Anti-Cancer Drugs,2006,10.1097/01.cad.0000190282.05748.63,https://experts.mcmaster.ca/display/publication1422857,2025-07-27T15:12:23.218810
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy",Brachytherapy,2006,10.1016/j.brachy.2005.12.002,https://experts.mcmaster.ca/display/publication276937,2025-07-27T15:12:23.218811
Gregory Pond,gpond@mcmaster.ca,journal_articles,A Multicenter Phase II Study of “Adjuvant” Irinotecan Following Resection of Colorectal Hepatic Metastases,American Journal of Clinical Oncology,2005,10.1097/01.coc.0000178031.69209.47,https://experts.mcmaster.ca/display/publication682781,2025-07-27T15:12:23.218812
Gregory Pond,gpond@mcmaster.ca,journal_articles,Assessment of the downstream portion of the mitochondrial pathway of caspase activation in patients with acute myeloid leukemia,Apoptosis : an international journal on programmed cell death,2005,10.1007/s10495-005-2764-4,https://experts.mcmaster.ca/display/publication1521856,2025-07-27T15:12:23.218813
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Weekly Cyclophosphamide and Alternate-Day Prednisone: An Effective, Convenient, and Well-Tolerated Oral Treatment for Relapsed Multiple Myeloma After Autologous Stem Cell Transplantation",Mayo Clinic proceedings,2005,10.4065/80.12.1578,https://experts.mcmaster.ca/display/publication1521874,2025-07-27T15:12:23.218814
Gregory Pond,gpond@mcmaster.ca,journal_articles,Radiation therapy for Bowen’s disease of the skin,International Journal of Radiation Oncology Biology Physics,2005,10.1016/j.ijrobp.2005.02.024,https://experts.mcmaster.ca/display/publication1521875,2025-07-27T15:12:23.218815
Gregory Pond,gpond@mcmaster.ca,journal_articles,Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies,International Journal of Gynecological Cancer,2005,10.1136/ijgc-00009577-200509000-00014,https://experts.mcmaster.ca/display/publication1977712,2025-07-27T15:12:23.218816
Gregory Pond,gpond@mcmaster.ca,journal_articles,Factors Influencing the Use of Single vs Multiple Fractions of Palliative Radiotherapy for Bone Metastases: A 5-Year Review,Clinical Oncology,2005,10.1016/j.clon.2005.03.012,https://experts.mcmaster.ca/display/publication1521881,2025-07-27T15:12:23.218817
Gregory Pond,gpond@mcmaster.ca,journal_articles,P-526 Phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC),Lung Cancer,2005,10.1016/s0169-5002(05)81019-0,https://experts.mcmaster.ca/display/publication2552572,2025-07-27T15:12:23.218818
Gregory Pond,gpond@mcmaster.ca,journal_articles,Sequential evaluation of prostate edema after permanent seed prostate brachytherapy using CT-MRI fusion,International Journal of Radiation Oncology Biology Physics,2005,10.1016/j.ijrobp.2004.12.012,https://experts.mcmaster.ca/display/publication276939,2025-07-27T15:12:23.218819
Gregory Pond,gpond@mcmaster.ca,journal_articles,A phase II study of BAY 43–9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC),Journal of Clinical Oncology,2005,10.1200/jco.2005.23.16_suppl.5566,https://experts.mcmaster.ca/display/publication1977724,2025-07-27T15:12:23.218820
Gregory Pond,gpond@mcmaster.ca,journal_articles,A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas (NECs),Journal of Clinical Oncology,2005,10.1200/jco.2005.23.16_suppl.3096,https://experts.mcmaster.ca/display/publication2552553,2025-07-27T15:12:23.218821
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Analysis of Treatment Practices for Elderly Cancer Patients in Ontario, Canada",Journal of Clinical Oncology,2005,10.1200/jco.2005.06.742,https://experts.mcmaster.ca/display/publication1521883,2025-07-27T15:12:23.218822
Gregory Pond,gpond@mcmaster.ca,journal_articles,Penile brachytherapy: Results for 49 patients,International Journal of Radiation Oncology Biology Physics,2005,10.1016/j.ijrobp.2004.10.016,https://experts.mcmaster.ca/display/publication276941,2025-07-27T15:12:23.218823
Gregory Pond,gpond@mcmaster.ca,journal_articles,Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors,Journal of Clinical Oncology,2005,10.1200/jco.2005.23.16_suppl.7253,https://experts.mcmaster.ca/display/publication2552554,2025-07-27T15:12:23.218823
Gregory Pond,gpond@mcmaster.ca,journal_articles,Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital [PMH] Phase II Consortium,Journal of Clinical Oncology,2005,10.1200/jco.2005.23.16_suppl.4677,https://experts.mcmaster.ca/display/publication2552552,2025-07-27T15:12:23.218824
Gregory Pond,gpond@mcmaster.ca,journal_articles,Predictive value of eTag dimerization assay in patients with metastatic colorectal cancer treated with erlotinib,Journal of Clinical Oncology,2005,10.1200/jco.2005.23.16_suppl.9618,https://experts.mcmaster.ca/display/publication2552556,2025-07-27T15:12:23.218825
Gregory Pond,gpond@mcmaster.ca,journal_articles,The impact and perception of mandatory tumor biopsies (Bx) for correlative studies in clinical trials of novel anticancer agents,Journal of Clinical Oncology,2005,10.1200/jco.2005.23.16_suppl.6006,https://experts.mcmaster.ca/display/publication1977725,2025-07-27T15:12:23.218826
Gregory Pond,gpond@mcmaster.ca,journal_articles,Willingness of older people with cancer to participate in cancer clinical trials is not a barrier to accrual,Journal of Clinical Oncology,2005,10.1200/jco.2005.23.16_suppl.8245,https://experts.mcmaster.ca/display/publication2552555,2025-07-27T15:12:23.218827
Gregory Pond,gpond@mcmaster.ca,journal_articles,Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells,Blood,2005,10.1182/blood-2004-08-3168,https://experts.mcmaster.ca/display/publication1521909,2025-07-27T15:12:23.218828
Gregory Pond,gpond@mcmaster.ca,journal_articles,Posttreatment Complications of Early-Stage Prostate Cancer Patients,Cancer Journal,2005,10.1097/00130404-200503000-00007,https://experts.mcmaster.ca/display/publication276940,2025-07-27T15:12:23.218829
Gregory Pond,gpond@mcmaster.ca,journal_articles,Assessing perfusion changes during whole brain irradiation for patients with cerebral metastases,Journal of Neuro-Oncology,2005,10.1007/s11060-004-1722-2,https://experts.mcmaster.ca/display/publication947837,2025-07-27T15:12:23.218835
Gregory Pond,gpond@mcmaster.ca,journal_articles,Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study,Journal of Clinical Oncology,2005,10.1200/jco.2005.06.125,https://experts.mcmaster.ca/display/publication1422930,2025-07-27T15:12:23.218836
Gregory Pond,gpond@mcmaster.ca,journal_articles,Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation,Bone Marrow Transplantation,2005,10.1038/sj.bmt.1704706,https://experts.mcmaster.ca/display/publication456769,2025-07-27T15:12:23.218837
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Weekly Cyclophosphamide and Alternate Day Prednisone: An Effective, Convenient and Well Tolerated Treatment for Relapsed Multiple Myeloma Following Autologous Stem Cell Transplant.",Blood,2004,10.1182/blood.v104.11.4917.4917,https://experts.mcmaster.ca/display/publication1977728,2025-07-27T15:12:23.218838
Gregory Pond,gpond@mcmaster.ca,journal_articles,Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status,International Journal of Radiation Oncology Biology Physics,2004,10.1016/j.ijrobp.2004.05.011,https://experts.mcmaster.ca/display/publication599155,2025-07-27T15:12:23.218839
Gregory Pond,gpond@mcmaster.ca,journal_articles,408 A phase II study of erlotinib in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (PHL-002e/NCIC CTG IND.157),"European Journal of Cancer, Supplement",2004,10.1016/s1359-6349(04)80415-4,https://experts.mcmaster.ca/display/publication2552567,2025-07-27T15:12:23.218840
Gregory Pond,gpond@mcmaster.ca,journal_articles,Sequential evaluation of prostate edema following permanent seed prostate brachytherapy using CT-MRI fusion,International Journal of Radiation Oncology Biology Physics,2004,10.1016/j.ijrobp.2004.07.365,https://experts.mcmaster.ca/display/publication2552561,2025-07-27T15:12:23.218841
Gregory Pond,gpond@mcmaster.ca,journal_articles,Prognostic factors in brain metastases: can we determine patients who do not benefit from whole-brain radiotherapy?,Clinical Oncology,2004,10.1016/j.clon.2004.03.006,https://experts.mcmaster.ca/display/publication1521898,2025-07-27T15:12:23.218842
Gregory Pond,gpond@mcmaster.ca,journal_articles,Comparison of outcomes of phase II trials (P2Ts) and subsequent randomized control trials (RCTs) using identical therapeutic regimens,Journal of Clinical Oncology,2004,10.1200/jco.2004.22.90140.6000,https://experts.mcmaster.ca/display/publication2552541,2025-07-27T15:12:23.218843
Gregory Pond,gpond@mcmaster.ca,journal_articles,Comparison of outcomes of phase II trials (P2Ts) and subsequent randomized control trials (RCTs) using identical therapeutic regimens,Journal of Clinical Oncology,2004,10.1200/jco.2004.22.14_suppl.6000,https://experts.mcmaster.ca/display/publication2552543,2025-07-27T15:12:23.218844
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Retrospective analysis of treatment practices for elderly cancer patients (Pts) in Ontario, Canada",Journal of Clinical Oncology,2004,10.1200/jco.2004.22.90140.8168,https://experts.mcmaster.ca/display/publication2552540,2025-07-27T15:12:23.218845
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Retrospective analysis of treatment practices for elderly cancer patients (Pts) in Ontario, Canada",Journal of Clinical Oncology,2004,10.1200/jco.2004.22.14_suppl.8168,https://experts.mcmaster.ca/display/publication2552542,2025-07-27T15:12:23.218846
Gregory Pond,gpond@mcmaster.ca,journal_articles,Tolerability of the Intergroup 0099 regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status,Journal of Clinical Oncology,2004,10.1200/jco.2004.22.14_suppl.5572,https://experts.mcmaster.ca/display/publication2552544,2025-07-27T15:12:23.218846
Gregory Pond,gpond@mcmaster.ca,journal_articles,Tolerability of the Intergroup 0099 regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status,Journal of Clinical Oncology,2004,10.1200/jco.2004.22.90140.5572,https://experts.mcmaster.ca/display/publication2552545,2025-07-27T15:12:23.218847
Gregory Pond,gpond@mcmaster.ca,journal_articles,Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience,Annals of Oncology,2004,10.1093/annonc/mdh172,https://experts.mcmaster.ca/display/publication1521878,2025-07-27T15:12:23.218848
Gregory Pond,gpond@mcmaster.ca,journal_articles,Defining a 0.5-Mb Region of Genomic Gain on Chromosome 6p22 in Bladder Cancer by Quantitative-Multiplex Polymerase Chain Reaction,American Journal of Pathology,2004,10.1016/s0002-9440(10)63118-5,https://experts.mcmaster.ca/display/publication1521884,2025-07-27T15:12:23.218849
Gregory Pond,gpond@mcmaster.ca,journal_articles,Measured and estimated GFR in healthy potential kidney donors,American Journal of Kidney Diseases,2004,10.1053/j.ajkd.2003.09.026,https://experts.mcmaster.ca/display/publication1521886,2025-07-27T15:12:23.218850
Gregory Pond,gpond@mcmaster.ca,journal_articles,191 Phase II trial of gemcitabine and capecitabine (GemCap) in patients with advanced biliary cancer,"European Journal of Cancer, Supplement",2003,10.1016/s1359-6349(03)90224-2,https://experts.mcmaster.ca/display/publication2552570,2025-07-27T15:12:23.218851
Gregory Pond,gpond@mcmaster.ca,journal_articles,A Phase I Study of Pegylated Liposomal Doxorubicin Hydrochloride (Caelyx™) in Combination with Cyclophosphamide and Vincristine as Second-Line Treatment of Patients with Small-Cell Lung Cancer,Clinical Lung Cancer,2003,10.3816/clc.2003.n.024,https://experts.mcmaster.ca/display/publication1521890,2025-07-27T15:12:23.218852
Gregory Pond,gpond@mcmaster.ca,journal_articles,Phase II study of pegylated liposomal doxorubicin HCI (caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer,Lung Cancer,2003,10.1016/s0169-5002(03)92523-2,https://experts.mcmaster.ca/display/publication2552569,2025-07-27T15:12:23.218853
Gregory Pond,gpond@mcmaster.ca,journal_articles,Speech Recognition as a Transcription Aid: A Randomized Comparison With Standard Transcription,Journal of the American Medical Informatics Association : JAMIA,2003,10.1197/jamia.m1130,https://experts.mcmaster.ca/display/publication1521889,2025-07-27T15:12:23.218854
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial",Supportive Care in Cancer,2003,10.1007/s00520-002-0378-8,https://experts.mcmaster.ca/display/publication276943,2025-07-27T15:12:23.218855
Gregory Pond,gpond@mcmaster.ca,journal_articles,Chemotherapy with gemcitabine‐containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma,Cancer,2002,10.1002/cncr.10995,https://experts.mcmaster.ca/display/publication1521888,2025-07-27T15:12:23.218856
Gregory Pond,gpond@mcmaster.ca,journal_articles,???PSA-itis???: Knowledge of Serum Prostate Specific Antigen and Other Causes of Anxiety in Men with Metastatic Prostate Cancer,Investigative Urology,2002,10.1097/00005392-200212000-00038,https://experts.mcmaster.ca/display/publication1977723,2025-07-27T15:12:23.218857
Gregory Pond,gpond@mcmaster.ca,journal_articles,Ethical communication in clinical trials,Cancer,2002,10.1002/cncr.10994,https://experts.mcmaster.ca/display/publication1521859,2025-07-27T15:12:23.218858
Gregory Pond,gpond@mcmaster.ca,journal_articles,“PSA-itis”: Knowledge of Serum Prostate Specific Antigen and Other Causes of Anxiety in Men with Metastatic Prostate Cancer,Investigative Urology,2002,10.1016/s0022-5347(05)64180-8,https://experts.mcmaster.ca/display/publication1521860,2025-07-27T15:12:23.218859
Gregory Pond,gpond@mcmaster.ca,journal_articles,Frequency of infection in patients with rheumatoid arthritis compared with controls: A population‐based study,Arthritis and Rheumatism,2002,10.1002/art.10524,https://experts.mcmaster.ca/display/publication1521895,2025-07-27T15:12:23.218860
Gregory Pond,gpond@mcmaster.ca,journal_articles,Predictors of infection in rheumatoid arthritis,Arthritis and Rheumatism,2002,10.1002/art.10529,https://experts.mcmaster.ca/display/publication1730545,2025-07-27T15:12:23.218861
Gregory Pond,gpond@mcmaster.ca,journal_articles,Prognostic factors for life expectancy in nonagenarians with nonmelanoma skin cancer: Implications for selecting surgical candidates,Journal of American Academy of Dermatology,2002,10.1067/mjd.2002.122740,https://experts.mcmaster.ca/display/publication1521894,2025-07-27T15:12:23.218861
Gregory Pond,gpond@mcmaster.ca,journal_articles,The Decision to Accept Treatment for Osteoporosis Following Hip Fracture: Exploring the Woman’s Perspective Using a Stage-of-Change Model,Osteoporosis International,2002,10.1007/s001980200073,https://experts.mcmaster.ca/display/publication1521893,2025-07-27T15:12:23.218862
Gregory Pond,gpond@mcmaster.ca,journal_articles,The Position of the Polycystic Kidney Disease 1 (PKD1) Gene Mutation Correlates with the Severity of Renal Disease,Journal of the American Society of Nephrology,2002,10.1097/01.asn.0000013300.11876.37,https://experts.mcmaster.ca/display/publication1521891,2025-07-27T15:12:23.218863
Gregory Pond,gpond@mcmaster.ca,journal_articles,Direct Medical Costs Attributable to Osteoporotic Fractures,Osteoporosis International,2002,10.1007/s001980200033,https://experts.mcmaster.ca/display/publication1521892,2025-07-27T15:12:23.218864
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty‐year period",Arthritis and Rheumatism,2002,10.1002/art.509,https://experts.mcmaster.ca/display/publication1521906,2025-07-27T15:12:23.218865
Gregory Pond,gpond@mcmaster.ca,journal_articles,Dermopathy of Graves' Disease (Pretibial Myxedema): Long-Term Outcome,Journal of Clinical Endocrinology and Metabolism (JCEM),2002,10.1210/jc.87.2.438,https://experts.mcmaster.ca/display/publication2553037,2025-07-27T15:12:23.218866
Gregory Pond,gpond@mcmaster.ca,journal_articles,Dermopathy of Graves’ Disease (Pretibial Myxedema): Long-Term Outcome,Journal of Clinical Endocrinology and Metabolism (JCEM),2002,10.1210/jcem.87.2.8220,https://experts.mcmaster.ca/display/publication1521897,2025-07-27T15:12:23.218867
Gregory Pond,gpond@mcmaster.ca,journal_articles,The utility of transition zone index in predicting acute urinary morbidity after 125I prostate brachytherapy,Brachytherapy,2002,10.1016/s1538-4721(02)00055-7,https://experts.mcmaster.ca/display/publication276942,2025-07-27T15:12:23.218868
Gregory Pond,gpond@mcmaster.ca,journal_articles,"Applications: Estimation of the Magnitude of Victory in One‐day Cricket RMIT University, Mayo Clinic Rochester and Simon Fraser University",Australian and New Zealand Journal of Statistics,2001,10.1111/1467-842x.00172,https://experts.mcmaster.ca/display/publication1521908,2025-07-27T15:12:23.218869
Gregory Pond,gpond@mcmaster.ca,journal_articles,Treating Fibromyalgia With a Brief Interdisciplinary Program: Initial Outcomes and Predictors of Response,Mayo Clinic proceedings,2001,10.4065/76.4.384,https://experts.mcmaster.ca/display/publication1521896,2025-07-27T15:12:23.218870
Gregory Pond,gpond@mcmaster.ca,journal_articles,Treating Fibromyalgia With a Brief Interdisciplinary Program: Initial Outcomes and Predictors of Response,Mayo Clinic proceedings,2001,10.1016/s0025-6196(11)62386-0,https://experts.mcmaster.ca/display/publication2552558,2025-07-27T15:12:23.218871
Gregory Pond,gpond@mcmaster.ca,journal_articles,Genetic Counselling Referral Rates and Uptake of BRCA1 and BRCA2 Testing among Women Diagnosed with Serous Ovarian Cancer in a Tertiary Care Cancer Centre,Genetic Syndromes and Gene Therapy,,10.4172/2157-7412.1000156,https://experts.mcmaster.ca/display/publication2552563,2025-07-27T15:12:23.218872
Gregory Pond,gpond@mcmaster.ca,chapters,Essential Statistical Tests,,2022,10.1007/978-3-319-52636-2_118,https://experts.mcmaster.ca/display/publication2552498,2025-07-27T15:12:23.218873
Gregory Pond,gpond@mcmaster.ca,chapters,Essential Statistical Tests,,2020,10.1007/978-3-319-52677-5_118-1,https://experts.mcmaster.ca/display/publication2552529,2025-07-27T15:12:23.218874
Gregory Pond,gpond@mcmaster.ca,chapters,Types of Variables and Distributions,,2018,10.1007/978-3-319-71324-3_3,https://experts.mcmaster.ca/display/publication1730544,2025-07-27T15:12:23.218875
Gregory Pond,gpond@mcmaster.ca,conferences,716 A randomized phase II window of opportunity clinical trial of PD-1 +/- IL-4 inhibition in early-stage ER+ HER2- breast cancer,,2024,10.1136/jitc-2024-sitc2024.0716,https://experts.mcmaster.ca/display/publication3492724,2025-07-27T15:12:23.218876
Gregory Pond,gpond@mcmaster.ca,conferences,Prognostic Value of Irradiated Cardiac and Metabolic Tumor Volume in Unresected LA-NSCLC Treated with Concurrent Chemo-Radiotherapy.,Journal of Thoracic Oncology,2024,,https://experts.mcmaster.ca/display/publication3511138,2025-07-27T15:12:23.218877
Gregory Pond,gpond@mcmaster.ca,conferences,A Real-World Comparison of First-Line Regimens in Transplant Ineligible Patients with Multiple Myeloma,"Clinical Lymphoma, Myeloma and Leukemia",2024,,https://experts.mcmaster.ca/display/publication3512506,2025-07-27T15:12:23.218878
Gregory Pond,gpond@mcmaster.ca,conferences,PHASE II RANDOMIZED TRIAL OF OPTIMAL RECURRENCE-DIRECTED THERAPY (RDT) WITHOUT OR WITH ANDROGEN-DEPRIVATION THERAPY (ADT) IN RADIO-RECURRENT OLIGO-METASTATIC HORMONE/CASTRATE SENSITIVE PROSTATE CANCER (ROMCSPC): THE OCOG-RATIONAL-PCS TRIAL,Radiotherapy and Oncology,2024,,https://experts.mcmaster.ca/display/publication3511142,2025-07-27T15:12:23.218879
Gregory Pond,gpond@mcmaster.ca,conferences,SEX-RELATED VARIATIONS IN POST-BURN PATHOPHYSIOLOGY IN ADULTS AND OLDER ADULTS,Shock,2024,,https://experts.mcmaster.ca/display/publication3512507,2025-07-27T15:12:23.218880
Gregory Pond,gpond@mcmaster.ca,conferences,Incidence of venous thromboembolism in newly diagnosed glioblastoma multi-forme and associated risk factors: A retrospective chart review,Journal of Clinical Oncology,2024,,https://experts.mcmaster.ca/display/publication3460999,2025-07-27T15:12:23.218881
Gregory Pond,gpond@mcmaster.ca,conferences,"Nivolumab in Squamous Cell Carcinomas of the Head and Neck (SCCHN): A Real-world Outcome Study in Ontario, Canada","Journal of immunotherapy (Hagerstown, Md. : 1997)",2024,10.1097/cji.0000000000000501,https://experts.mcmaster.ca/display/publication2446655,2025-07-27T15:12:23.218882
Gregory Pond,gpond@mcmaster.ca,conferences,SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma,Clinical Cancer Research,2023,10.1158/1078-0432.ccr-22-3207,https://experts.mcmaster.ca/display/publication1906780,2025-07-27T15:12:23.218883
Gregory Pond,gpond@mcmaster.ca,conferences,"Assessment of risk of overall and late distant recurrence by Breast Cancer Index in postmenopausal women with early-stage, HR plus breast cancer in the TEAM trial.",Journal of Clinical Oncology,2023,,https://experts.mcmaster.ca/display/publication3297236,2025-07-27T15:12:23.218884
Gregory Pond,gpond@mcmaster.ca,conferences,Can synthetic data accurately mimic oncology clinical trials?,Journal of Clinical Oncology,2023,,https://experts.mcmaster.ca/display/publication3297235,2025-07-27T15:12:23.218884
Gregory Pond,gpond@mcmaster.ca,conferences,"Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, Influence, CTS-5)? A TEAM Pathology substudy.",Journal of Clinical Oncology,2023,,https://experts.mcmaster.ca/display/publication3295630,2025-07-27T15:12:23.218885
Gregory Pond,gpond@mcmaster.ca,conferences,Evaluating response to interventions for vasomotor symptoms in patients with breast cancer: A patient-centered approach,Journal of Clinical Oncology,2023,,https://experts.mcmaster.ca/display/publication3297239,2025-07-27T15:12:23.218886
Gregory Pond,gpond@mcmaster.ca,conferences,Multisystem immune-related adverse events from dual agent immunotherapy use,Journal of Clinical Oncology,2023,,https://experts.mcmaster.ca/display/publication3295616,2025-07-27T15:12:23.218887
Gregory Pond,gpond@mcmaster.ca,conferences,Phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE trial.,Journal of Clinical Oncology,2023,,https://experts.mcmaster.ca/display/publication3297237,2025-07-27T15:12:23.218888
Gregory Pond,gpond@mcmaster.ca,conferences,Use of prophylactic and reactive feeding tubes in patients with esophageal cancer: A single-centre cohort study,Journal of Clinical Oncology,2023,,https://experts.mcmaster.ca/display/publication3297238,2025-07-27T15:12:23.218889
Gregory Pond,gpond@mcmaster.ca,conferences,A patient survey evaluating COVID-19-induced changes in follow-up of patients with EBC: opportunities for enhanced evidence-based practice?,Breast,2023,,https://experts.mcmaster.ca/display/publication3288300,2025-07-27T15:12:23.218890
Gregory Pond,gpond@mcmaster.ca,conferences,"A pragmatic randomised, multicentre trial evaluating the dose timing (morning vs evening) of endocrine therapy for early breast cancer (REaCT-CHRONO Study)",Breast,2023,,https://experts.mcmaster.ca/display/publication3288299,2025-07-27T15:12:23.218891
Gregory Pond,gpond@mcmaster.ca,conferences,Evolving strategies for the routine follow-up of patients with early breast cancer and the impact of COVID-19: a survey of healthcare providers,Breast,2023,,https://experts.mcmaster.ca/display/publication3288298,2025-07-27T15:12:23.218892
Gregory Pond,gpond@mcmaster.ca,conferences,"Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada",Blood,2022,10.1182/blood-2022-157815,https://experts.mcmaster.ca/display/publication2472763,2025-07-27T15:12:23.218893
Gregory Pond,gpond@mcmaster.ca,conferences,Variable Frailty Categorization Among Real-World Patient with Multiple Myeloma: A Prospective Cohort Study (MFRAIL),Blood,2022,10.1182/blood-2022-158301,https://experts.mcmaster.ca/display/publication2498896,2025-07-27T15:12:23.218894
Gregory Pond,gpond@mcmaster.ca,conferences,"545 A phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 (cisplatin, vinblastine) in early stage breast cancer: the INVINCIBLE trial",Journal for ImmunoTherapy of Cancer,2022,10.1136/jitc-2022-sitc2022.0545,https://experts.mcmaster.ca/display/publication2980494,2025-07-27T15:12:23.218895
Gregory Pond,gpond@mcmaster.ca,conferences,A randomized controlled trial evaluating two cognitive rehabilitation approaches for cancer survivors with perceived cognitive impairment,Asia-Pacific Journal of Clinical Oncology,2022,,https://experts.mcmaster.ca/display/publication2446653,2025-07-27T15:12:23.218896
Gregory Pond,gpond@mcmaster.ca,conferences,2022-RA-744-ESGO Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer centre: a quality improvement initiative,International Journal of Gynecological Cancer,2022,10.1136/ijgc-2022-esgo.405,https://experts.mcmaster.ca/display/publication3396734,2025-07-27T15:12:23.218897
Gregory Pond,gpond@mcmaster.ca,conferences,Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative.,Journal of Clinical Oncology,2022,,https://experts.mcmaster.ca/display/publication2686953,2025-07-27T15:12:23.218898
Gregory Pond,gpond@mcmaster.ca,conferences,Chronic Obstructive Pulmonary Disease Patients Receiving Immunotherapy for Lung Cancer: A Population-Based Study in Canada,Journal of Thoracic Oncology,2022,,https://experts.mcmaster.ca/display/publication2444688,2025-07-27T15:12:23.218899
Gregory Pond,gpond@mcmaster.ca,conferences,INCIDENCE AND MANAGEMENT TRENDS IN LOCALLY ADVANCED HEAD AND NECK NON-MELANOMA SKIN CANCER,Radiotherapy and Oncology,2022,,https://experts.mcmaster.ca/display/publication2498935,2025-07-27T15:12:23.218900
Gregory Pond,gpond@mcmaster.ca,conferences,OUTCOMES OF RADIOTHERAPY ALONE FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (LA-NSCLC) IN PATIENTS UNFIT FOR CHEMO-RADIOTHERAPY,Radiotherapy and Oncology,2022,,https://experts.mcmaster.ca/display/publication2498961,2025-07-27T15:12:23.218901
Gregory Pond,gpond@mcmaster.ca,conferences,"RADIATION DOSE, TECHNIQUE, AND USE OF BRAIN RADIATION ON OVERALL SURVIVAL IN PATIENTS WITH LIMITED-STAGE SMALL CELL LUNG CANCER",Radiotherapy and Oncology,2022,,https://experts.mcmaster.ca/display/publication2498960,2025-07-27T15:12:23.218901
Gregory Pond,gpond@mcmaster.ca,conferences,"RADIOTHERAPY DOSE, FDG-PET UTILIZATION AND SURVIVAL OUTCOMES OF UNRESECTED LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (LA-NSCLC). ONTARIO POPULATION OUTCOMES OF CONTEMPORARY RADIOTHERAPY ALONE AND STANDARD OF CARE CHEMO-RADIOTHERAPY",Radiotherapy and Oncology,2022,,https://experts.mcmaster.ca/display/publication2498959,2025-07-27T15:12:23.218902
Gregory Pond,gpond@mcmaster.ca,conferences,"THE EVOLUTION OF TECHNOLOGY IN THE MANAGEMENT OF EARLY-STAGE (T1) CANCER OF THE LARYNX, AN INSTITUTIONAL REVIEW OF RADIATION THERAPY OUTCOMES",Radiotherapy and Oncology,2022,,https://experts.mcmaster.ca/display/publication2498934,2025-07-27T15:12:23.218903
Gregory Pond,gpond@mcmaster.ca,conferences,OAB-042: The impact of marginalization on treatment receipt and overall survival in newly diagnosed multiple myeloma patients in Ontario: a population-based cohort study,"Clinical Lymphoma, Myeloma and Leukemia",2022,10.1016/s2152-2650(22)00315-9,https://experts.mcmaster.ca/display/publication2552497,2025-07-27T15:12:23.218904
Gregory Pond,gpond@mcmaster.ca,conferences,The impact of marginalization on treatment receipt and overall survival in Newly Diagnosed Multiple Myeloma patients in Ontario: A Population-Based Cohort Study.,"Clinical Lymphoma, Myeloma and Leukemia",2022,,https://experts.mcmaster.ca/display/publication2498900,2025-07-27T15:12:23.218905
Gregory Pond,gpond@mcmaster.ca,conferences,LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0luminal A breast cancer (BC).,Journal of Clinical Oncology,2022,,https://experts.mcmaster.ca/display/publication2717402,2025-07-27T15:12:23.218906
Gregory Pond,gpond@mcmaster.ca,conferences,Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative.,Journal of Clinical Oncology,2022,,https://experts.mcmaster.ca/display/publication2446421,2025-07-27T15:12:23.218907
Gregory Pond,gpond@mcmaster.ca,conferences,Intratumoral (IT) INT230-6 can cause tumor necrosis in vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study).,Journal of Clinical Oncology,2022,,https://experts.mcmaster.ca/display/publication2446657,2025-07-27T15:12:23.218908
Gregory Pond,gpond@mcmaster.ca,conferences,"Nivolumab in squamous cell carcinomas of the head and neck (SCCHN): A real-world outcome study in Ontario, Canada.",Journal of Clinical Oncology,2022,10.1200/jco.2022.40.16_suppl.e18017,https://experts.mcmaster.ca/display/publication2552504,2025-07-27T15:12:23.218909
Gregory Pond,gpond@mcmaster.ca,conferences,"Overall survival of patients with chronic obstructive pulmonary disease receiving immunotherapy for non-small cell lung cancer: A population-based analysis in Ontario, Canada.",Journal of Clinical Oncology,2022,,https://experts.mcmaster.ca/display/publication2444689,2025-07-27T15:12:23.218910
Gregory Pond,gpond@mcmaster.ca,conferences,SALVO: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.,Journal of Clinical Oncology,2022,,https://experts.mcmaster.ca/display/publication2446656,2025-07-27T15:12:23.218911
Gregory Pond,gpond@mcmaster.ca,conferences,The RADIO trial: Randomized assessment of cisplatin dosing interval for ototoxicity with curative concurrent chemo-radiation for locally advanced head and neck squamous cell carcinoma,Journal of Clinical Oncology,2022,,https://experts.mcmaster.ca/display/publication2446363,2025-07-27T15:12:23.218912
Gregory Pond,gpond@mcmaster.ca,conferences,The RADIO trial: Randomized assessment of cisplatin dosing interval for ototoxicity with curative concurrent chemo-radiation for locally advanced head and neck squamous cell carcinoma.,Journal of Clinical Oncology,2022,10.1200/jco.2022.40.16_suppl.tps12144,https://experts.mcmaster.ca/display/publication2552500,2025-07-27T15:12:23.218913
Gregory Pond,gpond@mcmaster.ca,conferences,Will COVID-19 directives to reduce regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer?,Journal of Clinical Oncology,2022,,https://experts.mcmaster.ca/display/publication2446654,2025-07-27T15:12:23.218914
Gregory Pond,gpond@mcmaster.ca,conferences,Impact of angiotensin-converting enzyme inhibitors (ACEi) on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).,Journal of Clinical Oncology,2022,10.1200/jco.2022.40.6_suppl.485,https://experts.mcmaster.ca/display/publication2184259,2025-07-27T15:12:23.218915
Gregory Pond,gpond@mcmaster.ca,conferences,Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).,Journal of Clinical Oncology,2022,10.1200/jco.2022.40.6_suppl.tps398,https://experts.mcmaster.ca/display/publication2171413,2025-07-27T15:12:23.218916
Gregory Pond,gpond@mcmaster.ca,conferences,Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK),Journal of Clinical Oncology,2022,10.1200/JCO.2022.40.6_suppl.TPS398,https://experts.mcmaster.ca/display/publication2499618,2025-07-27T15:12:23.218917
Gregory Pond,gpond@mcmaster.ca,conferences,Is Symptom Burden Associated with Health Care Utilization: A Longitudinal Population-Based Cohort Study of Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma,Blood,2021,10.1182/blood-2021-146862,https://experts.mcmaster.ca/display/publication2429512,2025-07-27T15:12:23.218918
Gregory Pond,gpond@mcmaster.ca,conferences,"EPV062/#354 Comparison of outcomes between abdominal, minimally invasive and combined vaginal- laparoscopic hysterectomy in patients with stage IAI/IA2 cervical cancer: 4C (Canadian cervical cancer collaborative) study",International Journal of Gynecological Cancer,2021,10.1136/ijgc-2021-igcs.130,https://experts.mcmaster.ca/display/publication2181174,2025-07-27T15:12:23.218919
Gregory Pond,gpond@mcmaster.ca,conferences,EPV063/#357 The impact of surgical approach in cases with no residual disease on hysterectomy specimen: a 4C (Canadian cervical cancer collaborative) working group study,International Journal of Gynecological Cancer,2021,10.1136/ijgc-2021-igcs.131,https://experts.mcmaster.ca/display/publication2181077,2025-07-27T15:12:23.218920
Gregory Pond,gpond@mcmaster.ca,conferences,OP005/#352 Safety of vaginal hysterectomy for cervical cancer: a multicenter cohort study on behalf of the 4C (Canadian cervical cancer collaborative) working group,International Journal of Gynecological Cancer,2021,10.1136/ijgc-2021-igcs.22,https://experts.mcmaster.ca/display/publication2181175,2025-07-27T15:12:23.218921
Gregory Pond,gpond@mcmaster.ca,conferences,"The Role of FDG-PET in Staging and Treatment for Stage III NSCLC in Ontario, Canada Between 2009-2017",International Journal of Radiation Oncology Biology Physics,2021,10.1016/j.ijrobp.2021.07.1224,https://experts.mcmaster.ca/display/publication2144620,2025-07-27T15:12:23.218922
Gregory Pond,gpond@mcmaster.ca,conferences,Extent of Surgical Resection in Inflammatory Bowel Disease Associated Colorectal Cancer: a Population-Based Study,Journal of Gastrointestinal Surgery,2021,10.1007/s11605-021-04913-6,https://experts.mcmaster.ca/display/publication1701786,2025-07-27T15:12:23.218922
Gregory Pond,gpond@mcmaster.ca,conferences,THE ROLE OF FDG-PET IN STAGING AND TREATMENT FOR STAGE III NSCLC IN ONTARIO BETWEEN 2009-2017,Radiotherapy and Oncology,2021,,https://experts.mcmaster.ca/display/publication2149421,2025-07-27T15:12:23.218923
Gregory Pond,gpond@mcmaster.ca,conferences,Impact of angiotensin blockade on response to PD1/L1 inhibitors for patients with metastatic urothelial carcinoma (mUC).,Journal of Clinical Oncology,2021,10.1200/jco.2021.39.6_suppl.453,https://experts.mcmaster.ca/display/publication1967498,2025-07-27T15:12:23.218924
Gregory Pond,gpond@mcmaster.ca,conferences,Impact of angiotensin inhibitors on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).,Journal of Clinical Oncology,2021,10.1200/jco.2021.39.6_suppl.432,https://experts.mcmaster.ca/display/publication1967499,2025-07-27T15:12:23.218925
Gregory Pond,gpond@mcmaster.ca,conferences,A physician survey evaluating real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast cancer,Cancer Research,2021,,https://experts.mcmaster.ca/display/publication1964850,2025-07-27T15:12:23.218926
Gregory Pond,gpond@mcmaster.ca,conferences,Symptom Burden in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Population-Based Study of Patient-Reported Outcomes,Blood,2020,10.1182/blood-2020-133369,https://experts.mcmaster.ca/display/publication1970155,2025-07-27T15:12:23.218927
Gregory Pond,gpond@mcmaster.ca,conferences,Trajectory of Symptoms after Autologous Stem Cell Transplant Among Patients with Multiple Myeloma: A Population-Based Study,Blood,2020,10.1182/blood-2020-133869,https://experts.mcmaster.ca/display/publication1970158,2025-07-27T15:12:23.218928
Gregory Pond,gpond@mcmaster.ca,conferences,Cardiac Morbidity Following Radical Thoracic Chemoradiotherapy for Locally Advanced Lung Cancer: A Population-Based Cohort Study,International Journal of Radiation Oncology Biology Physics,2020,10.1016/j.ijrobp.2020.07.1243,https://experts.mcmaster.ca/display/publication1942596,2025-07-27T15:12:23.218929
Gregory Pond,gpond@mcmaster.ca,conferences,Randomized Phase II Trial of Metformin in Combination with Chemoradiotherapy (CRT) in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC); the OCOG-ALMERA trial (NCT02115464),International Journal of Radiation Oncology Biology Physics,2020,10.1016/j.ijrobp.2020.07.2284,https://experts.mcmaster.ca/display/publication1942326,2025-07-27T15:12:23.218930
Gregory Pond,gpond@mcmaster.ca,conferences,"Predictors of Minimally Invasive Surgery for Uterine and Cervix Cancer from 2000 – 2017 in Ontario, Canada",Gynecologic Oncology,2020,10.1016/j.ygyno.2020.05.477,https://experts.mcmaster.ca/display/publication1942598,2025-07-27T15:12:23.218931
Gregory Pond,gpond@mcmaster.ca,conferences,Social determinants of health in uterine cancer patients in Ontario: Association with disease presentation and outcomes,Gynecologic Oncology,2020,10.1016/j.ygyno.2020.06.136,https://experts.mcmaster.ca/display/publication1942597,2025-07-27T15:12:23.218932
Gregory Pond,gpond@mcmaster.ca,conferences,CARDIAC MORBIDITY FOLLOWING RADICAL THORACIC CHEMORADIOTHERAPY FOR LOCALLY ADVANCED LUNG CANCER: A POPULATION-BASED COHORT STUDY,Radiotherapy and Oncology,2020,,https://experts.mcmaster.ca/display/publication1962110,2025-07-27T15:12:23.218933
Gregory Pond,gpond@mcmaster.ca,conferences,"DOSIMETRIC COMPARISON OF CONFORMAL RADIATION THERAPY (CRT), IMRT AND VMAT FOR ESOPHAGEAL CANCER TREATED WITH EXTERNAL RADIATION",Radiotherapy and Oncology,2020,,https://experts.mcmaster.ca/display/publication1962132,2025-07-27T15:12:23.218934
Gregory Pond,gpond@mcmaster.ca,conferences,A multicenter study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of taxotere/cyclophosphamide-induced febrile neutropenia in patients with early-stage breast cancer.,Journal of Clinical Oncology,2020,,https://experts.mcmaster.ca/display/publication1934355,2025-07-27T15:12:23.218935
Gregory Pond,gpond@mcmaster.ca,conferences,"Dissecting outcomes of patients (pts) with < ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration.",Journal of Clinical Oncology,2020,,https://experts.mcmaster.ca/display/publication1934284,2025-07-27T15:12:23.218936
Gregory Pond,gpond@mcmaster.ca,conferences,Impact of concurrent angiotensin inhibitors on outcomes with PD1/L1 inhibitors for patients (pts) with metastatic urothelial carcinoma (mUC).,Journal of Clinical Oncology,2020,,https://experts.mcmaster.ca/display/publication1962203,2025-07-27T15:12:23.218937
Gregory Pond,gpond@mcmaster.ca,conferences,Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV): Emergence of a new unmet need.,Journal of Clinical Oncology,2020,,https://experts.mcmaster.ca/display/publication1934356,2025-07-27T15:12:23.218938
Gregory Pond,gpond@mcmaster.ca,conferences,A Comparison of Radiation Techniques in Patients Treated With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer,International Journal of Radiation Oncology Biology Physics,2020,10.1016/j.ijrobp.2019.12.027,https://experts.mcmaster.ca/display/publication1680558,2025-07-27T15:12:23.218939
Gregory Pond,gpond@mcmaster.ca,conferences,A comparison of combined immune checkpoint inhibitors (IO) versus vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in the treatment of advanced clear cell renal cell carcinoma,Journal of Clinical Oncology,2020,,https://experts.mcmaster.ca/display/publication1906776,2025-07-27T15:12:23.218939
Gregory Pond,gpond@mcmaster.ca,conferences,Any regression of tumor (ART) within 12 weeks versus RECIST 1.1 response category as an intermediate endpoint to assess the activity of immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC),Journal of Clinical Oncology,2020,,https://experts.mcmaster.ca/display/publication1906778,2025-07-27T15:12:23.218941
Gregory Pond,gpond@mcmaster.ca,conferences,Conditional immune adverse event rate in urothelial and renal cell carcinoma patients treated with immune checkpoint inhibitors,Journal of Clinical Oncology,2020,,https://experts.mcmaster.ca/display/publication1906779,2025-07-27T15:12:23.218942
Gregory Pond,gpond@mcmaster.ca,conferences,FDG and PSMA PET in metastatic castration-resistant prostate cancer (mCRPC),Journal of Clinical Oncology,2020,,https://experts.mcmaster.ca/display/publication1906777,2025-07-27T15:12:23.218943
Gregory Pond,gpond@mcmaster.ca,conferences,FDG and PSMA PET in metastatic castration-resistant prostate cancer (mCRPC).,Journal of Clinical Oncology,2020,10.1200/jco.2020.38.6_suppl.23,https://experts.mcmaster.ca/display/publication1974020,2025-07-27T15:12:23.218944
Gregory Pond,gpond@mcmaster.ca,conferences,Impact of histology and toxicities on outcomes of patients with muscle invasive bladder cancer receiving neoadjuvant chemotherapy,Journal of Clinical Oncology,2020,,https://experts.mcmaster.ca/display/publication1906775,2025-07-27T15:12:23.218945
Gregory Pond,gpond@mcmaster.ca,conferences,Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK),Journal of Clinical Oncology,2020,,https://experts.mcmaster.ca/display/publication1903606,2025-07-27T15:12:23.218946
Gregory Pond,gpond@mcmaster.ca,conferences,Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).,Journal of Clinical Oncology,2020,10.1200/jco.2020.38.6_suppl.tps761,https://experts.mcmaster.ca/display/publication1977693,2025-07-27T15:12:23.218947
Gregory Pond,gpond@mcmaster.ca,conferences,Abstract P4-10-29: Identifying novel molecular markers of response to trastuzumab in metastatic breast cancer,Cancer Research,2020,10.1158/1538-7445.sabcs19-p4-10-29,https://experts.mcmaster.ca/display/publication1915519,2025-07-27T15:12:23.218948
Gregory Pond,gpond@mcmaster.ca,conferences,Geriatric Assessment and Frailty Changes in Older Patients with Newly-Diagnosed Multiple Myeloma Undergoing Treatment,Blood,2019,10.1182/blood-2019-122261,https://experts.mcmaster.ca/display/publication1942283,2025-07-27T15:12:23.218949
Gregory Pond,gpond@mcmaster.ca,conferences,Undertreatment of Older Patients with Newly-Diagnosed Multiple Myeloma: Real World Evidence from a Canadian Registry Cohort,Blood,2019,10.1182/blood-2019-121672,https://experts.mcmaster.ca/display/publication1925006,2025-07-27T15:12:23.218949
Gregory Pond,gpond@mcmaster.ca,conferences,Conditional immune toxicity rate with immune checkpoint inhibitors,Journal for ImmunoTherapy of Cancer,2019,,https://experts.mcmaster.ca/display/publication1680557,2025-07-27T15:12:23.218950
Gregory Pond,gpond@mcmaster.ca,conferences,EP618 The use of preoperative imaging in endometrial cancer: are ontario physicians following GOC guidelines?,International Journal of Gynecological Cancer,2019,10.1136/ijgc-2019-esgo.675,https://experts.mcmaster.ca/display/publication1704196,2025-07-27T15:12:23.218951
Gregory Pond,gpond@mcmaster.ca,conferences,GERIATRIC ASSESSMENT CHANGES IN OLDER PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA UNDERGOING TREATMENT,Journal of Geriatric Oncology,2019,10.1016/s1879-4068(19)31241-x,https://experts.mcmaster.ca/display/publication2552530,2025-07-27T15:12:23.218952
Gregory Pond,gpond@mcmaster.ca,conferences,CYBERKNIFE STEREOTACTIC RADIOSURGERY FOR TREATMENT OF BENIGN INTRACRANIAL MENINGIOMA: LONG-TERM SAFETY AND EFFICACY,Radiotherapy and Oncology,2019,,https://experts.mcmaster.ca/display/publication1680559,2025-07-27T15:12:23.218953
Gregory Pond,gpond@mcmaster.ca,conferences,Quality of Life Assessment in Older Patients with Newly-Diagnosed Multiple Myeloma,"Clinical Lymphoma, Myeloma and Leukemia",2019,10.1016/j.clml.2019.09.386,https://experts.mcmaster.ca/display/publication1676341,2025-07-27T15:12:23.218954
Gregory Pond,gpond@mcmaster.ca,conferences,A Comparison of Radiation Techniques in Patients Treated with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer,International Journal of Radiation Oncology Biology Physics,2019,10.1016/j.ijrobp.2019.06.2427,https://experts.mcmaster.ca/display/publication1669525,2025-07-27T15:12:23.218955
Gregory Pond,gpond@mcmaster.ca,conferences,Abstract CT122: Randomized assessment of cisplatin dose interval for ototoxicity in the treatment of locally advanced squamous cell carcinoma of the head and neck undergoing curative concurrent chemoradiotherapy (RADIO),Cancer Research,2019,10.1158/1538-7445.am2019-ct122,https://experts.mcmaster.ca/display/publication1671184,2025-07-27T15:12:23.218956
Gregory Pond,gpond@mcmaster.ca,conferences,Abstract CT122: Randomized assessment of cisplatin dose interval for ototoxicity in the treatment of locally advanced squamous cell carcinoma of the head and neck undergoing curative concurrent chemoradiotherapy (RADIO),Clinical Trials,2019,10.1158/1538-7445.sabcs18-ct122,https://experts.mcmaster.ca/display/publication2552581,2025-07-27T15:12:23.218957
Gregory Pond,gpond@mcmaster.ca,conferences,5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors.,Journal of Clinical Oncology,2019,10.1200/jco.2019.37.15_suppl.4552,https://experts.mcmaster.ca/display/publication1671414,2025-07-27T15:12:23.218958
Gregory Pond,gpond@mcmaster.ca,conferences,A randomized study comparing physician-directed or fixed-dose dexamethasone replacement following incomplete steroid premedication for docetaxel chemotherapy.,Journal of Clinical Oncology,2019,10.1200/jco.2019.37.15_suppl.6610,https://experts.mcmaster.ca/display/publication1671412,2025-07-27T15:12:23.218959
Gregory Pond,gpond@mcmaster.ca,conferences,Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).,Journal of Clinical Oncology,2019,,https://experts.mcmaster.ca/display/publication1671413,2025-07-27T15:12:23.218960
Gregory Pond,gpond@mcmaster.ca,conferences,"Cost disparities with age in the treatment of advanced non-small cell lung cancer (NSCLC) in Ontario, Canada.",Journal of Clinical Oncology,2019,10.1200/jco.2019.37.15_suppl.6629,https://experts.mcmaster.ca/display/publication1670270,2025-07-27T15:12:23.218961
Gregory Pond,gpond@mcmaster.ca,conferences,First-line PD(L)1 inhibitors for platinum-ineligible advanced urothelial carcinoma (aUC).,Journal of Clinical Oncology,2019,10.1200/jco.2019.37.15_suppl.e16024,https://experts.mcmaster.ca/display/publication1670766,2025-07-27T15:12:23.218962
Gregory Pond,gpond@mcmaster.ca,conferences,"The ESCAPADE Study: Early supportive care for advanced cancer patients, assessing care delivery and provider engagement.",Journal of Clinical Oncology,2019,10.1200/jco.2019.37.15_suppl.e23142,https://experts.mcmaster.ca/display/publication1670287,2025-07-27T15:12:23.218963
Gregory Pond,gpond@mcmaster.ca,conferences,"weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration resistant prostate cancer.",Journal of Clinical Oncology,2019,,https://experts.mcmaster.ca/display/publication1671411,2025-07-27T15:12:23.218964
Gregory Pond,gpond@mcmaster.ca,conferences,"A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases",Annals of Oncology,2019,,https://experts.mcmaster.ca/display/publication1660280,2025-07-27T15:12:23.218965
Gregory Pond,gpond@mcmaster.ca,conferences,The contribution of multiparametric pelvic and whole body MR to the interpretation of F-18-fluoromethylcholine(FCH) or Ga-68-HBED-CC PSMA-11 (PSMA) PET/CT in the detection of pelvic recurrence or distant metastases in patients with biochemical failure following radical prostatectomy.,Journal of Nuclear Medicine,2019,,https://experts.mcmaster.ca/display/publication1654153,2025-07-27T15:12:23.218966
Gregory Pond,gpond@mcmaster.ca,conferences,"The effect of age on referral to an oncologist and receipt of chemotherapy among small cell lung cancer patients in Ontario, Canada",Journal of Geriatric Oncology,2019,10.1016/j.jgo.2018.10.001,https://experts.mcmaster.ca/display/publication1521780,2025-07-27T15:12:23.218967
Gregory Pond,gpond@mcmaster.ca,conferences,First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).,Journal of Clinical Oncology,2019,10.1200/jco.2019.37.7_suppl.432,https://experts.mcmaster.ca/display/publication1672465,2025-07-27T15:12:23.218968
Gregory Pond,gpond@mcmaster.ca,conferences,Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma.,Journal of Clinical Oncology,2019,10.1200/jco.2019.37.7_suppl.435,https://experts.mcmaster.ca/display/publication1673194,2025-07-27T15:12:23.218968
Gregory Pond,gpond@mcmaster.ca,conferences,Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs).,Journal of Clinical Oncology,2019,10.1200/jco.2019.37.7_suppl.479,https://experts.mcmaster.ca/display/publication1673193,2025-07-27T15:12:23.218969
Gregory Pond,gpond@mcmaster.ca,conferences,PD-L1 in Breast Cancer: 3 Different Scoring Systems,Laboratory Investigation,2019,,https://experts.mcmaster.ca/display/publication1660278,2025-07-27T15:12:23.218970
Gregory Pond,gpond@mcmaster.ca,conferences,PD-L1 in Breast Cancer: 3 Different Scoring Systems,Modern Pathology,2019,,https://experts.mcmaster.ca/display/publication1660279,2025-07-27T15:12:23.218971
Gregory Pond,gpond@mcmaster.ca,conferences,Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors.,Journal of Clinical Oncology,2019,10.1200/jco.2019.37.7_suppl.476,https://experts.mcmaster.ca/display/publication1673192,2025-07-27T15:12:23.218972
Gregory Pond,gpond@mcmaster.ca,conferences,Increased Mortality in Younger Patients with Inflammatory Bowel Disease Associated Colorectal Cancer: A Population-Based Cohort Study,Annals of Surgical Oncology,2019,,https://experts.mcmaster.ca/display/publication1631783,2025-07-27T15:12:23.218973
Gregory Pond,gpond@mcmaster.ca,conferences,Oncologists and medical assistance in dying: Where do we stand?,Journal of Clinical Oncology,2018,10.1200/jco.2018.36.34_suppl.64,https://experts.mcmaster.ca/display/publication1641100,2025-07-27T15:12:23.218974
Gregory Pond,gpond@mcmaster.ca,conferences,DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS,Neuro-Oncology,2018,,https://experts.mcmaster.ca/display/publication1634457,2025-07-27T15:12:23.218975
Gregory Pond,gpond@mcmaster.ca,conferences,Does Modern Mediastinal Irradiation Cause Acute Subclinical Cardiac Toxicity? The Final Results of the MEDICATE Study (Mediastinal Irradiation and Cardio-Toxic Effects),International Journal of Radiation Oncology Biology Physics,2018,10.1016/j.ijrobp.2018.06.231,https://experts.mcmaster.ca/display/publication1609480,2025-07-27T15:12:23.218976
Gregory Pond,gpond@mcmaster.ca,conferences,Outcomes of Tri-Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer,International Journal of Radiation Oncology Biology Physics,2018,10.1016/j.ijrobp.2018.07.355,https://experts.mcmaster.ca/display/publication1610104,2025-07-27T15:12:23.218977
Gregory Pond,gpond@mcmaster.ca,conferences,Timing of Androgen Deprivation Therapy for Prostate Cancer Patients after Radiation: Planned Combined Analysis of Two Randomized Phase 3 Trials,International Journal of Radiation Oncology Biology Physics,2018,10.1016/j.ijrobp.2018.06.358,https://experts.mcmaster.ca/display/publication1610103,2025-07-27T15:12:23.218978
Gregory Pond,gpond@mcmaster.ca,conferences,P2.11-23 Risk Perception Among a Lung Cancer Screening Population,Journal of Thoracic Oncology,2018,10.1016/j.jtho.2018.08.1370,https://experts.mcmaster.ca/display/publication1618876,2025-07-27T15:12:23.218979
Gregory Pond,gpond@mcmaster.ca,conferences,"P2.15-31 The Evolution of Costs in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Ontario, Canada Between 1999 to 2014",Journal of Thoracic Oncology,2018,10.1016/j.jtho.2018.08.1473,https://experts.mcmaster.ca/display/publication1618959,2025-07-27T15:12:23.218980
Gregory Pond,gpond@mcmaster.ca,conferences,Improving quality of life for patients with breast cancer invading the chest wall: A prospective trial for patients undergoing full thickness chest wall resection,Annals of Surgical Oncology,2018,,https://experts.mcmaster.ca/display/publication1556002,2025-07-27T15:12:23.218981
Gregory Pond,gpond@mcmaster.ca,conferences,Timing of androgen deprivation therapy for prostate cancer patients after radiation: Planned combined analysis of two randomized phase 3 trials.,Journal of Clinical Oncology,2018,10.1200/jco.2018.36.15_suppl.5018,https://experts.mcmaster.ca/display/publication1899763,2025-07-27T15:12:23.218982
Gregory Pond,gpond@mcmaster.ca,conferences,Clinical Significance of the AJCC 8th Edition Prognostic Staging System for Triple Negative Breast Cancer (TNBC),Modern Pathology,2018,,https://experts.mcmaster.ca/display/publication1515020,2025-07-27T15:12:23.218983
Gregory Pond,gpond@mcmaster.ca,conferences,Clinical Significance of the AJCC 8th Edition Prognostic Staging System for Triple Negative Breast Cancer (TNBC),Laboratory Investigation,2018,,https://experts.mcmaster.ca/display/publication1631215,2025-07-27T15:12:23.218984
Gregory Pond,gpond@mcmaster.ca,conferences,C-reactive protein as a prognostic factor in advanced urothelial carcinoma receiving chemotherapy or immunotherapy.,Journal of Clinical Oncology,2018,10.1200/jco.2018.36.6_suppl.436,https://experts.mcmaster.ca/display/publication1615727,2025-07-27T15:12:23.218985
Gregory Pond,gpond@mcmaster.ca,conferences,Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.,Journal of Clinical Oncology,2018,10.1200/jco.2018.36.6_suppl.225,https://experts.mcmaster.ca/display/publication1619213,2025-07-27T15:12:23.218985
Gregory Pond,gpond@mcmaster.ca,conferences,New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.,Journal of Clinical Oncology,2018,10.1200/jco.2018.36.6_suppl.413,https://experts.mcmaster.ca/display/publication1615726,2025-07-27T15:12:23.218986
Gregory Pond,gpond@mcmaster.ca,conferences,Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma.,Journal of Clinical Oncology,2018,10.1200/jco.2018.36.6_suppl.451,https://experts.mcmaster.ca/display/publication1615725,2025-07-27T15:12:23.218987
Gregory Pond,gpond@mcmaster.ca,conferences,"Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study.",Journal of Clinical Oncology,2018,10.1200/jco.2018.36.6_suppl.448,https://experts.mcmaster.ca/display/publication1615724,2025-07-27T15:12:23.218988
Gregory Pond,gpond@mcmaster.ca,conferences,Statin use and outcomes of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) being treated with abiraterone (Abi).,Journal of Clinical Oncology,2018,10.1200/jco.2018.36.6_suppl.277,https://experts.mcmaster.ca/display/publication1612650,2025-07-27T15:12:23.218989
Gregory Pond,gpond@mcmaster.ca,conferences,Prognostic relevance of neutrophil-to-lymphocyte ratio (NLR) in young women with breast cancer (BC),Cancer Research,2018,,https://experts.mcmaster.ca/display/publication1506718,2025-07-27T15:12:23.218990
Gregory Pond,gpond@mcmaster.ca,conferences,Abstract A100: Seamless phase I/II clinical trials in oncology: retrospective analysis of the last 7 years,Molecular Cancer Therapeutics,2018,10.1158/1535-7163.targ-17-a100,https://experts.mcmaster.ca/display/publication1942595,2025-07-27T15:12:23.218991
Gregory Pond,gpond@mcmaster.ca,conferences,MA 20.11 Chronic Obstructive Pulmonary Disease Prevalence in a Lung Cancer Screening Population,Journal of Thoracic Oncology,2017,10.1016/j.jtho.2017.09.650,https://experts.mcmaster.ca/display/publication1638863,2025-07-27T15:12:23.218992
Gregory Pond,gpond@mcmaster.ca,conferences,"A Phase 3, Multicenter, Randomized Trial to Evaluate the Symptomatic and Quality of Life Improvements in Lung Cancer Patients Receiving External Beam Radiation With or Without High Dose Rate Intraluminal Brachytherapy",International Journal of Radiation Oncology Biology Physics,2017,10.1016/j.ijrobp.2017.06.273,https://experts.mcmaster.ca/display/publication1472735,2025-07-27T15:12:23.218993
Gregory Pond,gpond@mcmaster.ca,conferences,Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population,Annals of Oncology,2017,,https://experts.mcmaster.ca/display/publication1470472,2025-07-27T15:12:23.218994
Gregory Pond,gpond@mcmaster.ca,conferences,Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape.,Journal of Clinical Oncology,2017,10.1200/jco.2017.35.15_suppl.4534,https://experts.mcmaster.ca/display/publication1641671,2025-07-27T15:12:23.218995
Gregory Pond,gpond@mcmaster.ca,conferences,"Neurocognitive functions and psychological distress in young adults with cancer (YAC): A prospective, longitudinal study.",Journal of Clinical Oncology,2017,10.1200/jco.2017.35.15_suppl.10064,https://experts.mcmaster.ca/display/publication1624880,2025-07-27T15:12:23.218996
Gregory Pond,gpond@mcmaster.ca,conferences,Nomogram to assess survival benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials.,Journal of Clinical Oncology,2017,10.1200/jco.2017.35.15_suppl.e16012,https://experts.mcmaster.ca/display/publication1629674,2025-07-27T15:12:23.218997
Gregory Pond,gpond@mcmaster.ca,conferences,Retrospective analysis of ipilimumab-induced diarrhea and/or colitis: A single centre review.,Journal of Clinical Oncology,2017,10.1200/jco.2017.35.15_suppl.e21064,https://experts.mcmaster.ca/display/publication1480693,2025-07-27T15:12:23.218998
Gregory Pond,gpond@mcmaster.ca,conferences,Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.,Journal of Clinical Oncology,2017,10.1200/jco.2017.35.15_suppl.e16503,https://experts.mcmaster.ca/display/publication1470619,2025-07-27T15:12:23.218999
Gregory Pond,gpond@mcmaster.ca,conferences,Use of a marketing plan for recruitment to a lung cancer screening study.,Journal of Clinical Oncology,2017,10.1200/jco.2017.35.15_suppl.1548,https://experts.mcmaster.ca/display/publication1470241,2025-07-27T15:12:23.219000
Gregory Pond,gpond@mcmaster.ca,conferences,"A randomized, double-blind, placebo-controlled window of opportunity trial evaluating clinical effects of high dose vitamin D in patients with breast cancer",Annals of Oncology,2017,,https://experts.mcmaster.ca/display/publication310537,2025-07-27T15:12:23.219001
Gregory Pond,gpond@mcmaster.ca,conferences,Prognostic classification of muscle-invasive bladder cancer (MIBC) following radical cystectomy (RC) alone or with perioperative chemotherapy: Analysis of the U.S. National Cancer Database (NCDB).,Journal of Clinical Oncology,2017,10.1200/jco.2017.35.6_suppl.372,https://experts.mcmaster.ca/display/publication1624879,2025-07-27T15:12:23.219002
Gregory Pond,gpond@mcmaster.ca,conferences,Abstract P6-09-30: Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab,Cancer Research,2017,10.1158/1538-7445.sabcs16-p6-09-30,https://experts.mcmaster.ca/display/publication310527,2025-07-27T15:12:23.219003
Gregory Pond,gpond@mcmaster.ca,conferences,MA05.06 Diagnosis of Chronic Obstructive Pulmonary Disease in Lung Cancer - A Population Based Study,Journal of Thoracic Oncology,2017,10.1016/j.jtho.2016.11.410,https://experts.mcmaster.ca/display/publication1482538,2025-07-27T15:12:23.219004
Gregory Pond,gpond@mcmaster.ca,conferences,Dovitinib in advanced adenoid cystic carcinoma of the salivary glands: Ontario Clinical Oncology Group DOVE trial,Annals of Oncology,2016,10.1093/annonc/mdw376.24,https://experts.mcmaster.ca/display/publication310522,2025-07-27T15:12:23.219004
Gregory Pond,gpond@mcmaster.ca,conferences,Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis,Annals of Oncology,2016,10.1093/annonc/mdw373.66,https://experts.mcmaster.ca/display/publication310523,2025-07-27T15:12:23.219005
Gregory Pond,gpond@mcmaster.ca,conferences,Prognostic ability of HR-QoL parameters in metastatic renal cell carcinoma (mRCC),Annals of Oncology,2016,10.1093/annonc/mdw373.44,https://experts.mcmaster.ca/display/publication310528,2025-07-27T15:12:23.219006
Gregory Pond,gpond@mcmaster.ca,conferences,Prognostic ability of early tumor shrinkage on overall survival (OS) in metastatic renal cell carcinoma (mRCC) – a validation study,Annals of Oncology,2016,10.1093/annonc/mdw373.38,https://experts.mcmaster.ca/display/publication310533,2025-07-27T15:12:23.219007
Gregory Pond,gpond@mcmaster.ca,conferences,The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus,International Journal of Radiation Oncology Biology Physics,2016,10.1016/j.ijrobp.2016.06.1419,https://experts.mcmaster.ca/display/publication310530,2025-07-27T15:12:23.219008
Gregory Pond,gpond@mcmaster.ca,conferences,INDENTIFICATION OF CURCULATING MIRNA ASSOCIATED WITH DEVELOPMENT OF CASTRATE RESISTANCE IN HIGH-RISK AND BIOCHEMICALLY RECURRENT PROSTATE CANCER PATIENTS,Radiotherapy and Oncology,2016,,https://experts.mcmaster.ca/display/publication3261364,2025-07-27T15:12:23.219009
Gregory Pond,gpond@mcmaster.ca,conferences,PATHOLOGIC AND TREATMENT FACTORS ASSOCIATED WITH RECURRENCE IN STAGE IA SEROUS ADENOCARCINOMA OF THE UTERUS,Radiotherapy and Oncology,2016,,https://experts.mcmaster.ca/display/publication3261363,2025-07-27T15:12:23.219010
Gregory Pond,gpond@mcmaster.ca,conferences,Do women who self-report cognitive symptoms after breast cancer treatment have more cognitive impairment than those who do not report symptoms? A mechanistic cohort study with functional brain MRI.,Journal of Clinical Oncology,2016,10.1200/jco.2016.34.15_suppl.10097,https://experts.mcmaster.ca/display/publication1654252,2025-07-27T15:12:23.219011
Gregory Pond,gpond@mcmaster.ca,conferences,Dynamic angiogenic switch as predictor of response to chemotherapy+ bevacizumab in patients with metastatic colorectal cancer.,Journal of Clinical Oncology,2016,10.1200/jco.2016.34.15_suppl.e15126,https://experts.mcmaster.ca/display/publication1649671,2025-07-27T15:12:23.219012
Gregory Pond,gpond@mcmaster.ca,conferences,Suggested reclassification strategy applied to intermediate and poor risk nonseminomatous germ cell tumors (NSGCT): A two-institution combined analysis.,Journal of Clinical Oncology,2016,10.1200/jco.2016.34.15_suppl.4546,https://experts.mcmaster.ca/display/publication1649670,2025-07-27T15:12:23.219013
Gregory Pond,gpond@mcmaster.ca,conferences,Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421.,Journal of Clinical Oncology,2016,10.1200/jco.2016.34.15_suppl.5079,https://experts.mcmaster.ca/display/publication1662880,2025-07-27T15:12:23.219014
Gregory Pond,gpond@mcmaster.ca,conferences,Metabolic stress to sensitize non-small cell lung cancer (NSCLC) to radiotherapy: Studies from bench to bedside,Journal of Thoracic Oncology,2016,10.1016/S1556-0864(16)30197-6,https://experts.mcmaster.ca/display/publication1470217,2025-07-27T15:12:23.219015
Gregory Pond,gpond@mcmaster.ca,conferences,Abstract P3-07-16: Comparing surrogates of oncotype Dx recurrence scores in invasive ductal carcinoma: How complicated does it have to be?,Cancer Research,2016,10.1158/1538-7445.sabcs15-p3-07-16,https://experts.mcmaster.ca/display/publication310539,2025-07-27T15:12:23.219016
Gregory Pond,gpond@mcmaster.ca,conferences,Comparing surrogates of oncotype Dx recurrence scores in invasive ductal carcinoma: How complicated does it have to be?,Cancer Research,2016,10.1158/1538-7445.SABCS15-P3-07-16,https://experts.mcmaster.ca/display/publication310552,2025-07-27T15:12:23.219017
Gregory Pond,gpond@mcmaster.ca,conferences,OCOG-ALMERA: A phase II trial investigating the ability of metformin to chemo-radio-sensitize and prevent recurrence in locally advanced (LA) non-small cell lung cancer (NSCLC)∗,Journal of Thoracic Oncology,2016,10.1016/j.jtho.2015.12.083,https://experts.mcmaster.ca/display/publication1510330,2025-07-27T15:12:23.219017
Gregory Pond,gpond@mcmaster.ca,conferences,Targeting tumor metabolism to improve radio-sensitivity in non-small cell lung cancer (NSCLC),Journal of Thoracic Oncology,2016,10.1016/j.jtho.2015.12.082,https://experts.mcmaster.ca/display/publication1511048,2025-07-27T15:12:23.219019
Gregory Pond,gpond@mcmaster.ca,conferences,Neurocognitive function and psychological distress in young adults (YA) with cancer.,Journal of Clinical Oncology,2016,10.1200/jco.2016.34.3_suppl.199,https://experts.mcmaster.ca/display/publication1521750,2025-07-27T15:12:23.219020
Gregory Pond,gpond@mcmaster.ca,conferences,Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC).,Journal of Clinical Oncology,2016,10.1200/jco.2016.34.2_suppl.386,https://experts.mcmaster.ca/display/publication1521832,2025-07-27T15:12:23.219021
Gregory Pond,gpond@mcmaster.ca,conferences,Impact of single agent daily prednisone on survival and toxicities in post-docetaxel men with metastatic castration-resistant prostate cancer (mCRPC): An analysis of 2 phase III trials.,Journal of Clinical Oncology,2016,10.1200/jco.2016.34.2_suppl.213,https://experts.mcmaster.ca/display/publication1521836,2025-07-27T15:12:23.219022
Gregory Pond,gpond@mcmaster.ca,conferences,Integration of bone scan (BS) and computerized tomography (CT) findings as an endpoint to assess bone metastasis in metastatic castration-resistant prostate cancer (mCRPC).,Journal of Clinical Oncology,2016,10.1200/jco.2016.34.2_suppl.191,https://experts.mcmaster.ca/display/publication337153,2025-07-27T15:12:23.219023
Gregory Pond,gpond@mcmaster.ca,conferences,Outcomes of advanced urothelial carcinoma following discontinuation of programmed death (PD)-1 or PD-ligand (L)-1 inhibitors.,Journal of Clinical Oncology,2016,10.1200/jco.2016.34.2_suppl.385,https://experts.mcmaster.ca/display/publication1521830,2025-07-27T15:12:23.219024
Gregory Pond,gpond@mcmaster.ca,conferences,A Phase 2 Multi-institutional Clinical Trial Assessing Fractionated Simultaneous In-field Boost Radiation Therapy for Brain Oligometastases,International Journal of Radiation Oncology Biology Physics,2015,10.1016/j.ijrobp.2015.07.095,https://experts.mcmaster.ca/display/publication310547,2025-07-27T15:12:23.219025
Gregory Pond,gpond@mcmaster.ca,conferences,OUTCOME OF NEUROFIBROMATOSIS TYPE 1 PATIENTS TREATED WITH FIRST LINE VINBLASTINE FOR OPTIC PATHWAY GLIOMAS (OPG): A CANADIAN MULTICENTER STUDY,Pediatric Blood and Cancer,2015,,https://experts.mcmaster.ca/display/publication310550,2025-07-27T15:12:23.219026
Gregory Pond,gpond@mcmaster.ca,conferences,QUALITY OF LIFE IN CHILDREN WITH LOW-GRADE GLIOMA RECEIVING VINBLASTINE AS FIRST-LINE TREATMENT: A CANADIAN MULTICENTER STUDY,Pediatric Blood and Cancer,2015,,https://experts.mcmaster.ca/display/publication310545,2025-07-27T15:12:23.219026
Gregory Pond,gpond@mcmaster.ca,conferences,Survival in Patients With Brain Metastases From Non-Small Cell Lung Cancer Treated in the Radiosurgery Era,International Journal of Radiation Oncology Biology Physics,2015,10.1016/j.ijrobp.2015.07.1654,https://experts.mcmaster.ca/display/publication310553,2025-07-27T15:12:23.219027
Gregory Pond,gpond@mcmaster.ca,conferences,Gemcitabine and Platinum (GC) chemotherapy alone or with a Taxane (GC-T) as first-line therapy for urothelial cancer (UC): a meta-analysis,Annals of Oncology,2015,,https://experts.mcmaster.ca/display/publication310546,2025-07-27T15:12:23.219028
Gregory Pond,gpond@mcmaster.ca,conferences,A Phase II Study of Dovitinib in Previously-Treated Malignant Pleural Mesothelioma: The Ontario Clinical Oncology Group DOVE-M Trial,Journal of Thoracic Oncology,2015,,https://experts.mcmaster.ca/display/publication1143619,2025-07-27T15:12:23.219029
Gregory Pond,gpond@mcmaster.ca,conferences,Comparative Survival in Patients with Brain Metastases from Non-Small Cell Lung Cancer Treated before and after Implementation of Radiosurgery,Journal of Thoracic Oncology,2015,,https://experts.mcmaster.ca/display/publication1229549,2025-07-27T15:12:23.219030
Gregory Pond,gpond@mcmaster.ca,conferences,Cancer-related cognitive dysfunction (CRCD) and psychosocial development in young adult cancer survivors.,Journal of Clinical Oncology,2015,,https://experts.mcmaster.ca/display/publication1521751,2025-07-27T15:12:23.219031
Gregory Pond,gpond@mcmaster.ca,conferences,Expression of thyroid hormone receptor alpha (THR alpha) isoforms in triple negative breast cancer (TNBC),Journal of Clinical Oncology,2015,,https://experts.mcmaster.ca/display/publication1179888,2025-07-27T15:12:23.219032
Gregory Pond,gpond@mcmaster.ca,conferences,Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC).,Journal of Clinical Oncology,2015,10.1200/jco.2015.33.15_suppl.4527,https://experts.mcmaster.ca/display/publication1521819,2025-07-27T15:12:23.219033
Gregory Pond,gpond@mcmaster.ca,conferences,Gemcitabine and platinum (GC) chemotherapy alone or with a taxane (GC-T) as first-line therapy for urothelial cancer (UC): A meta-analysis.,Journal of Clinical Oncology,2015,10.1200/jco.2015.33.15_suppl.e15526,https://experts.mcmaster.ca/display/publication1521805,2025-07-27T15:12:23.219034
Gregory Pond,gpond@mcmaster.ca,conferences,Meta-analysis of the impact of single agent daily prednisone on outcomes and toxicities in metastatic castration-resistant prostate cancer (mCRPC).,Journal of Clinical Oncology,2015,10.1200/jco.2015.33.15_suppl.e16095,https://experts.mcmaster.ca/display/publication1521822,2025-07-27T15:12:23.219035
Gregory Pond,gpond@mcmaster.ca,conferences,Outcome of neurofibromatosis type 1 patients treated with first line vinblastine for optic pathway gliomas: A Canadian multicenter study.,Journal of Clinical Oncology,2015,10.1200/jco.2015.33.15_suppl.2019,https://experts.mcmaster.ca/display/publication936460,2025-07-27T15:12:23.219036
Gregory Pond,gpond@mcmaster.ca,conferences,The role of PET-CT in treatment decision making for women with locally advanced cervical cancer.,Journal of Clinical Oncology,2015,10.1200/jco.2015.33.15_suppl.5523,https://experts.mcmaster.ca/display/publication195065,2025-07-27T15:12:23.219037
Gregory Pond,gpond@mcmaster.ca,conferences,Validation of correlation of RECIST changes with survival in metastatic castration-resistant prostate cancer (mCRPC).,Journal of Clinical Oncology,2015,10.1200/jco.2015.33.15_suppl.5057,https://experts.mcmaster.ca/display/publication1521840,2025-07-27T15:12:23.219038
Gregory Pond,gpond@mcmaster.ca,conferences,The Specimen Margin Assessment Technique (SMART) Trial: A Novel Method of Identifying the Most Accurate Method of Specimen Orientation in Breast Cancer Surgery,Annals of Surgical Oncology,2015,,https://experts.mcmaster.ca/display/publication310551,2025-07-27T15:12:23.219039
Gregory Pond,gpond@mcmaster.ca,conferences,Association of changes in measurable disease by RECIST with survival in metastatic castration-resistant prostate cancer (mCRPC).,Journal of Clinical Oncology,2015,10.1200/jco.2015.33.7_suppl.186,https://experts.mcmaster.ca/display/publication1521745,2025-07-27T15:12:23.219040
Gregory Pond,gpond@mcmaster.ca,conferences,Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy.,Journal of Clinical Oncology,2015,10.1200/jco.2015.33.7_suppl.335,https://experts.mcmaster.ca/display/publication337489,2025-07-27T15:12:23.219041
Gregory Pond,gpond@mcmaster.ca,conferences,Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma.,Journal of Clinical Oncology,2015,10.1200/jco.2015.33.7_suppl.311,https://experts.mcmaster.ca/display/publication1521781,2025-07-27T15:12:23.219042
Gregory Pond,gpond@mcmaster.ca,conferences,Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation (TMT): An international collaboration.,Journal of Clinical Oncology,2015,,https://experts.mcmaster.ca/display/publication1104434,2025-07-27T15:12:23.219043
Gregory Pond,gpond@mcmaster.ca,conferences,INFLAMMATION AND COGNITION,Asia-Pacific Journal of Clinical Oncology,2014,,https://experts.mcmaster.ca/display/publication310554,2025-07-27T15:12:23.219044
Gregory Pond,gpond@mcmaster.ca,conferences,205 Metformin to modulate AMP-kinase and enhance chemotherapy and radiotherapy in non-small cell lung cancer,European Journal of Cancer,2014,10.1016/s0959-8049(14)70331-4,https://experts.mcmaster.ca/display/publication208627,2025-07-27T15:12:23.219045
Gregory Pond,gpond@mcmaster.ca,conferences,A Prospective Comparative Analysis of 3 Methods of Rectal Retraction for High-Dose-Rate Brachytherapy in Cervical Carcinoma: Effect on Organs at Risk,International Journal of Radiation Oncology Biology Physics,2014,10.1016/j.ijrobp.2014.05.1479,https://experts.mcmaster.ca/display/publication310555,2025-07-27T15:12:23.219046
Gregory Pond,gpond@mcmaster.ca,conferences,A Retrospective Review of Patient Outcomes Following High-Dose-Rate Brachytherapy in the Treatment of Cervical Cancer,International Journal of Radiation Oncology Biology Physics,2014,10.1016/j.ijrobp.2014.05.1511,https://experts.mcmaster.ca/display/publication310543,2025-07-27T15:12:23.219047
Gregory Pond,gpond@mcmaster.ca,conferences,"Assessment of galectin-3, N-terminal pro-brain natriuretic peptide and inflammatory cytokines in patients with myocardial injury after initiation of adjuvant trastuzumab therapy",Clinical Biochemistry,2014,10.1016/j.clinbiochem.2014.06.032,https://experts.mcmaster.ca/display/publication310563,2025-07-27T15:12:23.219048
Gregory Pond,gpond@mcmaster.ca,conferences,"ANTI-TUMOR ACTIVITY OF SELINEXOR (KPT-330), AN ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE), +/- DEXAMETHASONE IN MULTIPLE MYELOMA PRECLINICAL MODELS & TRANSLATION IN PATIENTS WITH MULTIPLE MYELOMA",Haematologica,2014,,https://experts.mcmaster.ca/display/publication310556,2025-07-27T15:12:23.219048
Gregory Pond,gpond@mcmaster.ca,conferences,"A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.",Journal of Clinical Oncology,2014,10.1200/jco.2014.32.15_suppl.2537,https://experts.mcmaster.ca/display/publication310542,2025-07-27T15:12:23.219049
Gregory Pond,gpond@mcmaster.ca,conferences,A phase 1 multicenter clinical trial of alemtuzumab and CHOP chemotherapy for peripheral T-cell lymphomas.,Journal of Clinical Oncology,2014,10.1200/jco.2014.32.15_suppl.8551,https://experts.mcmaster.ca/display/publication1360788,2025-07-27T15:12:23.219050
Gregory Pond,gpond@mcmaster.ca,conferences,"Androgen pathway manipulation and outcome in elderly men with non-small cell lung cancer: A population-based study from Ontario, Canada.",Journal of Clinical Oncology,2014,10.1200/jco.2014.32.15_suppl.e17662,https://experts.mcmaster.ca/display/publication1521808,2025-07-27T15:12:23.219051
Gregory Pond,gpond@mcmaster.ca,conferences,Chemoradiation for locally advanced penile squamous cell carcinoma (PSCC): A multi-institution retrospective study.,Journal of Clinical Oncology,2014,10.1200/jco.2014.32.15_suppl.e15616,https://experts.mcmaster.ca/display/publication1521839,2025-07-27T15:12:23.219052
Gregory Pond,gpond@mcmaster.ca,conferences,Do patients with small cell lung cancer (SCLC) who have chemotherapy initiated during a hospital admission benefit from therapy?,Journal of Clinical Oncology,2014,10.1200/jco.2014.32.15_suppl.e17661,https://experts.mcmaster.ca/display/publication1521795,2025-07-27T15:12:23.219053
Gregory Pond,gpond@mcmaster.ca,conferences,External validation of nomogram to predict progression-free survival at 6 months (PFS6) in patients receiving salvage therapy for advanced urothelial carcinoma (UC).,Journal of Clinical Oncology,2014,10.1200/jco.2014.32.15_suppl.4542,https://experts.mcmaster.ca/display/publication1521803,2025-07-27T15:12:23.219054
Gregory Pond,gpond@mcmaster.ca,conferences,Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors.,Journal of Clinical Oncology,2014,10.1200/jco.2014.32.15_suppl.4514,https://experts.mcmaster.ca/display/publication1521779,2025-07-27T15:12:23.219055
Gregory Pond,gpond@mcmaster.ca,conferences,Using Magee equations to predict Oncotype DX recurrence scores: A potential cost and time saving strategy?,Journal of Clinical Oncology,2014,10.1200/jco.2014.32.15_suppl.e22109,https://experts.mcmaster.ca/display/publication1521810,2025-07-27T15:12:23.219056
Gregory Pond,gpond@mcmaster.ca,conferences,Increasing Utilization of Breast MRI: A Population Study,Annals of Surgical Oncology,2014,,https://experts.mcmaster.ca/display/publication310569,2025-07-27T15:12:23.219057
Gregory Pond,gpond@mcmaster.ca,conferences,Impact of Wait Times on Survival for Women With Uterine Cancer,Obstetrical and Gynecological Survey,2014,10.1097/ogx.0000000000000038,https://experts.mcmaster.ca/display/publication1122126,2025-07-27T15:12:23.219058
Gregory Pond,gpond@mcmaster.ca,conferences,Clinical-Pathologic Significance of Androgen Receptor (AR) Expression in Hormone Receptor (HR) Negative Breast Cancer,Modern Pathology,2014,,https://experts.mcmaster.ca/display/publication310562,2025-07-27T15:12:23.219059
Gregory Pond,gpond@mcmaster.ca,conferences,Clinical-Pathologic Significance of Androgen Receptor (AR) Expression in Hormone Receptor (HR) Negative Breast Cancer,Laboratory Investigation,2014,,https://experts.mcmaster.ca/display/publication310571,2025-07-27T15:12:23.219060
Gregory Pond,gpond@mcmaster.ca,conferences,Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy.,Journal of Clinical Oncology,2014,10.1200/jco.2014.32.4_suppl.353,https://experts.mcmaster.ca/display/publication1521792,2025-07-27T15:12:23.219061
Gregory Pond,gpond@mcmaster.ca,conferences,Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy.,Journal of Clinical Oncology,2014,10.1200/jco.2014.32.4_suppl.336,https://experts.mcmaster.ca/display/publication1521757,2025-07-27T15:12:23.219062
Gregory Pond,gpond@mcmaster.ca,conferences,Prognostic impact of C-reactive protein (CRP) in metastatic prostate cancer (MPC): A systematic review and meta-analysis.,Journal of Clinical Oncology,2014,10.1200/jco.2014.32.4_suppl.43,https://experts.mcmaster.ca/display/publication1312399,2025-07-27T15:12:23.219063
Gregory Pond,gpond@mcmaster.ca,conferences,"Safety and antitumor activity of selinexor (KPT-330), a first-in-class, oral XPO1 selective inhibitor of nuclear export: A phase I study expanded with colon cancer cohort.",Journal of Clinical Oncology,2014,10.1200/jco.2014.32.3_suppl.482,https://experts.mcmaster.ca/display/publication310560,2025-07-27T15:12:23.219064
Gregory Pond,gpond@mcmaster.ca,conferences,"Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom's Macroglobulinemia (WM)",Blood,2013,,https://experts.mcmaster.ca/display/publication310561,2025-07-27T15:12:23.219064
Gregory Pond,gpond@mcmaster.ca,conferences,"Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML)",Blood,2013,,https://experts.mcmaster.ca/display/publication310570,2025-07-27T15:12:23.219065
Gregory Pond,gpond@mcmaster.ca,conferences,Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL),Blood,2013,10.1182/blood.v122.21.90.90,https://experts.mcmaster.ca/display/publication310578,2025-07-27T15:12:23.219066
Gregory Pond,gpond@mcmaster.ca,conferences,"A LONGITUDINAL, PROSPECTIVE STUDY EVALUATING FATIGUE AND QUALITY OF LIFE IN COLORECTAL CANCER (CRC) PATIENTS",Asia-Pacific Journal of Clinical Oncology,2013,,https://experts.mcmaster.ca/display/publication1496017,2025-07-27T15:12:23.219067
Gregory Pond,gpond@mcmaster.ca,conferences,"ASSESSMENT OF HEALTH CARE PATTERNS FOR ELDERLY LUNG CANCER PATIENTS IN ONTARIO, CANADA",Journal of Thoracic Oncology,2013,,https://experts.mcmaster.ca/display/publication1521777,2025-07-27T15:12:23.219068
Gregory Pond,gpond@mcmaster.ca,conferences,WEEKLY VINBLASTINE IN CHEMOTHERAPY NAIVE CHILDREN AND ADOLESCENT WITH UNRESECTABLE OR PROGRESSIVE LOW GRADE GLIOMA: A CANADIAN COOPERATIVE STUDY,Neuro-Oncology,2013,,https://experts.mcmaster.ca/display/publication310587,2025-07-27T15:12:23.219069
Gregory Pond,gpond@mcmaster.ca,conferences,Abstract A124: Characterization of claudin-low breast cancers,Molecular Cancer Research,2013,10.1158/1557-3125.advbc-a124,https://experts.mcmaster.ca/display/publication195185,2025-07-27T15:12:23.219070
Gregory Pond,gpond@mcmaster.ca,conferences,"The feasibility, acceptability and safety of Molecular Breast Imaging (MBI) using a breast specific gamma camera and 99mTc-sestamibi in patients with a high risk of breast cancer",European Journal of Nuclear Medicine and Molecular Imaging,2013,,https://experts.mcmaster.ca/display/publication310589,2025-07-27T15:12:23.219071
Gregory Pond,gpond@mcmaster.ca,conferences,Prognostic risk stratification of men with advanced penile squamous cell cancer (PSCC) receiving first-line systemic therapy,European Journal of Cancer,2013,,https://experts.mcmaster.ca/display/publication310591,2025-07-27T15:12:23.219072
Gregory Pond,gpond@mcmaster.ca,conferences,WEEKLY VINBLASTINE IN CHEMOTHERAPY NAIVE CHILDREN WITH UNRESECTABLE OR PROGRESSIVE LOW GRADE GLIOMA: A CANADIAN COOPERATIVE STUDY,Pediatric Blood and Cancer,2013,,https://experts.mcmaster.ca/display/publication310595,2025-07-27T15:12:23.219073
Gregory Pond,gpond@mcmaster.ca,conferences,"First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.",Journal of Clinical Oncology,2013,,https://experts.mcmaster.ca/display/publication310566,2025-07-27T15:12:23.219074
Gregory Pond,gpond@mcmaster.ca,conferences,Impact of response to prior chemotherapy (RTPC) on outcomes in second-line therapy for advanced urothelial carcinoma (UC): Implications for trial design.,Journal of Clinical Oncology,2013,,https://experts.mcmaster.ca/display/publication1521823,2025-07-27T15:12:23.219075
Gregory Pond,gpond@mcmaster.ca,conferences,Impact of wait times on survival of women with uterine cancer.,Journal of Clinical Oncology,2013,,https://experts.mcmaster.ca/display/publication521496,2025-07-27T15:12:23.219076
Gregory Pond,gpond@mcmaster.ca,conferences,Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC),Journal of Clinical Oncology,2013,,https://experts.mcmaster.ca/display/publication337725,2025-07-27T15:12:23.219077
Gregory Pond,gpond@mcmaster.ca,conferences,"Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study-NCT00811369.",Journal of Clinical Oncology,2013,,https://experts.mcmaster.ca/display/publication1191363,2025-07-27T15:12:23.219077
Gregory Pond,gpond@mcmaster.ca,conferences,Rapid assessment of frailty prior to treatment of elderly colorectal cancer patients.,Journal of Clinical Oncology,2013,,https://experts.mcmaster.ca/display/publication1392677,2025-07-27T15:12:23.219078
Gregory Pond,gpond@mcmaster.ca,conferences,Rapid assessment of frailty prior to treatment of elderly colorectal cancer patients.,Journal of Clinical Oncology,2013,10.1200/jco.2013.31.15_suppl.e20522,https://experts.mcmaster.ca/display/publication1977699,2025-07-27T15:12:23.219079
Gregory Pond,gpond@mcmaster.ca,conferences,Weekly vinblastine in chemotherapy-naive children with unresectable or progressive low grade glioma: A Canadian cooperative study,Journal of Clinical Oncology,2013,,https://experts.mcmaster.ca/display/publication936494,2025-07-27T15:12:23.219080
Gregory Pond,gpond@mcmaster.ca,conferences,Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC).,Journal of Clinical Oncology,2013,10.1200/jco.2013.31.6_suppl.301,https://experts.mcmaster.ca/display/publication337896,2025-07-27T15:12:23.219081
Gregory Pond,gpond@mcmaster.ca,conferences,Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy.,Journal of Clinical Oncology,2013,10.1200/jco.2013.31.6_suppl.256,https://experts.mcmaster.ca/display/publication1521834,2025-07-27T15:12:23.219082
Gregory Pond,gpond@mcmaster.ca,conferences,Study of the impact of Charlson comorbidity index and hypertension on survival in patients with metastatic castration-resistant prostate cancer.,Journal of Clinical Oncology,2013,10.1200/jco.2013.31.6_suppl.111,https://experts.mcmaster.ca/display/publication1521820,2025-07-27T15:12:23.219083
Gregory Pond,gpond@mcmaster.ca,conferences,Analytical Variables That Affect the Prognostic Utility of Ki67 in Invasive Breast Cancer,Modern Pathology,2013,,https://experts.mcmaster.ca/display/publication194962,2025-07-27T15:12:23.219084
Gregory Pond,gpond@mcmaster.ca,conferences,Analytical Variables That Affect the Prognostic Utility of Ki67 in Invasive Breast Cancer,Laboratory Investigation,2013,,https://experts.mcmaster.ca/display/publication195037,2025-07-27T15:12:23.219085
Gregory Pond,gpond@mcmaster.ca,conferences,Abstract P6-09-02: Pre-treatment cognitive function (CF) in women with locally advanced breast cancer (LABC) and in healthy controls.,Cancer Research,2012,10.1158/0008-5472.sabcs12-p6-09-02,https://experts.mcmaster.ca/display/publication310540,2025-07-27T15:12:23.219086
Gregory Pond,gpond@mcmaster.ca,conferences,ASSOCIATION OF PROGRESSION BY PROSTATE CANCER WORKING GROUP (PCWG)-2 CRITERIA AND SURVIVAL IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER,Annals of Oncology,2012,,https://experts.mcmaster.ca/display/publication310582,2025-07-27T15:12:23.219087
Gregory Pond,gpond@mcmaster.ca,conferences,PROGNOSTIC STRATIFICATION OF ADVANCED UROTHELIAL CARCINOMA (UC) RECEIVING SECOND-LINE SYSTEMIC THERAPY INCLUDING TIME FROM PRIOR CHEMOTHERAPY (TFPC) AS A PROGNOSTIC FACTOR,Annals of Oncology,2012,,https://experts.mcmaster.ca/display/publication310590,2025-07-27T15:12:23.219088
Gregory Pond,gpond@mcmaster.ca,conferences,"COGNITIVE FUNCTION AND FATIGUE IN COLORECTAL CANCER PATIENTS: A PROSPECTIVE, LONGITUDINAL CONTROLLED STUDY",Asia-Pacific Journal of Clinical Oncology,2012,,https://experts.mcmaster.ca/display/publication310612,2025-07-27T15:12:23.219089
Gregory Pond,gpond@mcmaster.ca,conferences,PATIENT FACTORS INVOLVED IN REFERRAL FOR LYNCH SYNDROME,Annals of Oncology,2012,,https://experts.mcmaster.ca/display/publication310597,2025-07-27T15:12:23.219090
Gregory Pond,gpond@mcmaster.ca,conferences,Cognitive function and fatigue in colorectal cancer (CRC) patients: A prospective longitudinal controlled study,Journal of Clinical Oncology,2012,,https://experts.mcmaster.ca/display/publication1521747,2025-07-27T15:12:23.219091
Gregory Pond,gpond@mcmaster.ca,conferences,Pretreatment neurocognitive function (NCF) status in head and neck cancer (HNC) patients (pts) with comparison to control cohort,Journal of Clinical Oncology,2012,,https://experts.mcmaster.ca/display/publication1521752,2025-07-27T15:12:23.219092
Gregory Pond,gpond@mcmaster.ca,conferences,Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial,Journal of Clinical Oncology,2012,,https://experts.mcmaster.ca/display/publication1521841,2025-07-27T15:12:23.219093
Gregory Pond,gpond@mcmaster.ca,conferences,Quantitative immunohistochemical (IHC) assessment of ataxia-telangiectasia mutated (ATM) in estrogen receptor (ER) negative early breast cancer (BC).,Journal of Clinical Oncology,2012,,https://experts.mcmaster.ca/display/publication1521833,2025-07-27T15:12:23.219093
Gregory Pond,gpond@mcmaster.ca,conferences,Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy.,Journal of Clinical Oncology,2012,,https://experts.mcmaster.ca/display/publication1521771,2025-07-27T15:12:23.219094
Gregory Pond,gpond@mcmaster.ca,conferences,A Prospective Quality Assurance Study Of The Impact Of Cognitive Function On Proper Utilization Of Metered Dose Inhalers In A Medical Inpatient Population,,2012,10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a3716,https://experts.mcmaster.ca/display/publication3492726,2025-07-27T15:12:23.219095
Gregory Pond,gpond@mcmaster.ca,conferences,Knowledge Of Metered Dose Inhaler Technique Among Healthcare Professionals,,2012,10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a2901,https://experts.mcmaster.ca/display/publication3492727,2025-07-27T15:12:23.219096
Gregory Pond,gpond@mcmaster.ca,conferences,"Impact of Survivorship Care Plans (SCP) On Adherence to Guidelines, Health Service Measures, and Patient-reported Outcomes (PRO): Extended Results of a Multicenter Randomized Clinical Trial (RCT) with Breast Cancer Survivors",European Journal of Cancer,2012,,https://experts.mcmaster.ca/display/publication310609,2025-07-27T15:12:23.219097
Gregory Pond,gpond@mcmaster.ca,conferences,Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC).,Journal of Clinical Oncology,2012,10.1200/jco.2012.30.5_suppl.204,https://experts.mcmaster.ca/display/publication1521812,2025-07-27T15:12:23.219098
Gregory Pond,gpond@mcmaster.ca,conferences,Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC).,Journal of Clinical Oncology,2012,10.1200/jco.2012.30.5_suppl.51,https://experts.mcmaster.ca/display/publication1521818,2025-07-27T15:12:23.219099
Gregory Pond,gpond@mcmaster.ca,conferences,Claudin-Low Breast Cancer; a Molecular Subtype Associated with Poor Prognosis,Modern Pathology,2012,,https://experts.mcmaster.ca/display/publication195006,2025-07-27T15:12:23.219100
Gregory Pond,gpond@mcmaster.ca,conferences,Claudin-Low Breast Cancer; a Molecular Subtype Associated with Poor Prognosis,Laboratory Investigation,2012,,https://experts.mcmaster.ca/display/publication195023,2025-07-27T15:12:23.219101
Gregory Pond,gpond@mcmaster.ca,conferences,Morphological Characteristics of HER2 Over-Expressing and Basal-Like Breast Cancers and the Association between Lymphocytic Tumor Infiltrate and Prognosis,Modern Pathology,2012,,https://experts.mcmaster.ca/display/publication195024,2025-07-27T15:12:23.219102
Gregory Pond,gpond@mcmaster.ca,conferences,Morphological Characteristics of HER2 Over-Expressing and Basal-Like Breast Cancers and the Association between Lymphocytic Tumor Infiltrate and Prognosis,Laboratory Investigation,2012,,https://experts.mcmaster.ca/display/publication195063,2025-07-27T15:12:23.219103
Gregory Pond,gpond@mcmaster.ca,conferences,P4-12-05: Impact of the Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer (LISA) Weight Loss Intervention upon Physical Activity.,Cancer Research,2011,10.1158/0008-5472.sabcs11-p4-12-05,https://experts.mcmaster.ca/display/publication310541,2025-07-27T15:12:23.219104
Gregory Pond,gpond@mcmaster.ca,conferences,"Abstract A50: Biomarker analysis of PTEN, targeted oncogenic mutations, and HPV in a phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor dacomitinib (D) (PF-299804) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).",Molecular Cancer Therapeutics,2011,10.1158/1535-7163.targ-11-a50,https://experts.mcmaster.ca/display/publication2552557,2025-07-27T15:12:23.219105
Gregory Pond,gpond@mcmaster.ca,conferences,A PROSPECTIVE QUALITY ASSURANCE STUDY OF PROPER UTILIZATION OF METERED DOSE INHALERS IN THE MEDICAL INPATIENT POPULATION,Respirology,2011,,https://experts.mcmaster.ca/display/publication310604,2025-07-27T15:12:23.219106
Gregory Pond,gpond@mcmaster.ca,conferences,1314 POSTER Quality of Reporting of Modern Randomized Controlled Trials in Oncology,European Journal of Cancer,2011,10.1016/s0959-8049(11)70888-7,https://experts.mcmaster.ca/display/publication310605,2025-07-27T15:12:23.219107
Gregory Pond,gpond@mcmaster.ca,conferences,DO BETA-BLOCKERS ALTER DYSPNEA AND FATIGUE IN ADVANCED LUNG CANCER? A RETROSPECTIVE ANALYSIS,Journal of Thoracic Oncology,2011,,https://experts.mcmaster.ca/display/publication1521902,2025-07-27T15:12:23.219108
Gregory Pond,gpond@mcmaster.ca,conferences,"A randomized, double-blind, placebo-controlled cross over trial of the effect on quality of life (QOL) of continuing dexamethasone beyond 24 hours following moderately emetogenic chemotherapy in women with breast cancer.",Journal of Clinical Oncology,2011,10.1200/jco.2011.29.15_suppl.9020,https://experts.mcmaster.ca/display/publication310574,2025-07-27T15:12:23.219109
Gregory Pond,gpond@mcmaster.ca,conferences,Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP).,Journal of Clinical Oncology,2011,10.1200/jco.2011.29.15_suppl.e15019,https://experts.mcmaster.ca/display/publication310559,2025-07-27T15:12:23.219110
Gregory Pond,gpond@mcmaster.ca,conferences,Cost-effectiveness of a survivorship care plan for breast cancer survivors.,Journal of Clinical Oncology,2011,10.1200/jco.2011.29.15_suppl.6082,https://experts.mcmaster.ca/display/publication310557,2025-07-27T15:12:23.219111
Gregory Pond,gpond@mcmaster.ca,conferences,Do high symptom scores trigger clinical actions by providers? Assessing the effect of standardized symptom screening.,Journal of Clinical Oncology,2011,10.1200/jco.2011.29.15_suppl.9127,https://experts.mcmaster.ca/display/publication310564,2025-07-27T15:12:23.219112
Gregory Pond,gpond@mcmaster.ca,conferences,Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC).,Journal of Clinical Oncology,2011,10.1200/jco.2011.29.15_suppl.4582,https://experts.mcmaster.ca/display/publication310576,2025-07-27T15:12:23.219113
Gregory Pond,gpond@mcmaster.ca,conferences,Expected benefits versus actual outcomes in oncology phase III randomized controlled trials (RCTs).,Journal of Clinical Oncology,2011,10.1200/jco.2011.29.15_suppl.2562,https://experts.mcmaster.ca/display/publication310558,2025-07-27T15:12:23.219114
Gregory Pond,gpond@mcmaster.ca,conferences,Neurocognitive function (NCF) in patients (pts) treated with chemo/bio-radiotherapy (C/B-RT) for head and neck cancers (HNC).,Journal of Clinical Oncology,2011,,https://experts.mcmaster.ca/display/publication310567,2025-07-27T15:12:23.219115
Gregory Pond,gpond@mcmaster.ca,conferences,Randomized trial of a lifestyle intervention for women with early-stage breast cancer (BC) receiving adjuvant hormone therapy: Initial results.,Journal of Clinical Oncology,2011,10.1200/jco.2011.29.15_suppl.512,https://experts.mcmaster.ca/display/publication310568,2025-07-27T15:12:23.219116
Gregory Pond,gpond@mcmaster.ca,conferences,Tolerability and efficacy of chemotherapy in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial.,Journal of Clinical Oncology,2011,10.1200/jco.2011.29.15_suppl.4530,https://experts.mcmaster.ca/display/publication310572,2025-07-27T15:12:23.219117
Gregory Pond,gpond@mcmaster.ca,conferences,Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC).,Journal of Clinical Oncology,2011,10.1200/jco.2011.29.7_suppl.185,https://experts.mcmaster.ca/display/publication310577,2025-07-27T15:12:23.219118
Gregory Pond,gpond@mcmaster.ca,conferences,Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.,Journal of Clinical Oncology,2011,10.1200/jco.2011.29.7_suppl.118,https://experts.mcmaster.ca/display/publication310573,2025-07-27T15:12:23.219119
Gregory Pond,gpond@mcmaster.ca,conferences,Blocking Integrin Function Combined with Ionizing Radiation for Eradication of Bone Metastasis,International Journal of Radiation Oncology Biology Physics,2010,10.1016/j.ijrobp.2010.07.1448,https://experts.mcmaster.ca/display/publication310603,2025-07-27T15:12:23.219119
Gregory Pond,gpond@mcmaster.ca,conferences,HIGH INCONSISTENCIES AMONG LISTS OF CAUTIONED and PROHIBITED DRUGS IN ONCOLOGY PHASE 1 AND PHASE 2 TRIALS,Annals of Oncology,2010,,https://experts.mcmaster.ca/display/publication310614,2025-07-27T15:12:23.219120
Gregory Pond,gpond@mcmaster.ca,conferences,Accuracy of computerized tomography (CT) imaging in predicting pathologic stage for patients undergoing surgery for transitional cell carcinoma (TCC) of the bladder.,Journal of Clinical Oncology,2010,10.1200/jco.2010.28.15_suppl.e15111,https://experts.mcmaster.ca/display/publication310581,2025-07-27T15:12:23.219121
Gregory Pond,gpond@mcmaster.ca,conferences,Adequacy of data provision and analysis in oncology phase III trials over the past 5 years.,Journal of Clinical Oncology,2010,10.1200/jco.2010.28.15_suppl.6122,https://experts.mcmaster.ca/display/publication310583,2025-07-27T15:12:23.219122
Gregory Pond,gpond@mcmaster.ca,conferences,Breast cancer survivors perception of family physician (FP) or specialist as principal provider of routine follow-up care.,Journal of Clinical Oncology,2010,10.1200/jco.2010.28.15_suppl.9090,https://experts.mcmaster.ca/display/publication310594,2025-07-27T15:12:23.219123
Gregory Pond,gpond@mcmaster.ca,conferences,Consistency in reporting of primary endpoints (PEP) from registration to publication for modern randomized oncology phase III trials.,Journal of Clinical Oncology,2010,10.1200/jco.2010.28.15_suppl.6031,https://experts.mcmaster.ca/display/publication310584,2025-07-27T15:12:23.219124
Gregory Pond,gpond@mcmaster.ca,conferences,Early stopping rules employing early progression and response compared with conventional stopping rules in actual phase II trials.,Journal of Clinical Oncology,2010,10.1200/jco.2010.28.15_suppl.e13004,https://experts.mcmaster.ca/display/publication310596,2025-07-27T15:12:23.219125
Gregory Pond,gpond@mcmaster.ca,conferences,Inconsistencies among lists of cautioned/prohibited drugs in oncology phase I and phase II trials.,Journal of Clinical Oncology,2010,10.1200/jco.2010.28.15_suppl.e13084,https://experts.mcmaster.ca/display/publication310586,2025-07-27T15:12:23.219126
Gregory Pond,gpond@mcmaster.ca,conferences,Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX327 study.,Journal of Clinical Oncology,2010,10.1200/jco.2010.28.15_suppl.4686,https://experts.mcmaster.ca/display/publication310585,2025-07-27T15:12:23.219127
Gregory Pond,gpond@mcmaster.ca,conferences,Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial.,Journal of Clinical Oncology,2010,10.1200/jco.2010.28.15_suppl.4637,https://experts.mcmaster.ca/display/publication310579,2025-07-27T15:12:23.219128
Gregory Pond,gpond@mcmaster.ca,conferences,CISPLATIN DOSE INTENSITY CORRELATES WITH OUTCOME IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA RECEIVING CONCURRENT CISPLATIN BASED CHEMORADIATION: A MULTI-INSTITUTIONAL EXPERIENCE,Annals of Oncology,2009,,https://experts.mcmaster.ca/display/publication310598,2025-07-27T15:12:23.219129
Gregory Pond,gpond@mcmaster.ca,conferences,8506 Cisplatin dose intensity correlates with outcome in patients with locally advanced head and neck squamous cell carcinoma receiving concurrent cisplatin based chemoradiation: a multi-institutional experience,"European Journal of Cancer, Supplement",2009,10.1016/s1359-6349(09)71597-6,https://experts.mcmaster.ca/display/publication310621,2025-07-27T15:12:23.219130
Gregory Pond,gpond@mcmaster.ca,conferences,Comparison of randomized phase II studies (RP2s) and subsequent randomized controlled studies (RCTs) using identical systemic therapies,Journal of Clinical Oncology,2009,,https://experts.mcmaster.ca/display/publication310611,2025-07-27T15:12:23.219131
Gregory Pond,gpond@mcmaster.ca,conferences,Effect of geographic distance from a cancer centre on choice of systemic therapy in metastatic colorectal cancer,Journal of Clinical Oncology,2009,10.1200/jco.2009.27.15_suppl.e17559,https://experts.mcmaster.ca/display/publication1977686,2025-07-27T15:12:23.219132
Gregory Pond,gpond@mcmaster.ca,conferences,Effect of geographic distance from a cancer centre on choice of systemic therapy in metastatic colorectal cancer,Journal of Clinical Oncology,2009,,https://experts.mcmaster.ca/display/publication310599,2025-07-27T15:12:23.219133
Gregory Pond,gpond@mcmaster.ca,conferences,Trends in the application of dynamic allocation methods in multiarm cancer clinical trials,Journal of Clinical Oncology,2009,,https://experts.mcmaster.ca/display/publication310625,2025-07-27T15:12:23.219134
Gregory Pond,gpond@mcmaster.ca,conferences,382 POSTER Comparison of phase I trial (P1T) abstract quality between the EORTC-NCI-AACR and ASCO meetings,"European Journal of Cancer, Supplement",2008,10.1016/s1359-6349(08)72316-4,https://experts.mcmaster.ca/display/publication310618,2025-07-27T15:12:23.219135
Gregory Pond,gpond@mcmaster.ca,conferences,DELIVERY OF LESS THAN INTENDED CISPLATIN (COOP) DOSE INTENSITY IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (LA-HNSCC) RECEIVING CONCURRENT CHEMORADIATION (CRT) CORRELATES WITH POORER OUTCOME,Radiotherapy and Oncology,2008,,https://experts.mcmaster.ca/display/publication1556001,2025-07-27T15:12:23.219135
Gregory Pond,gpond@mcmaster.ca,conferences,Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck,Investigational New Drugs,2008,10.1007/s10637-007-9098-8,https://experts.mcmaster.ca/display/publication1521772,2025-07-27T15:12:23.219136
Gregory Pond,gpond@mcmaster.ca,conferences,A phase I study of concurrent pemetrexed (P)/cisplatin (C)/radiation (RT) for unresectable stage IIIA/B non-small cell lung cancer (NSCLC),Journal of Clinical Oncology,2008,10.1200/jco.2008.26.15_suppl.7550,https://experts.mcmaster.ca/display/publication310593,2025-07-27T15:12:23.219137
Gregory Pond,gpond@mcmaster.ca,conferences,A phase II prospective study of standardized steroid dosing for patients with brain metastases undergoing whole brain radiotherapy,Journal of Clinical Oncology,2008,10.1200/jco.2008.26.15_suppl.2050,https://experts.mcmaster.ca/display/publication310607,2025-07-27T15:12:23.219138
Gregory Pond,gpond@mcmaster.ca,conferences,Correlation of deviation from intended cisplatin (CDDP) dose intensity with outcome in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) receiving concurrent chemoradiation (CRT),Journal of Clinical Oncology,2008,10.1200/jco.2008.26.15_suppl.6052,https://experts.mcmaster.ca/display/publication310602,2025-07-27T15:12:23.219139
Gregory Pond,gpond@mcmaster.ca,conferences,Expanded phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors,Journal of Clinical Oncology,2008,10.1200/jco.2008.26.15_suppl.11096,https://experts.mcmaster.ca/display/publication310592,2025-07-27T15:12:23.219140
Gregory Pond,gpond@mcmaster.ca,conferences,Influence of independent review committees (IRC) on assessment of response rate and progression free survival in phase III clinical trials,Journal of Clinical Oncology,2008,10.1200/jco.2008.26.15_suppl.6567,https://experts.mcmaster.ca/display/publication310606,2025-07-27T15:12:23.219141
Gregory Pond,gpond@mcmaster.ca,conferences,The quality of informed consent forms for oncology clinical trials,Journal of Clinical Oncology,2008,10.1200/jco.2008.26.15_suppl.6544,https://experts.mcmaster.ca/display/publication310613,2025-07-27T15:12:23.219142
Gregory Pond,gpond@mcmaster.ca,conferences,Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006,Annals of Oncology,2008,10.1093/annonc/mdm486,https://experts.mcmaster.ca/display/publication310463,2025-07-27T15:12:23.219143
Gregory Pond,gpond@mcmaster.ca,conferences,NON-RISK ADAPTED SURVEILLANCE IN STAGE I NONSEMINOMATOUS GERM CELL TUMOURS (NSGCT): IMPROVED RECENT OUTCOMES,European Urology Open Science,2008,10.1016/s1569-9056(08)60063-9,https://experts.mcmaster.ca/display/publication310476,2025-07-27T15:12:23.219144
Gregory Pond,gpond@mcmaster.ca,conferences,Fluororescence in situ hybridization (FISH) gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors (MSGT) treated with lapatinib,Molecular Cancer Therapeutics,2007,,https://experts.mcmaster.ca/display/publication310477,2025-07-27T15:12:23.219145
Gregory Pond,gpond@mcmaster.ca,conferences,Association of Rectal Dosimetry and Toxicity With Body Mass Index After Permanent Brachytherapy for Low Risk Prostate Cancer,International Journal of Radiation Oncology Biology Physics,2007,10.1016/j.ijrobp.2007.07.1400,https://experts.mcmaster.ca/display/publication310464,2025-07-27T15:12:23.219146
Gregory Pond,gpond@mcmaster.ca,conferences,Concurrent Pemetrexed/Cisplatin/Radiation for Unresectable Stage IIIA/B Non-Small Cell Lung Cancer: A Phase I/II Study,International Journal of Radiation Oncology Biology Physics,2007,10.1016/j.ijrobp.2007.07.1698,https://experts.mcmaster.ca/display/publication310467,2025-07-27T15:12:23.219147
Gregory Pond,gpond@mcmaster.ca,conferences,A phase I study of concurrent pemetrexed Cisplatin radiation for unresectable stage IIIA/B non-small cell lung cancer,Radiotherapy and Oncology,2007,,https://experts.mcmaster.ca/display/publication310468,2025-07-27T15:12:23.219148
Gregory Pond,gpond@mcmaster.ca,conferences,Can we standardize steroid dose in patients with brain metastases? A prospective study,Radiotherapy and Oncology,2007,,https://experts.mcmaster.ca/display/publication310473,2025-07-27T15:12:23.219148
Gregory Pond,gpond@mcmaster.ca,conferences,Is body mass index a predictor for rectal dosimetry and toxicity in 125I permanent implant for low-risk prostate cancer?,Radiotherapy and Oncology,2007,,https://experts.mcmaster.ca/display/publication310471,2025-07-27T15:12:23.219149
Gregory Pond,gpond@mcmaster.ca,conferences,Long term urinary sequelae following iodine 125 prostate brachytherapy,Radiotherapy and Oncology,2007,,https://experts.mcmaster.ca/display/publication310475,2025-07-27T15:12:23.219150
Gregory Pond,gpond@mcmaster.ca,conferences,The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry,Radiotherapy and Oncology,2007,,https://experts.mcmaster.ca/display/publication310470,2025-07-27T15:12:23.219151
Gregory Pond,gpond@mcmaster.ca,conferences,6550 POSTER A phase I study of concurrent pemetrexed/cisplatin/radiation for unresectable stage IIIA/B non-small cell lung cancer,"European Journal of Cancer, Supplement",2007,10.1016/s1359-6349(07)71378-2,https://experts.mcmaster.ca/display/publication310466,2025-07-27T15:12:23.219152
Gregory Pond,gpond@mcmaster.ca,conferences,Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma,Journal of Clinical Oncology,2007,10.1200/jco.2006.10.2871,https://experts.mcmaster.ca/display/publication1521773,2025-07-27T15:12:23.219153
Gregory Pond,gpond@mcmaster.ca,conferences,PD3-2-5: Preoperative gefitinib in clinical stage I NSCLC,Journal of Thoracic Oncology,2007,10.1097/01.jto.0000283407.07873.7c,https://experts.mcmaster.ca/display/publication1521901,2025-07-27T15:12:23.219154
Gregory Pond,gpond@mcmaster.ca,conferences,PD6-1-7: A phase II study of UCN-01 in combination with topotecan in patients (pts) with chemosensitive relapsed small cell lung cancer (SCLC): a study of the Princess Margaret Hospital phase II consortium (PMH-C).,Journal of Thoracic Oncology,2007,10.1097/01.jto.0000283329.83483.2b,https://experts.mcmaster.ca/display/publication310498,2025-07-27T15:12:23.219155
Gregory Pond,gpond@mcmaster.ca,conferences,A phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors,Journal of Clinical Oncology,2007,,https://experts.mcmaster.ca/display/publication1621328,2025-07-27T15:12:23.219156
Gregory Pond,gpond@mcmaster.ca,conferences,A review of 565 phase II trial abstracts from ASCO 2005: Design characteristics of contemporary trials evaluating cytotoxic versus non-cytotoxic regimens,Journal of Clinical Oncology,2007,,https://experts.mcmaster.ca/display/publication1621336,2025-07-27T15:12:23.219157
Gregory Pond,gpond@mcmaster.ca,conferences,"A single agent, phase I pharmacodynamic study of nimotuzumab (TheraClM-h-R3) in patients with advanced refractory solid tumors",Journal of Clinical Oncology,2007,,https://experts.mcmaster.ca/display/publication1621331,2025-07-27T15:12:23.219158
Gregory Pond,gpond@mcmaster.ca,conferences,Adherence to surveillance guidelines following curative resection for stage II and III colorectal cancer,Journal of Clinical Oncology,2007,,https://experts.mcmaster.ca/display/publication1621334,2025-07-27T15:12:23.219159
Gregory Pond,gpond@mcmaster.ca,conferences,CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib-A trial of the PMH Phase II Consortium,Journal of Clinical Oncology,2007,,https://experts.mcmaster.ca/display/publication1621329,2025-07-27T15:12:23.219160
Gregory Pond,gpond@mcmaster.ca,conferences,Cognitive function and fatigue in cancer patients after chemotherapy: A longitudinal cohort study in patients with colorectal cancer (CRC),Journal of Clinical Oncology,2007,,https://experts.mcmaster.ca/display/publication1621339,2025-07-27T15:12:23.219161
Gregory Pond,gpond@mcmaster.ca,conferences,Correlation between changes in 2-or 3-year disease-free survival (DFS) and 5-year overall survival (OS) in adjuvant breast cancer trials from 1966-2006,Journal of Clinical Oncology,2007,,https://experts.mcmaster.ca/display/publication1621338,2025-07-27T15:12:23.219162
Gregory Pond,gpond@mcmaster.ca,conferences,Initial versus recent outcomes with a non-risk adapted surveillance policy in stage I non-seminomatous germ cell tumors (NSGCT),Journal of Clinical Oncology,2007,,https://experts.mcmaster.ca/display/publication1621341,2025-07-27T15:12:23.219163
Gregory Pond,gpond@mcmaster.ca,conferences,Nomograms to predict serious adverse events (SAEs) in patients (pts) enrolled in phase II clinical trials of molecularly targeted agents (MTAs),Journal of Clinical Oncology,2007,,https://experts.mcmaster.ca/display/publication1621337,2025-07-27T15:12:23.219164
Gregory Pond,gpond@mcmaster.ca,conferences,"Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium",Journal of Clinical Oncology,2007,,https://experts.mcmaster.ca/display/publication1621330,2025-07-27T15:12:23.219165
Gregory Pond,gpond@mcmaster.ca,conferences,"Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium",Journal of Clinical Oncology,2007,10.1200/jco.2007.25.18_suppl.5093,https://experts.mcmaster.ca/display/publication1977740,2025-07-27T15:12:23.219165
Gregory Pond,gpond@mcmaster.ca,conferences,The quality of phase I trial (P1T) abstracts submitted to ASCO meetings,Journal of Clinical Oncology,2007,,https://experts.mcmaster.ca/display/publication1621340,2025-07-27T15:12:23.219166
Gregory Pond,gpond@mcmaster.ca,conferences,W Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival of the TAX 327 study,Journal of Clinical Oncology,2007,,https://experts.mcmaster.ca/display/publication1621332,2025-07-27T15:12:23.219167
Gregory Pond,gpond@mcmaster.ca,conferences,Evaluation of Cognitive Function Associated With Chemotherapy: A Review of Published Studies and Recommendations for Future Research,Journal of Clinical Oncology,2007,10.1200/jco.2006.08.1604,https://experts.mcmaster.ca/display/publication1621333,2025-07-27T15:12:23.219168
Gregory Pond,gpond@mcmaster.ca,conferences,Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study,Journal of Clinical Oncology,2007,10.1200/jco.2006.07.6547,https://experts.mcmaster.ca/display/publication1521770,2025-07-27T15:12:23.219169
Gregory Pond,gpond@mcmaster.ca,conferences,Pharmacist Medication Assessments in a Surgical Preadmission Clinic,JAMA Internal Medicine,2007,10.1001/archinte.167.10.1034,https://experts.mcmaster.ca/display/publication1521783,2025-07-27T15:12:23.219170
Gregory Pond,gpond@mcmaster.ca,conferences,Fractionated stereotactic radiotherapy for acoustic neuroma,Cancer,2007,10.1002/cncr.22499,https://experts.mcmaster.ca/display/publication1521749,2025-07-27T15:12:23.219171
Gregory Pond,gpond@mcmaster.ca,conferences,Predictors of Blood Transfusion Requirements in Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma.,Blood,2006,10.1182/blood.v108.11.2990.2990,https://experts.mcmaster.ca/display/publication310479,2025-07-27T15:12:23.219172
Gregory Pond,gpond@mcmaster.ca,conferences,2160,International Journal of Radiation Oncology Biology Physics,2006,10.1016/j.ijrobp.2006.07.565,https://experts.mcmaster.ca/display/publication310480,2025-07-27T15:12:23.219173
Gregory Pond,gpond@mcmaster.ca,conferences,2413,International Journal of Radiation Oncology Biology Physics,2006,10.1016/j.ijrobp.2006.07.823,https://experts.mcmaster.ca/display/publication310489,2025-07-27T15:12:23.219174
Gregory Pond,gpond@mcmaster.ca,conferences,47 POSTER A phase II study of Sorafenib (BAY 43-9006) in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal cancer (NPC): final results,"European Journal of Cancer, Supplement",2006,10.1016/s1359-6349(06)70053-2,https://experts.mcmaster.ca/display/publication310490,2025-07-27T15:12:23.219175
Gregory Pond,gpond@mcmaster.ca,conferences,550 POSTER Dual inhibition of the MAPK pathway by combination targeted therapy: a phase I trial of sorafenib (SOR) and erlotinib (ERL) in advanced solid tumors,"European Journal of Cancer, Supplement",2006,10.1016/s1359-6349(06)70555-9,https://experts.mcmaster.ca/display/publication310487,2025-07-27T15:12:23.219176
Gregory Pond,gpond@mcmaster.ca,conferences,A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas,British Journal of Cancer,2006,10.1038/sj.bjc.6603419,https://experts.mcmaster.ca/display/publication310485,2025-07-27T15:12:23.219177
Gregory Pond,gpond@mcmaster.ca,conferences,Impact and Perceptions of Mandatory Tumor Biopsies for Correlative Studies in Clinical Trials of Novel Anticancer Agents,Journal of Clinical Oncology,2006,10.1200/jco.2005.03.4496,https://experts.mcmaster.ca/display/publication1521766,2025-07-27T15:12:23.219178
Gregory Pond,gpond@mcmaster.ca,conferences,The impact of cognitive dysfunction upon the non-metastatic colorectal cancer patient's psychosocial adjustment and quality of life,Psycho-Oncology,2006,,https://experts.mcmaster.ca/display/publication310492,2025-07-27T15:12:23.219179
Gregory Pond,gpond@mcmaster.ca,conferences,162 Radiation dose to the internal pudendal arteries from iodine 125 prostate brachytherapy,Radiotherapy and Oncology,2006,10.1016/s0167-8140(06)80903-5,https://experts.mcmaster.ca/display/publication310482,2025-07-27T15:12:23.219180
Gregory Pond,gpond@mcmaster.ca,conferences,63 Primary and adjuvant chemoradiotherapy for locally advanced pancreatic cancer: A phase I/II study with long term outcome,Radiotherapy and Oncology,2006,10.1016/s0167-8140(06)80804-2,https://experts.mcmaster.ca/display/publication310483,2025-07-27T15:12:23.219181
Gregory Pond,gpond@mcmaster.ca,conferences,69 The impact of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) on radiotherapy planning in carcinoma of the esophagus,Radiotherapy and Oncology,2006,10.1016/s0167-8140(06)80810-8,https://experts.mcmaster.ca/display/publication310493,2025-07-27T15:12:23.219182
Gregory Pond,gpond@mcmaster.ca,conferences,A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first line treatment in hormone refractory prostate cancer (HRPC),Journal of Clinical Oncology,2006,10.1200/jco.2006.24.18_suppl.13015,https://experts.mcmaster.ca/display/publication1977735,2025-07-27T15:12:23.219182
Gregory Pond,gpond@mcmaster.ca,conferences,A randomized controlled trial to evaluate the impact of an educational DVD an cancer patients considering participation in a phase I clinical trial.,Journal of Clinical Oncology,2006,,https://experts.mcmaster.ca/display/publication310494,2025-07-27T15:12:23.219183
Gregory Pond,gpond@mcmaster.ca,conferences,Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study.,Journal of Clinical Oncology,2006,,https://experts.mcmaster.ca/display/publication310511,2025-07-27T15:12:23.219184
Gregory Pond,gpond@mcmaster.ca,conferences,Cognitive impairment associated with chemotherapy for breast cancer: An exploratory case-control study.,Journal of Clinical Oncology,2006,,https://experts.mcmaster.ca/display/publication310495,2025-07-27T15:12:23.219185
Gregory Pond,gpond@mcmaster.ca,conferences,Cytokine levels in patients (pts) with localized colorectal cancer (CRC) after surgery and their relationship to fatigue and cognitive function.,Journal of Clinical Oncology,2006,,https://experts.mcmaster.ca/display/publication310518,2025-07-27T15:12:23.219186
Gregory Pond,gpond@mcmaster.ca,conferences,Long-term results of concurrent gemcitabine (G) and radiotherapy (GRT) for locally advanced (LA) or high-risk resected (R) pancreatic cancer.,Journal of Clinical Oncology,2006,,https://experts.mcmaster.ca/display/publication310506,2025-07-27T15:12:23.219187
Gregory Pond,gpond@mcmaster.ca,conferences,Neuroendocrine tumors (NET) of the gastrointestinal tract: A decade of experience at the Princess Margaret Hospital.,Journal of Clinical Oncology,2006,,https://experts.mcmaster.ca/display/publication310513,2025-07-27T15:12:23.219188
Gregory Pond,gpond@mcmaster.ca,conferences,Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial,Journal of Clinical Oncology,2006,10.1200/jco.2005.03.8331,https://experts.mcmaster.ca/display/publication1521907,2025-07-27T15:12:23.219189
Gregory Pond,gpond@mcmaster.ca,conferences,Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial.,Journal of Clinical Oncology,2006,,https://experts.mcmaster.ca/display/publication310499,2025-07-27T15:12:23.219190
Gregory Pond,gpond@mcmaster.ca,conferences,Quality of life (QOL) of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) following treatment with docetaxel or mitoxantrone in the TAX-327 study.,Journal of Clinical Oncology,2006,,https://experts.mcmaster.ca/display/publication310505,2025-07-27T15:12:23.219191
Gregory Pond,gpond@mcmaster.ca,conferences,A phase II study of ispinesib in patients (PTS) with recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSC),Annals of Oncology,2006,,https://experts.mcmaster.ca/display/publication1521903,2025-07-27T15:12:23.219192
Gregory Pond,gpond@mcmaster.ca,conferences,Cognitive impairment associated with chemotherapy for breast cancer: A mechanistic cohort study.,Breast Cancer Research and Treatment,2006,,https://experts.mcmaster.ca/display/publication310497,2025-07-27T15:12:23.219193
Gregory Pond,gpond@mcmaster.ca,conferences,Correlation between 2 or 3 year (y) disease-free survival (DFS) and 5y overall survival (OS) in adjuvant systemic trials of early stage breast cancer.,Breast Cancer Research and Treatment,2006,,https://experts.mcmaster.ca/display/publication310496,2025-07-27T15:12:23.219194
Gregory Pond,gpond@mcmaster.ca,conferences,"Mechanisms of cognitive function and fatigue: A prospective, longitudinal cohort study in colorectal cancer patients",Annals of Oncology,2006,,https://experts.mcmaster.ca/display/publication310488,2025-07-27T15:12:23.219196
Gregory Pond,gpond@mcmaster.ca,conferences,Phase I clinical trials referrals and enrollment: Five-year experience at the Princess Margaret Hospital,Annals of Oncology,2006,,https://experts.mcmaster.ca/display/publication1293741,2025-07-27T15:12:23.219197
Gregory Pond,gpond@mcmaster.ca,conferences,A phase 2 study of GTI-2040 plus docetaxel and prednisone as 1st line treatment in hormone-refractory prostate cancer (HRPC).,Clinical Cancer Research,2005,,https://experts.mcmaster.ca/display/publication1521855,2025-07-27T15:12:23.219198
Gregory Pond,gpond@mcmaster.ca,conferences,Correlation between erlotinib concentrations and severity of skin rash.,Clinical Cancer Research,2005,,https://experts.mcmaster.ca/display/publication1521899,2025-07-27T15:12:23.219199
Gregory Pond,gpond@mcmaster.ca,conferences,Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination.,Clinical Cancer Research,2005,,https://experts.mcmaster.ca/display/publication310514,2025-07-27T15:12:23.219200
Gregory Pond,gpond@mcmaster.ca,conferences,Pharmacodynamic evaluations of paired tumor biopsies in advanced neuroendocrine carcinomas (NECs) treated with the mTOR inhibitor temsirolimus.,Clinical Cancer Research,2005,,https://experts.mcmaster.ca/display/publication1521904,2025-07-27T15:12:23.219201
Gregory Pond,gpond@mcmaster.ca,conferences,Pharmacodynamic studies of erlotinib in tumor and skin tissue samples of patients (Pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).,Clinical Cancer Research,2005,,https://experts.mcmaster.ca/display/publication1293805,2025-07-27T15:12:23.219202
Gregory Pond,gpond@mcmaster.ca,conferences,Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A study of the PMH phase II consortium.,Clinical Cancer Research,2005,,https://experts.mcmaster.ca/display/publication310512,2025-07-27T15:12:23.219203
Gregory Pond,gpond@mcmaster.ca,conferences,A Phase II study of Sorafenib (BAY 43-9006) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC),"European Journal of Cancer, Supplement",2005,,https://experts.mcmaster.ca/display/publication310509,2025-07-27T15:12:23.219204
Gregory Pond,gpond@mcmaster.ca,conferences,A Prospective Study to Evaluate the Need for an Immobilization Device for Treating Modified Mantle Fields in Lymphoma Patients,International Journal of Radiation Oncology Biology Physics,2005,10.1016/j.ijrobp.2005.07.721,https://experts.mcmaster.ca/display/publication310503,2025-07-27T15:12:23.219205
Gregory Pond,gpond@mcmaster.ca,conferences,Analysis of Gross Target Volume (GTV) Observer Variability with FDG-PET and Contrast Enhanced CT in Head and Neck Cancer Using Finite Element Modeling,International Journal of Radiation Oncology Biology Physics,2005,10.1016/j.ijrobp.2005.07.621,https://experts.mcmaster.ca/display/publication310517,2025-07-27T15:12:23.219206
Gregory Pond,gpond@mcmaster.ca,conferences,Comparison of Outcomes of Phase II Studies and Subsequent Randomized Control Studies Using Identical Chemotherapeutic Regimens,Journal of Clinical Oncology,2005,10.1200/jco.2005.06.679,https://experts.mcmaster.ca/display/publication1521870,2025-07-27T15:12:23.219207
Gregory Pond,gpond@mcmaster.ca,conferences,Development of fractionated stereotactic radiotherapy for meningioma,"European Journal of Cancer, Supplement",2005,,https://experts.mcmaster.ca/display/publication310486,2025-07-27T15:12:23.219208
Gregory Pond,gpond@mcmaster.ca,conferences,Phase II study of Sorafenib (BAY 43-9006) in combination with Gemcitabine in recurrent epithelial ovarian cancer - a study of the PMH phase II consortium,"European Journal of Cancer, Supplement",2005,,https://experts.mcmaster.ca/display/publication310491,2025-07-27T15:12:23.219209
Gregory Pond,gpond@mcmaster.ca,conferences,Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy,"European Journal of Cancer, Supplement",2005,,https://experts.mcmaster.ca/display/publication310481,2025-07-27T15:12:23.219210
Gregory Pond,gpond@mcmaster.ca,conferences,"The Relationship of International Prostate Symptom Score with Urinary Flow Studies, and Catheterization Rates Following Iodine 125 Prostate Brachytherapy",International Journal of Radiation Oncology Biology Physics,2005,10.1016/j.ijrobp.2005.07.534,https://experts.mcmaster.ca/display/publication310507,2025-07-27T15:12:23.219211
Gregory Pond,gpond@mcmaster.ca,conferences,The influence of mentorship on research productivity in oncology,"European Journal of Cancer, Supplement",2005,,https://experts.mcmaster.ca/display/publication310484,2025-07-27T15:12:23.219212
Gregory Pond,gpond@mcmaster.ca,conferences,"202 Relationship of the International Prostate Symptom Score with urinary flow studies, and catherization rates following iodine 125 prostate brachytherapy",Radiotherapy and Oncology,2005,10.1016/s0167-8140(05)80363-9,https://experts.mcmaster.ca/display/publication310515,2025-07-27T15:12:23.219213
Gregory Pond,gpond@mcmaster.ca,conferences,58 Radiation target volume delineation (TVD) using FDG-PET and contrast enhanced CT (CECT) for patients with head and neck cancer,Radiotherapy and Oncology,2005,10.1016/s0167-8140(05)80219-1,https://experts.mcmaster.ca/display/publication310510,2025-07-27T15:12:23.219214
Gregory Pond,gpond@mcmaster.ca,conferences,73 A prospective study to evaluate the need for an immobilization device for treating modified mantle fields in lymphoma patients,Radiotherapy and Oncology,2005,10.1016/s0167-8140(05)80234-8,https://experts.mcmaster.ca/display/publication310519,2025-07-27T15:12:23.219215
Gregory Pond,gpond@mcmaster.ca,conferences,95 Stereotactic program development in the management of meningioma,Radiotherapy and Oncology,2005,10.1016/s0167-8140(05)80256-7,https://experts.mcmaster.ca/display/publication310520,2025-07-27T15:12:23.219216
Gregory Pond,gpond@mcmaster.ca,conferences,Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies,International Journal of Gynecological Cancer,2005,10.1111/j.1525-1438.2005.00139.x,https://experts.mcmaster.ca/display/publication521389,2025-07-27T15:12:23.219217
Gregory Pond,gpond@mcmaster.ca,conferences,Phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC),Lung Cancer,2005,,https://experts.mcmaster.ca/display/publication310516,2025-07-27T15:12:23.219217
Gregory Pond,gpond@mcmaster.ca,conferences,A phase II study of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC).,Journal of Clinical Oncology,2005,,https://experts.mcmaster.ca/display/publication1521863,2025-07-27T15:12:23.219218
Gregory Pond,gpond@mcmaster.ca,conferences,A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas (NECs).,Journal of Clinical Oncology,2005,,https://experts.mcmaster.ca/display/publication1521900,2025-07-27T15:12:23.219219
Gregory Pond,gpond@mcmaster.ca,conferences,Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors.,Journal of Clinical Oncology,2005,,https://experts.mcmaster.ca/display/publication1521861,2025-07-27T15:12:23.219220
Gregory Pond,gpond@mcmaster.ca,conferences,Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the princess margaret hospital [PMH] phase II consortium.,Journal of Clinical Oncology,2005,,https://experts.mcmaster.ca/display/publication310536,2025-07-27T15:12:23.219221
Gregory Pond,gpond@mcmaster.ca,conferences,Predictive value of eTag dimerization assay in patients with metastatic colorectal cancer treated with erlotinib.,Journal of Clinical Oncology,2005,,https://experts.mcmaster.ca/display/publication310504,2025-07-27T15:12:23.219222
Gregory Pond,gpond@mcmaster.ca,conferences,The impact and perception of mandatory tumor biopsies (Bx) for correlative studies in clinical trials of novel anticancer agents.,Journal of Clinical Oncology,2005,,https://experts.mcmaster.ca/display/publication1521857,2025-07-27T15:12:23.219223
Gregory Pond,gpond@mcmaster.ca,conferences,Willingness of older people with cancer to participate in cancer clinical trials is not a barrier to accrual.,Journal of Clinical Oncology,2005,,https://experts.mcmaster.ca/display/publication310508,2025-07-27T15:12:23.219224
Gregory Pond,gpond@mcmaster.ca,conferences,Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial,Journal of Clinical Oncology,2005,10.1200/jco.2005.51.008,https://experts.mcmaster.ca/display/publication1521867,2025-07-27T15:12:23.219225
Gregory Pond,gpond@mcmaster.ca,conferences,Preemptive therapy with ganciclovir and short-course intravenous immunoglobulin does not prevent recurrent cytomegalovirus infection (CBMTG-102 study),Transplantation and Cellular Therapy,2005,10.1016/j.bbmt.2004.12.268,https://experts.mcmaster.ca/display/publication1352479,2025-07-27T15:12:23.219226
Gregory Pond,gpond@mcmaster.ca,conferences,"The impact of mandatory tumor biopsies (Bx) for correlative studies in clinical trials of anticancer agents, as perceived by patients, physicians and institution review board members (IRBs)",Annals of Oncology,2005,,https://experts.mcmaster.ca/display/publication1521872,2025-07-27T15:12:23.219227
Gregory Pond,gpond@mcmaster.ca,conferences,"Weekly cyclophosphamide and alternate day prednisone: An effective, convenient and well tolerated treatment for relapsed multiple myeloma following autologous stem cell transplant.",Blood,2004,,https://experts.mcmaster.ca/display/publication310501,2025-07-27T15:12:23.219228
Gregory Pond,gpond@mcmaster.ca,conferences,Computerized tomographic simulation compared to clinical mark-up in palliative radiotherapy: A prospective study,Radiotherapy and Oncology,2004,,https://experts.mcmaster.ca/display/publication310525,2025-07-27T15:12:23.219229
Gregory Pond,gpond@mcmaster.ca,conferences,Penile brachytherapy: Results for 49 patients,Radiotherapy and Oncology,2004,,https://experts.mcmaster.ca/display/publication310521,2025-07-27T15:12:23.219230
Gregory Pond,gpond@mcmaster.ca,conferences,Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: Does dose escalation improve local recurrence free survival and disease free survival?,Radiotherapy and Oncology,2004,,https://experts.mcmaster.ca/display/publication310532,2025-07-27T15:12:23.219231
Gregory Pond,gpond@mcmaster.ca,conferences,"Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: Effect of dose escalation on pathological complete response, local recurrence free survival &disease free survival",International Journal of Radiation Oncology Biology Physics,2004,10.1016/j.ijrobp.2004.07.090,https://experts.mcmaster.ca/display/publication310529,2025-07-27T15:12:23.219232
Gregory Pond,gpond@mcmaster.ca,conferences,Sequential evaluation of prostate edema following permanent seed prostate brachytherapy using CT-MRI fusion,International Journal of Radiation Oncology Biology Physics,2004,10.1016/s0360-3016(04)01669-4,https://experts.mcmaster.ca/display/publication310531,2025-07-27T15:12:23.219233
Gregory Pond,gpond@mcmaster.ca,conferences,The use and toxicity of steroids in the management of patients with brain metastases.,Radiotherapy and Oncology,2004,,https://experts.mcmaster.ca/display/publication310524,2025-07-27T15:12:23.219234
Gregory Pond,gpond@mcmaster.ca,conferences,Which radiation regimen should be used for Bowen's disease of the skin?,Radiotherapy and Oncology,2004,,https://experts.mcmaster.ca/display/publication1521879,2025-07-27T15:12:23.219234
Gregory Pond,gpond@mcmaster.ca,conferences,Comparison of outcomes of phase II trials (P2Ts) and subsequent randomized control trials (RCTs) using identical therapeutic regimens.,Journal of Clinical Oncology,2004,,https://experts.mcmaster.ca/display/publication1521887,2025-07-27T15:12:23.219235
Gregory Pond,gpond@mcmaster.ca,conferences,"Retrospective analysis of treatment practices for elderly cancer patients (Pts) in Ontario, Canada",Journal of Clinical Oncology,2004,,https://experts.mcmaster.ca/display/publication1521905,2025-07-27T15:12:23.219236
Gregory Pond,gpond@mcmaster.ca,conferences,Tolerability of the Intergroup 0099 regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status.,Journal of Clinical Oncology,2004,,https://experts.mcmaster.ca/display/publication1191327,2025-07-27T15:12:23.219237
Gregory Pond,gpond@mcmaster.ca,conferences,Brachytherapy for penile cancer: results for 49 patients,Radiotherapy and Oncology,2004,,https://experts.mcmaster.ca/display/publication310526,2025-07-27T15:12:23.219238
Gregory Pond,gpond@mcmaster.ca,conferences,Radiation therapy for Bowen's disease of the skin,International Journal of Radiation Oncology Biology Physics,2004,,https://experts.mcmaster.ca/display/publication1521876,2025-07-27T15:12:23.219239
Gregory Pond,gpond@mcmaster.ca,conferences,Are Older Cancer Patients Being Referred to Oncologists? A Mail Questionnaire of Ontario Primary Care Practitioners to Evaluate Their Referral Patterns,Journal of Clinical Oncology,2003,10.1200/jco.2003.06.073,https://experts.mcmaster.ca/display/publication1521873,2025-07-27T15:12:23.219240
Gregory Pond,gpond@mcmaster.ca,conferences,A phase I/Il Study of erlotinib (Tarceva) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (HNSCC).,Clinical Cancer Research,2003,,https://experts.mcmaster.ca/display/publication1521877,2025-07-27T15:12:23.219241
Gregory Pond,gpond@mcmaster.ca,conferences,A phase I/Il Study of erlotinib (Tarceva) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (HNSCC).,Clinical Cancer Research,2003,,https://experts.mcmaster.ca/display/publication2553036,2025-07-27T15:12:23.219242
Gregory Pond,gpond@mcmaster.ca,conferences,Phase II study of OSI-774 in patients with metastatic colorectal cancer,European Journal of Cancer,2002,,https://experts.mcmaster.ca/display/publication310601,2025-07-27T15:12:23.219243
Gregory Pond,gpond@mcmaster.ca,conferences,"Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota 1970-1999.",Arthritis and Rheumatism,2001,,https://experts.mcmaster.ca/display/publication3512512,2025-07-27T15:12:23.219244
Gregory Pond,gpond@mcmaster.ca,conferences,Oral contraceptives estrogen replacement therapy and the risk of rheumatoid arthritis,Arthritis and Rheumatism,2001,,https://experts.mcmaster.ca/display/publication3512511,2025-07-27T15:12:23.219245
Gregory Pond,gpond@mcmaster.ca,conferences,Risk of infection in persons with rheumatoid arthritis compared to controls - A population-based study,Arthritis and Rheumatism,2001,,https://experts.mcmaster.ca/display/publication3512510,2025-07-27T15:12:23.219246
Gregory Pond,gpond@mcmaster.ca,conferences,"Trends in incidence and mortality in rheumatoid arthritis in Rochester, MN over a 40-year period.",Arthritis and Rheumatism,2001,,https://experts.mcmaster.ca/display/publication3512513,2025-07-27T15:12:23.219247
Gregory Pond,gpond@mcmaster.ca,conferences,Direct medical costs attributable to osteoporotic fractures.,Arthritis and Rheumatism,2000,,https://experts.mcmaster.ca/display/publication3512514,2025-07-27T15:12:23.219248
Gregory Pond,gpond@mcmaster.ca,conferences,Geriatric assessment and frailty changes in older patients with Newly-Diagnosed Multiple Myeloma.,,,,https://experts.mcmaster.ca/display/publication2498907,2025-07-27T15:12:23.219249
Gregory Pond,gpond@mcmaster.ca,conferences,Quality of life assessment in older patients with Newly Diagnosed Multiple Myeloma.,,,,https://experts.mcmaster.ca/display/publication2498908,2025-07-27T15:12:23.219250
Gregory Pond,gpond@mcmaster.ca,conferences,Trajectory of symptoms after autologous stem cell transplant among patients with Multiple Myeloma: A Population-Based Study,,,,https://experts.mcmaster.ca/display/publication2498902,2025-07-27T15:12:23.219251
Gregory Pond,gpond@mcmaster.ca,preprints,Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected Locally Advanced Non-Small Cell Lung Cancer treated with chemo- radiotherapy.,,2024,10.21203/rs.3.rs-4266135/v1,https://experts.mcmaster.ca/display/publication3424765,2025-07-27T15:12:23.219252
Gregory Pond,gpond@mcmaster.ca,preprints,Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy,,2023,10.21203/rs.3.rs-2907146/v1,https://experts.mcmaster.ca/display/publication3233448,2025-07-27T15:12:23.219253
Gregory Pond,gpond@mcmaster.ca,preprints,Artichoke Phytocomplex Modulates Serum microRNAs in Patients Exposed to Asbestos: A First Step of a Phase II Clinical Trial,,2022,10.21203/rs.3.rs-1811920/v1,https://experts.mcmaster.ca/display/publication3234299,2025-07-27T15:12:23.219254
Gregory Pond,gpond@mcmaster.ca,preprints,Will COVID-19 directives to reduce regularly scheduled physical examinations affect recurrence detection in early breast cancer patients?,,2022,10.21203/rs.3.rs-1522576/v1,https://experts.mcmaster.ca/display/publication3234300,2025-07-27T15:12:23.219254
Gregory Pond,gpond@mcmaster.ca,preprints,Disparities in the survival of endometrial cancer patients in a public healthcare system: A population-based cohort study.,,2020,10.22541/au.160684330.03315389/v1,https://experts.mcmaster.ca/display/publication3232222,2025-07-27T15:12:23.219255
Gregory Pond,gpond@mcmaster.ca,preprints,Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study (Preprint),,,10.2196/preprints.66821,https://experts.mcmaster.ca/display/publication3596583,2025-07-27T15:12:23.219256
Gregory Pond,gpond@mcmaster.ca,preprints,"CAPOX vs. FOLFOX for Colorectal Cancer - Real World Outcomes in Ontario, Canada",,,10.20944/preprints202506.2438.v1,https://experts.mcmaster.ca/display/publication3610582,2025-07-27T15:12:23.219257
Gregory Pond,gpond@mcmaster.ca,preprints,Incidence of Venous Thromboembolism in Newly Diagnosed Glioblastoma Multiforme and Associated Risk Factors: A retrospective Chart Review,,,10.20944/preprints202506.1194.v1,https://experts.mcmaster.ca/display/publication3607062,2025-07-27T15:12:23.219258
